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Abstract: Multicellular complex organisms utilize oxygen as the final electron acceptor in the cellular
aerobic glucose catabolism and ￿-oxidation of fatty acids to efficiently generate ATP. Hence, oxygen depri-
vation (hypoxia) requires adaptive mechanisms to respond to this stress stimulus. Response to hypoxia
is governed by the transcription factor hypoxia-inducible factor (HIF) that regulates the expression of at
least 70 known target genes that allow the organism to adapt on the cellular, local and systemic level.
HIF is a heterodimeric protein complex that consists of an oxygen-dependently regulated HIF-￿ subunit
and a constitutively expressed HIF-￿ subunit. The HIF-￿ subunit protein stability is tightly regulated
by hydroxylation of specific prolines in the oxygen-dependent degradation domain (ODDD) by prolyl-
4-hydroxylases (PHDs) that require oxygen as a substrate for their enzymatic reaction. Hydroxylated
HIF-￿ is targeted by the von Hippel-Lindau tumor suppressor protein (pVHL), the recognition compo-
nent of an E3 ubiquitin ligase complex, and subsequently degraded in the 26S proteasome. Besides HIF-￿,
only a few other PHD hydroxylation targets have been described so far. We investigated the possibility
of further hydroxylation targets for the PHD2 isoform and if other regulatory mechanisms apart from
molecular oxygen might be important in the PHD2 protein regulation. A yeast two-hybrid screening was
carried out to identify novel PHD2 interacting partners. Among the identified interactors, we found the
FK506-binding protein 38 (FKBP38). The specific interaction of FKBP38 with PHD2 but not PHD1
or PHD3 was confirmed in a variety of interaction assays, including yeast and mammalian twohybrid
analysis, GST pull-down and co-immunoprecipitation experiments and fluorescence resonance energy
transfer (FRET) analysis. FKBP38 was shown to bind with a linear minimal glutamate rich binding
motif from amino acid (aa) 37 to 56 to PHD2. Conversely, PHD2 interacts with its N-terminal region
from aa 1 to 114, containing a MYND-type Zn2+ finger domain, with FKBP38. Originally FKBP38
was identified as a target of the immunosuppressive drug FK506 and it has been proposed that FKBP38
regulates cell death or survival. FKBP38 belongs to the family of peptidyl prolyl cis/trans isomerases
(PPIases) that participate in the conformational change of the aa proline from the cis to the trans po-
sition, providing the basis for a potential regulatory switch. Thus, we speculated that FKBP38 might
be a co-factor that is involved in the PHD-mediated enzymatic proline hydroxylation of HIF-￿ subunits.
Stable RNA interference (RNAi)-mediated downregulation of FKBP38 increased PHD2 protein abun-
dance and cellular hydroxylation activity. Conversely, elevated PHD2 protein levels decreased hypoxic
HIF-1￿ protein accumulation and attenuated HIF-dependent transcriptional regulation. Reconstitution
of FKBP38 normalized PHD2 protein levels and therefore cellular hydroxylation capacity and HIF-1
response. Strikingly, increased PHD2 protein abundance was due to prolonged PHD2 protein stability,
suggesting that FKBP38 determines PHD2 protein levels. However, we did not find any involvement
of the FKBP38 enzymatic PPIase activity in the regulation of PHD2 protein abundance. So far, little
is known about PHD2 protein regulation and we therefore further explored the molecular mechanism
of FKBP38-dependent PHD2 protein regulation. PHD2 protein stability was neither influenced by a
variety of protease inhibitors nor by inhibition of the ubiquitindependent proteasomal degradation path-
way. Interestingly, in cellular assays the Cterminal transmembrane domain of FKBP38 is required for a
specific interaction with PHD2 in spite of the existence of a functional FKBP38 interaction domain at
the Nterminus. Consistent with these data, we could co-isolate FKBP38 and PHD2 from endoplasmatic
reticulum and mitochondria membranes. Strikingly, regulation of PHD2 protein abundance requires the
correct sub-cellular localization of FKBP38. As an outlook, targeting FKBP38:PHD2 protein interac-
tion by chemical compounds might be an attractive strategy to specifically increase PHD2 amount and
therefore attenuate HIF protein levels in tumors.
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1 Abbreviations 
AKT Synonym for protein kinase B 
ANG Angiopoietin 
ANT Adenine nucleotide translocase 
Apaf-1 Apoptotic protease activating factor-1 
APP Amyloid precursor protein 
AQP-1 Aquaporin-1 
ARD1 Arrest-defective-1 protein 
ARNT Aryl hydrocarbon receptor nuclear translocator 
ATF4 Activating transcription factor-4 
Bcl-2 B-cell CLL/Lymphoma 2 
bHLH Basic helix-loop-helix 
CAIX Carbonic anhydrase 9 
CaM Calmodulin 
CBP CREB-binding protein 
Cdr2 Cerebellar degeneration-related protein 2 
CFTR Cystic fibrosis transmembrane conductance regulator 
CH-domain Cysteine/histidine rich domain 
CHX Cycloheximide 
CRM1 Exportin 1 
CsA Cyclosporin A 
CTAD C-terminal transactivation domain 
Cyp Cyclophilin 
Cyt c Cytochrome c 
DFX Desferroxamine 
DMOG Dimethyloxalylglycine 
DSS Dextran-sodium sulphate 
4E-BP1 Eukaryotic translation initiation factor 4E-binding protein 
ED Embryonic day 
EGL-9 Egg-laying abnormal-9 
eIF4E Eukaryotic initiation factor 4E 
EPAS-1 Endothelial PAS protein 1 
EPO Erythropoietin 
ETC Electron transfer chain 
FAD Familial Alzheimer disease 
FH Fumarate hydratase 
FIH Factor inhibiting HIF 
FKBP FK506-binding protein  
FRET Fluorescence resonance energy transfer 
Gli Glioma associated oncogene homolog 
GLUT1 Glucose transporter 1  
HBS HIF-binding site 
HERG Potassium voltage-gated channel subfamily H member 2 
HIF Hypoxia-inducible factor 
HNSCC Head and neck squamous cell carcinoma 
HRE Hypoxia-response element 
HSP70/90 Heat shock protein 70/90 
IκB Inhibitor of NFκB 
IKK IκB kinase 
IOP1 Iron-only hydrogenase-like protein 
ING4 Inhibitor of growth family member 4 
IPAS Inhibitory PAS protein 
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IRES Internal ribosome entry site 
Km Michaelis-Menten constant 
LDHA Lactate dehydrogenase A 
mTOR Mammalian target of rapamycin 
MAPK Mitogen-activated protein kinase 
Mdm2 Mouse double minute 2  
MEF  Mouse embryonic fibroblast 
MLCK Myosine light chain kinase 
MMP9 Matrix metalloproteinase 9 
MORG1 MAPK organizer 1 
MPTP Mitochondrial permeability transition pore 
MYND Myeloid, nervy and DEAF-1 
MW  Molecular weight 
NDRG1 N-myc downstream-regulated gene 1  
NFAT Nuclear factor of activated T-cells 
NFκB Nuclear factor-kappa B 
NGF Nerve growth factor 
NO Nitric oxide 
NOS Nitric oxide synthase 
NQO1 NAD(P)H quinone oxidoreductase 1 
NTAD N-terminal transactivation domain 
ODDD Oxygen-dependent degradation domain 
OS9 Amplified in osteosarcoma 9 
PAS PER-ARNT-SIM 
PCNA Proliferating cell nuclear antigen 
PDH Pyruvate dehydrogenase 
PDK1/4 Pyruvate-dehydrogenase kinase 1/4 
PER Period circadian protein 
PGK Phosphoglycerate kinase 
PHD Prolyl-4-hydroxylase 
PKA Protein kinase A 
PI3K Phosphatidylinositol-3-kinase 
PML Promyelocytic leukaemia protein 
pO2 Oxygen partial pressure 
PPIase Peptidyl prolyl cis/trans isomerase 
Ptch1 Patched 1 
PTB Polypyrimidine tract binding protein 
PTEN Phosphatase and tensin homolog 
pVHL Von Hippel-Lindau tumor suppressor protein 
RACK1 Receptor of activated protein C kinase 1 
REDD1 Regulated in development and DNA damage response 1 protein 
Rheb Ras homolog enriched in brain  
RNAi RNA interference 
ROS Reactive oxygen species 
RP1 RNA polymerase 1 
S6K Ribosomal protein S6 kinase 
SDH Succinate dehydrogenase 
SENP Sentrin/SUMO-specific protease 
SHH Sonic hedgehog protein 
SIAH Seven in absentia drosophila homolog 
SIM Single-minded protein 
Smo Smoothenend 
SSAT1 Spermidine/spermine-N-acetyltransferase-1 
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SUMO Small ubiquitin-related modifier 
SDC1 Syndecan 1 
TAD Transactivation domain 
TCA Tricarboxylic acid cycle (Krebs cycle) 
TGFβ Transforming growth factor β 
TNF  Tumor necrosis factor 
5’-TOP 5’-terminal oligopyrimidine tract 
TPEN N,N,N,N’-tetrakis (2-pyridylmethyl) ethylendiamine 
TPR Tetratricopeptide repeat 
TriC TCP1 ring complex polypeptide 
TSC1/2 Tuberous sclerosis complex 1/2 tumor suppressor protein 
UTR Untranslated region 
VDAC Voltage-dependent anion transporter (VDAC) 
VEGF Vascular endothelial growth factor 
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2 Summary 
Multicellular complex organisms utilize oxygen as the final electron acceptor in the 
cellular aerobic glucose catabolism and β-oxidation of fatty acids to efficiently 
generate ATP. Hence, oxygen deprivation (hypoxia) requires adaptive mechanisms 
to respond to this stress stimulus. Response to hypoxia is governed by the 
transcription factor hypoxia-inducible factor (HIF) that regulates the expression of at 
least 70 known target genes that allow the organism to adapt on the cellular, local 
and systemic level. HIF is a heterodimeric protein complex that consists of an 
oxygen-dependently regulated HIF-α subunit and a constitutively expressed HIF-β 
subunit. The HIF-α subunit protein stability is tightly regulated by hydroxylation of 
specific prolines in the oxygen-dependent degradation domain (ODDD) by prolyl-4-
hydroxylases (PHDs) that require oxygen as a substrate for their enzymatic reaction. 
Hydroxylated HIF-α is targeted by the von Hippel-Lindau tumor suppressor protein 
(pVHL), the recognition component of an E3 ubiquitin ligase complex, and 
subsequently degraded in the 26S proteasome. Besides HIF-α, only a few other PHD 
hydroxylation targets have been described so far. We investigated the possibility of 
further hydroxylation targets for the PHD2 isoform and if other regulatory 
mechanisms apart from molecular oxygen might be important in the PHD2 protein 
regulation. 
A yeast two-hybrid screening was carried out to identify novel PHD2 interacting 
partners. Among the identified interactors, we found the FK506-binding protein 38 
(FKBP38). The specific interaction of FKBP38 with PHD2 but not PHD1 or PHD3 was 
confirmed in a variety of interaction assays, including yeast and mammalian two-
hybrid analysis, GST pull-down and co-immunoprecipitation experiments and 
fluorescence resonance energy transfer (FRET) analysis. FKBP38 was shown to 
bind with a linear minimal glutamate rich binding motif from amino acid (aa) 37 to 56 
to PHD2. Conversely, PHD2 interacts with its N-terminal region from aa 1 to 114, 
containing a MYND-type Zn2+ finger domain, with FKBP38. 
Originally FKBP38 was identified as a target of the immunosuppressive drug FK506 
and it has been proposed that FKBP38 regulates cell death or survival. FKBP38 
belongs to the family of peptidyl prolyl cis/trans isomerases (PPIases) that participate 
in the conformational change of the aa proline from the cis to the trans position, 
providing the basis for a potential regulatory switch. Thus, we speculated that 
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FKBP38 might be a co-factor that is involved in the PHD-mediated enzymatic proline 
hydroxylation of HIF-α subunits. 
Stable RNA interference (RNAi)-mediated downregulation of FKBP38 increased 
PHD2 protein abundance and cellular hydroxylation activity. Conversely, elevated 
PHD2 protein levels decreased hypoxic HIF-1α protein accumulation and attenuated 
HIF-dependent transcriptional regulation. Reconstitution of FKBP38 normalized 
PHD2 protein levels and therefore cellular hydroxylation capacity and HIF-1 
response. Strikingly, increased PHD2 protein abundance was due to prolonged 
PHD2 protein stability, suggesting that FKBP38 determines PHD2 protein levels. 
However, we did not find any involvement of the FKBP38 enzymatic PPIase activity 
in the regulation of PHD2 protein abundance. So far, little is known about PHD2 
protein regulation and we therefore further explored the molecular mechanism of 
FKBP38-dependent PHD2 protein regulation. PHD2 protein stability was neither 
influenced by a variety of protease inhibitors nor by inhibition of the ubiquitin-
dependent proteasomal degradation pathway. Interestingly, in cellular assays the C-
terminal transmembrane domain of FKBP38 is required for a specific interaction with 
PHD2 in spite of the existence of a functional FKBP38 interaction domain at the N-
terminus. Consistent with these data, we could co-isolate FKBP38 and PHD2 from 
endoplasmatic reticulum and mitochondria membranes. Strikingly, regulation of 
PHD2 protein abundance requires the correct sub-cellular localization of FKBP38. As 
an outlook, targeting FKBP38:PHD2 protein interaction by chemical compounds 
might be an attractive strategy to specifically increase PHD2 amount and therefore 
attenuate HIF protein levels in tumors. 
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3 Zusammenfassung 
Multizelluläre komplexe Organismen benötigen Sauerstoff als terminalen 
Elektronenakzeptor im zellulären Glukoseabbau und bei der β-Oxidation von 
Fettsäuren, um effizient ATP zu produzieren. Deshalb werden bei Sauerstoffmangel 
(Hypoxie) Anpassungsmechanismen benötigt, um auf diesen Stressstimulus adäquat 
zu antworten. Die Antwort auf Hypoxie wird durch den Transkriptionsfaktor Hypoxie-
induzierbarer Faktor (HIF) gesteuert, der die Expression von mehr als 70 bekannten 
Zielgenen reguliert, die es dem Organismus ermöglichen, sich auf zellulärer, lokaler 
und systemischer Ebene anzupassen. HIF ist ein heterodimerer Proteinkomplex, der 
aus einer HIF-α Untereinheit besteht, die sauerstoffabhängig reguliert wird und aus 
einer konstitutiv exprimierten HIF-β Untereinheit. Die Proteinstabilität der HIF-α 
Untereinheit wird streng reguliert durch die Hydroxylierung von spezifischen Prolinen 
in der sauerstoffabhängigen Destabilisierungsdomäne (ODDD) durch Prolyl-4-
Hydroxylasen, die molekularen Sauerstoff als Substrat für die enzymatische Reaktion 
essentiell benötigen. Hydroxyliertes HIF-α wird an das von Hippel-Lindau Tumor 
Suppressor Protein (pVHL) gebunden, das die Erkennungseinheit eines E3 Ubiquitin-
Ligase Komplexes darstellt, und anschließend im 26S Proteasom abgebaut. Außer 
HIF-α sind gegenwärtig nur wenig andere Hydroxylierungssubstrate der PHDs 
bekannt. Wir untersuchten die Möglichkeit, ob weitere Hydroxylierungssubstrate für 
die PHD2 Isoform existieren und ob es neben Sauerstoff noch andere regulatorische 
Mechanismen gibt, die PHD2 regulieren. 
Ein Zwei-Hybrid Screening in der Hefe wurde durchgeführt, um neue PHD2 
interagierende Partner zu identifizieren. Unter den neu entdeckten Interaktoren 
fanden wir das FK506-bindende Protein 38 (FKBP38). Die spezifische Interaktion von 
FKBP38 mit PHD2 bestätigten wir in einer Vielzahl von Interaktionsstudien wie Hefe 
und Säugetier Zwei-Hybrid Interaktionsanalysen, in GST pull-down- und Co-
Immunopräzipitationsexperimenten und in der Fluoreszenz Resonanz Energie 
Transfer (FRET) Analyse. FKBP38 bindet an ein lineares glutamatreiches minimales 
Bindungsmotiv von Aminosäure 37 bis 56 in PHD2. Umgekehrt interagiert PHD2 mit 
seiner N-terminalen Region von Aminosäure 1 bis 114 in FKBP38, die eine MYND 
ähnliche Zn2+ Fingerdomäne enthält. 
FKBP38 entdeckte man ursprünglich als eine Zielstruktur für den immunsuppressiven 
Wirkstoff FK506 und es wird angenommen, dass FKBP38 den Zelltod oder das 
Überleben von Zellen reguliert. FKBP38 gehört zur Familie der Peptidylprolyl-
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cis/trans-Isomerasen (PPIase), die die Konformationsänderung der Aminosäure 
Prolin von der cis in die trans Position steuern und kann die Basis für eine 
regulatorische Veränderung bilden. 
Deshalb spekulierten wir, dass FKBP38 womöglich als Kofaktor fungiert, um die PHD 
gesteuerte enzymatische Prolinhydroxylierung der HIF-α Untereinheit zu regulieren. 
Jedoch erhöhte sich die PHD2 Proteinmenge und die zelluläre 
Hydroxylierungsaktivität durch die stabile Herunterregulation von FKBP38 durch RNA 
Interferenz (RNAi). Durch die erhöhte PHD2 Proteinmenge akkumulierte HIF-1α 
Protein in der Hypoxie weniger und die HIF-abhängige transkriptionelle Aktivität war 
abgeschwächt. Überraschenderweise war die Zunahme der PHD2 Proteinmenge 
aufgrund einer verlängerten PHD2 Proteinstabilität und deshalb schlagen wir vor, das 
FKBP38 die PHD2 Proteinmenge reguliert. Wir konnten bisher keine Beteiligung der 
FKBP38 PPIase Aktivitätsdomäne als Regulator der PHD2 Proteinmenge feststellen. 
Bisher ist sehr wenig über die PHD2 Proteinregulation bekannt und deshalb 
untersuchten wir den molekularen Mechanismus der FKBP38-abhängigen PHD2 
Proteinregulierung. Die PHD2 Stabilität war weder durch eine Vielzahl von 
Proteaseninhibitoren beeinflusst noch durch die Blockierung des Ubiquitin-Proteasom 
Degradationssignalweges. Interessanterweise wird die C-terminale 
Transmembrandomäne von FKBP38 in zellulären Experimenten für die spezifische 
Interaktion mit PHD2 benötigt, obwohl die funktionsfähige Interaktionsdomäne am N-
Terminus noch vorhanden ist. Konsistent mit diesen Daten konnten wir FKBP38 und 
PHD2 in endoplasmatischen und Mitochondrienmembranen isolieren und 
detektieren. Überraschenderweise benötigte die Regulation der PHD2 Menge die 
korrekte subzelluläre Lokalisation von FKBP38. Die Aufhebung der FKBP38:PHD2 
Interaktion durch chemische Wirkstoffe könnte eine interessante Zielstruktur sein, um 
spezifisch durch die Zunahme von PHD2 die HIF Proteinmenge in Tumoren zu 
reduzieren. 
INTRODUCTION 
- 8 - 
4 Introduction 
4.1 The hypoxia-inducible factor (HIF) 
Reduced oxygen partial pressure (pO2) greatly challenges human being at high 
altitude. The human body compensates a drop in barometric pressure by inducing a 
variety of physiological responses in order to maximally increase the delivery of 
oxygen as well as to optimize oxygen consumption within cells and tissues. Within 
minutes at arrival at high altitude the minute ventilation as well as cardiac output is 
increased. Later, in the process of acclimatization the number of red blood cells 
raises in the circulation due to stimulation of erythroid progenitor stem cells in the 
bone marrow by erythropoietin (EPO). Humans who constantly live above 3500 m in 
Bolivia or Tibet have roughly 10% higher hematocrit compared to residents at sea 
levels (1). But for a long time, it remained elusive what triggers the expression of 
EPO in the fetal liver and adult kidney in specialized peritubular fibroblasts within the 
cortex and outer medulla after exposure to low pO2. 
 
4.1.1 Discovery of the HIF complex 
In 1991, a 50 nucleotide large cis-acting DNA element in the 3’flanking region of the 
human EPO gene was identified that mediates the hypoxic induction of a transiently 
transfected reporter gene plasmid in the hepatoma cell line Hep3B (2). A hypoxic 
binding activity was found to bind to the hypoxia responsive enhancer and its binding 
capacity was greatly enhanced upon hypoxia and sensitive to blocking translation by 
cycloheximide (CHX) (3). In 1995, Wang and Semenza succeeded to purify this 
hypoxic binding activity that turned out to be a heterodimeric protein complex 
consisting of a α-subunit (HIF-1α) and a β-subunit (HIF-1β) (4). HIF-1β  also known 
as aryl hydrocarbon receptor nuclear translocator (ARNT) was already previously 
identified as heterodimerization partner of the dioxin receptor / aryl hydrocarbon 
receptor (AhR) and mediates xenobiotic responses (5). 
Both proteins belong to the PAS family (period circadian protein (PER), ARNT and 
single-minded protein (SIM)) of basic helix-loop-helix (bHLH) transcription factors. So 
far three different α-subunits (HIF-1α, HIF-2α and HIF-3α) and one β-subunit (HIF-
1β) are known. 
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4.1.2 Genetic ablation of HIF-α subunits 
Genetic ablation of HIF-1α and HIF-2α showed non-redundant and different functions 
of both subunits during mouse embryonic development. Loss of HIF-1α led to 
developmental arrest and death at embryonic day (ED) E10.5 due to defects in 
neuronal tube formation, vascular and pharyngeal structures and cardiovascular 
malformation (6), (7). The vascular regression and abnormal remodeling of the 
vascular network was mainly due to HIF-1α dependent mesenchymal cell death 
rather than to the action of the vascular endothelial growth factor (VEGF) (8). 
Germline deletion of HIF-2α showed diverse phenotypes depending on the mouse 
strain used. In C57BL/6 mice, genetic ablation of HIF-2α resulted in embryonic death 
at mid-gestation. The mice suffered from pronounced bradycardia due to lowered 
production of catecholamine in the organ of Zuckerkandl resulting in improper cardiac 
function and circulatory failure (9). In ICR/129 sv genetic background, HIF-2α mice 
died because of defects in remodeling and formation of the vascular network (10). 
Furthermore, the deficiency of sufficient surfactant production by alveolar type 2 cells 
led to respiratory stress syndrome and subsequently death of neonatal mice (11). So 
far, no HIF-3α knockout mouse has been reported. 
 
4.1.3 Expression pattern of HIF-α subunits 
HIF-1α is ubiquitously expressed in different tissues and organs. In contrast to HIF-
1α, HIF-2α and HIF-3α show a more restrictive expression pattern. HIF-2α also 
known as endothelial PAS protein 1 (EPAS-1) shares 48% identity with HIF-1α and 
its expression is highly detectable in embryonic and adult endothelium (12). Human 
HIF-3α has 6 alternative expressed splice variants (HIF-3α1 to 6). HIF-3α1 is 
proposed to be the full length protein and is mainly expressed in the kidney (13). 
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4.1.4 Composition of the HIF complex 
HIF-α subunits contain a N-terminal basic helix-loop-helix (bHLH) DNA binding 
domain and a PAS domain that mediates HIF-1β dimerization (Fig. 1). Furthermore, 
HIF-α subunits possess two transactivation domains (TAD), a C-terminal TAD 
(CTAD) and a N-terminal TAD (NTAD) that overlaps with the oxygen-dependent 
degradation domain (ODDD) (Fig. 1). The ODDD is required for the stability of HIF-α 
subunits (14). Furthermore, a nuclear localization signal can be found. In contrast to 
HIF-1α and HIF-2α, HIF-3α1 does not contain a CTAD. Interestingly, most prominent 
expression of a HIF-3α splice variant (HIF-3α4) or known as inhibitory PAS (IPAS) 
protein is observed in mouse corneal epithelium. It might inhibit vessel formation to 
maintain an avascular phenotype in the cornea by binding to HIF-1α and therefore 
preventing HIF-1 complex formation and activation of HIF-1 induced target gene 
expression (15). Furthermore, the splice variant HIF-3α4 forms a complex with HIF-
2α and interferes with the HIF-2 dependent hypoxia-induced gene expression and 
prevents tumor progression (16). 
 
 
 
Figure 1. Domain architecture of HIF-α and HIF-1β 
bHLH - basic helix-loop-helix domain; PAS - PER/ARNT/SIM; ODDD - oxygen-dependent degradation (ODD) domain; NTAD - 
N'terminal transactivation domain; CTAD – C-terminal transactivation domain; NLS - nuclear localization sequence; LZIP – 
leucine zipper domain 
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4.1.5 Oxygen-dependent regulation of HIF-α protein stability and 
transactivation activity 
The protein levels of HIF-α subunits are tightly oxygen-dependently regulated and its 
half-live is less than 5 minutes. However, HIF-α mRNA levels are not affected. In 
normoxia, HIF-α subunits are rapidly degraded by the ubiquitin-proteasome pathway 
irrespective of its sub-cellular localization (17). 
 
Figure 2. Oxygen sensing by HIF hydroxylases (18) 
HIF-α subunits are regulated by PHDs and FIH via oxygen-dependent hydroxylation of conserved prolyl residues which leads to 
a pVHL mediated proteasomal degradation and inhibition of transcription of target genes by disrupting co-activator recruitment 
of the transcription initiation complex. Under reduced pO2 HIF hydroxylase activity is decreased thereby leading to HIF-α 
stabilization and induction of expression of target genes.  
A prerequisite for the ubiquitin-dependent degradation of HIF-α subunits by the 26S 
proteasome is the hydroxylation of specific prolines within the ODDD by oxygen-
dependent prolyl-4-hydroxylases (PHDs) and subsequent binding of the von Hippel-
Lindau (pVHL) tumor suppressor protein (19), (20), (21), (22). VHL is the recognition 
component of a multi-component E3 ubiquitin ligase (pVHL - elongin B - elongin C - 
Cul2 - Rbx) and targets HIF-α subunits for ubiquitinylation and rapid destruction by 
the 26S proteasome (Fig. 2). Loss of pVHL stabilizes HIF-α subunits under normoxia 
as manifest in vascular tumors like clear cell carcinoma, hemangioblastoma and 
pheochromocytoma (21). Additionally, the mouse acetyltransferase arrest-defective-1 
(mARD1) has been suggested to acetylate amino acid (aa) 532 of HIF-1α, thereby 
enhancing the association with pVHL and accelerating HIF-1α degradation (23). 
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Contrary, other groups found no evidence for HIF-1α destabilization by acetylation 
(24), (25), (26).  
Under hypoxia due to decreased PHD activity, HIF-α subunits are stabilized, 
translocate to the nucleus, heterodimerize with constitutively expressed HIF-1β, bind 
to hypoxia responsive element (HRE) and drive gene expression that mediates the 
adaptation to altered pO2 (27). Furthermore, HIF transcriptional activity is regulated 
by factor inhibiting HIF (FIH) (28). FIH hydroxylates aa asparagine (N) 803 in HIF-1α 
and N847 in HIF-2α in the CTAD. Asparagine hydroxylation interferes with the 
binding of the cysteine/histidine rich (CH)-1 domain of p300/CBP and prevents 
transcriptional activation of the HIF complex (29). Michaelis Menten constant (Km) 
values of O2 are in the range between 230-250 µM for the prolyl-4-hydroxylases 
which correlates with the oxygen partial pressure and 90 µM for FIH (30), (31). 
Recently, lower Km values of O2 for the PHDs have been suggested depending on 
the length of the used HIF-derived substrate (32). This mechanism provides an 
elegant way to modulate oxygen-dependently HIF-α protein stability and 
transcriptional activity: Because PHDs are absolutely dependent on molecular 
oxygen, it provides a direct link between oxygen tension and HIF-α protein stability. 
Furthermore, oxygen-dependent full HIF complex activation is accomplished by a 
further drop in pO2 leading to inactivation of FIH. 
 
4.1.6 HIF complex function  
HIF-α/β dimers bind to HREs and induce target gene expression. HREs consist of 
one or multiple minimal cis HIF binding sites (HBS) with the core sequence 
G/ACGTG (33). 
So far, HIF is known to bind to about 70 HREs in genes and by microarray analysis it 
is suggested that there might exist more than 200 potential HIF target genes (33). In 
Figure 3 an overview about HIF target genes is given that are involved in the 
systemic, local and cellular response to hypoxia. HIF induces the expression of EPO 
that stimulates the production of red blood cells or the formation of new blood vessels 
by VEGF induction. 
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Figure 3. Putative induced target genes by HIF’s (33) 
ANP - atrial natriuretic peptide; BNIP3 - Bcl2/adenovirus E1B 19kDa interacting protein 3;CAIX - carbonic anhydrase 9; eNOS - 
endothelial nitric oxide synthase; GAPDH - glyceraldehyde-3-P-dehydrogenase; Id2 - inhibitor of DNA binding 2; GRP94 - 94 
kDa glucose-regulated protein; IGFBP-1 - insulin like growth factor binding protein 1; Mcl-1 - myeloid cell leukaemia 1; MDR1 - 
multi drug resistance protein 1; MT1 - metallothionein 1;  Noxa - phorbol-12-myristate-13-acetate-induced protein 1; PAI-1 - 
plasminogen-activator inhibitor 1; PHD2/3 - prolyl-4-hydroxylase 2/3; REDD1 - regulated in development and DNA damage 
response protein; TERT - telomerase reverse transcriptase; TGF-β3 - transforming growth factor β3; VEGF - vascular 
endothelial growth factor;  
In addition, oxygen deprivation forces cells to change their cellular metabolism to 
anerobic glycolysis and lactate production to generate ATP. The HIF induced target 
gene pyruvate dehydrogenase kinase 1 (PDK1) phosphorylates pyruvate 
dehydrogenase (PDH) thereby actively suppressing the conversion of pyruvate to 
acetyl-CoA (34), (35). Therefore, pyruvate is exluded from mitochondrial consumption 
and PDK1 promotes the conversion of pyruvate to lactate by anerobic glycolysis. 
Furthermore, cell growth and proliferation is altered in hypoxia. It has been shown 
that mammalian target of rapamycin (mTOR) function is regulated upon hypoxia by 
HIF-1. Under hypoxia (1.5% O2) it has been published that mTOR as well as its 
targets are regulated to conserve energy (36). Essential for this inhibition of the 
mTOR pathway and therefore cell growth and proliferation, is a functional tuberous 
sclerosis (TSC) complex as well as the newly discovered protein regulated in 
development and DNA damage response (REDD1) (Fig. 10). Mouse embryonic 
fibroblasts (MEFs) derived from Tsc, p53 double knockout embryos as well as Redd1 
deficient MEFs were not able to downregulate S6 kinase (S6K) under hypoxic 
conditions. Accumulation of REDD1 and RNA interference (RNAi)-mediated 
downregulation of tuberous sclerosis complex 2 (TSC2) tumor suppressor protein 
abolished this effect, placing REDD1 upstream of the TSC1/2 complex (37). 
Additionally, under growth supporting conditions TSC1/2 function is inactivated by 
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phosphorylation-dependent interaction with 14-3-3 proteins. In response to hypoxia, 
induced REDD1 expression by HIF-1 competes with TSC2 for 14-3-3 protein binding 
and subsequently stimulates TSC1/2 mediated mTOR pathway inhibition (38). 
HIF-1 and HIF-2 complexes are closely related proteins and stimulate the expression 
of similar as well as unique target genes. HIF-1 appears to control glucose 
metabolism to induce a shift from aerobic to anerobic glycolysis like 
phosphoglycerate kinase (PGK), lactate dehydrogenase A (LDHA) and carbonic 
anhydrase 9 (CAIX) (39), (40), (41). HIF-2 might influence long-term hypoxic 
response and sustain mitochondrial homeostasis (42), (43). EPO, Oct4, Cyclin D and 
antioxidant enzymes Sod2 and Frataxin are suggested to be specific HIF-2 target 
genes (44), (45), (46), (47). Other target genes like VEGF, glucose transporter 1 
(GLUT1) and NDRG1 are regulated by both proteins (48). So far, more research is 
required to discriminate between HIF-1 and HIF-2 dependent target gene expression. 
HIF-1α and HIF-2α possess two TADs: NTAD and CTAD. NTAD shows low 
homology to CTAD (49). Recently, the different roles of the NTAD and CTAD in 
regard to differential HIF target gene expression have been investigated. Results 
suggest that the TCAD is the predominant domain that contributes to the 
transcriptional activation of HIF target genes. However, a subset of genes was 
exclusively dependent on NTAD (50). NTAD determines the HIF-1 and HIF-2 target 
specificity. The replacement of HIF-1α NTAD by HIF-2α NTAD was sufficient to 
convert HIF-1α to HIF-2α transactivation activity (51). 
 
4.1.7 Regulation of HIF function 
HIF is a target of posttranslational modification apart from hydroxylation. HIF-1α 
nitrosylation occurs at cysteine (C) 533 during tumor irradiation through generation of 
nitric oxide (NOS) by inducible NOS (iNOS) of activated macrophages in the tumor 
microenvironment (52). This posttranslational modification of HIF-1α resulted in HIF-
1α protein accumulation and appears to be an alternative pathway independent of 
PHD-mediated HIF-1α degradation pathway. Nitrosylated HIF-1α ODDD does not 
bind to pVHL thereby enhancing HIF-1α accumulation and target gene expression. 
Additionally, nitrosylation of C800 of HIF-1α has been reported (53), (54). p300 
binding to nitrosylated HIF-1α was decreased by quantitative interaction studies (53). 
Contrary, nitrosylation enhanced HIF-1 transcriptional activity as well (54). 
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HIF is described to be a phosphorylation target by the mitogen-activated protein 
kinase (MAPK) pathway. Initial studies demonstrated an in vitro HIF phosphorylation 
by p42/p44 MAPK, resulting in enhanced HIF transcriptional activity (55), (56). 
Phosphorylation of Serine (S) 641 and 643 by MAPK governs exportin 1 (CRM1) 
mediated nuclear translocation of HIF-1α and thereby controls HIF-1 transcriptional 
activity (57). Other reports suggested that p42/p44 MAPK is required for p300/CBP 
phosphorylation and subsequent binding to HIF-1α CTAD (58), (59). 
In hypoxia, HIF-1α is modified by small ubiquitin-related modifier (SUMO) but this 
posttranslational modification and its functional consequence are a matter of debate. 
HIF-1α consists of 4 potential sumoylation sites but only lysine 391, 477 near the 
ODDD have been shown to be modified by SUMO 1 to 3 (60), (61). Recently, 
knockdown of Sentrin/SUMO-specific protease 1 (SENP1) in mice resulted in severe 
fetal anemia and embryonic death around day E13 to E15. These mice produced 
insufficient amount of EPO due to decreased stabilization of HIF-1α. Further analysis 
showed convincingly that sumoylated HIF-1α is VHL-dependently degraded by the 
proteasome and SENP1 could stabilize HIF-1α by removing SUMO from HIF. 
Therefore, hypoxic sumoylation might serve as a degradation signal in addition to 
proline hydroxylation for HIF-1α protein destruction even under hypoxic conditions. 
Contrary, other reports suggested that sumoylation stabilizes HIF in hypoxia and 
influences its protein stability and/or transcriptional activity (61), (60), (62). 
Furthermore, HIF-1α protein levels might be dependent on its protein synthesis rate. 
It has been shown that a variety of growth factors, cytokines and mutated proteins 
involved in the mTOR signalling cascade, like loss of phosphatase and tensin 
homolog (PTEN) protein, induce HIF-1α protein synthesis due to increased 
translation (63), (64), (65), (66). Loss of promyelocytic leukaemia protein (PML) 
facilitates tumor angiogenesis by enhancing HIF-1α translation (67). Interestingly, 
under hypoxic conditions where mTOR activity and subsequently overall mRNA 
translation is reduced, HIF-1α mRNA however is still efficiently translated (68), (69). 
Originally, Lang et al. found an internal ribosome entry site (IRES) in the 
5'untranslated region (UTR) of the mouse HIF-1α mRNA. This IRES allows an 
hypoxia-independent alternative mode of translational initiation and does not require 
eIF4E and a 5’cap (68). The polypyrimidine tract-binding protein (PTB) interacts with 
HIF-1α IRES and is enhanced upon hypoxia. PTB binding to HIF-1α mRNA IRES 
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participates in efficient translation in hypoxia (70). However, the widely used 
measurement of cellular 5’UTRs for IRES activity by dicistronic reporter plasmids has 
been questioned (71), (72), (73). 
Additionally, the heat shock protein 90 (Hsp90) has been implicated in HIF regulation. 
Under normoxia, Hsp90 and Hsp70 are bound to the PAS B domain of HIF-α 
subunits and are replaced by ARNT upon hypoxia. Embryonic stem (ES) cells 
deficient for Hsp90 as well as treatment of the wild-type ES cells with geldanamycin 
delayed hypoxic HIF-1α accumulation (74). The receptor of activated protein C 
kinase 1 (RACK1) has been identified as a HIF-1α interaction partner. It binds to the 
PAS A domain of HIF-1α and competes with Hsp90 for binding. RACK1 depletion 
slightly stabilizes HIF-1α in normoxia and enhances HIF normoxic and hypoxic 
transcriptional activity. RACK1 mediated HIF-1α degradation is not influenced by 
oxygen but is dependent on functional 26S proteasome. RACK1 facilitates HIF-1α 
binding to elongin-C and therefore ubiquitinylation and degradation (75). RACK1-HIF-
1α interaction is stabilized by spermidine/spermine-N-acetyltransferase-1 (SSAT1) 
(76). Interestingly, Hsp90 inhibitor 17-AAG, 17-DMAG and geldanamycin show a 
biphasic pattern in regard to HIF-accumulation and transcriptional activity. With low 
doses, the HIF transcriptional activity increased whereas under higher concentration 
HIF activity was lowered (77). 
INTRODUCTION 
- 17 - 
4.2 Prolyl-4-hydroxylases (PHDs) 
4.2.1 Discovery and characterization of PHDs 
It remained unknown how cells sense changes in oxygen partial pressure and 
subsequently regulate the stability of HIF-α subunits until quite recently. In 2001, by 
candidate gene approach in C.elegans a unique HIF prolyl-4-hydroxylase named 
egg-laying abnormal-9 (EGL-9) was discovered (78). In mammals, three HIF-prolyl 
hydroxylase domain containing proteins (PHDs) PHD1 (alternatively termed EGLN2, 
HPH3), PHD2 (EGLN1, HPH2) and PHD3 (EGLN3, HPH1) were identified (78), (79), 
(80). These enzymes are proposed to be the cellular oxygen sensors because of 
their ability to modulate HIF-α stability in dependency of the oxygen concentration. 
Two PHD3 splice variants were described as a result of alternative splicing (81), (30). 
In PHD3∆4 exon 4 is deleted and results in 646 bp long mRNA. The 24 kDa PHD3∆4 
protein is still functionally active. PHD3∆1 has a large deletion in exon 1 and the 
expressed 13 kDa protein does not retain it’s prolyl hydroxylase activity. Two splice 
variants have been reported for PHD2 lacking either exon 3 or 4 and led to inactive 
polypeptides (30). So far, no splice variant has been described for PHD1. However, a 
34 aa shorter isoform (p40) of PHD1 is generated by alternative translational initiation 
with a molecular weight (MW) of 40 kDa which retains full hydroxylase activity (82). 
PHD1 p40 is less stable compared to the full length PHD1 with a MW of 43 kDa and 
like PHD1 not oxygen-dependently regulated. Recently, an endoplasmatic reticulum 
associated PHD proline 4-hydroxylase-related protein 4 (PH-4), was discovered (83), 
(84). This enzyme is able to hydroxylate both prolines in the ODDD of HIF-1α in vitro 
but the functional relevance of PH-4 in the oxygen-sensing pathway needs to be 
clarified. 
 
4.2.2 PHDs are members of the 2-oxoglutarate-dependent family of 
dioxygenases 
PHDs belong to the non-hem, Fe2+- and 2-oxoglutarate-dependent family of 
dioxygenases. The catalytic domain consists of eight conserved antiparallel β-
strands, which comprises the two β-sheets that constitute a jelly-roll-motif (85). The 
first known 2-oxoglutarate dioxygenase was the procollagen prolyl-hydroxylase that 
catalyses the prolyl hydroxylation of procollagen that is essential to stabilize the triple 
helix structure of collagen (86). Members of the 2-oxoglutarate-dependent  
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Figure 4. Proline hydroxylation catalyzed by HIF hydroxylases (87) 
dioxygenases require di-oxygen, Fe2+ and 2-oxoglutarate for there enzymatic 
reaction.During catalysis, one oxygen atom is incorporated to a peptidyl proline (P) of 
the substrate to form a hydroxyproline and the other oxygen atom is used for a 
coupled decarboxylation reaction that converts 2-oxoglutarate into succinate and CO2 
(Fig. 4). Additionally, ascorbate is an essential component for a functional 
hydroxylase reaction and might protect the iron in the active center of the enzyme or 
the enzyme itself from oxidation by uncoupled reaction beside target hydroxylation 
(88), (89). Replacement of ascorbate by the antioxidant N-acetyl-L-cysteine did not 
restore PHD activity in in vitro VHL-dependent hydroxylation assays and emphasizes 
the important requirement of ascorbate for enzymatic activity (89). 
PHD1 to 3 hydroxylate P564 of the ODDD of HIF-1α in vitro whereas P402 is only 
hydroxylated by PHD1 and PHD2 in vitro (78). Overexpression of each PHD in 
cellular systems suggests that all PHDs are active on both proline hydroxylation sites 
(90). At 20% oxygen P564 of HIF-1α was hydroxylated prior to P402 and 
hydroxylated P564 was required for P402 hydroxylation. PHD1 and PHD2 preferred 
to hydroxylate P564 based on its conformational structure whereas PHD3 favored 
P564 sequence independently of its localization. With decreasing pO2 P402 
hydroxylation was inhibited prior to P564 hydroxylation inhibition. Loss of P402 
hydroxylation was already sufficient to stabilize HIF-1α at 0.5% oxygen whereas 
P564 was still hydroxylated (90). 
PHDs are capable to hydroxylate HIF-1α peptides in vitro but with different specific 
activity. PHD2 and PHD3 from crude cell extracts from Sf9 cells display similar 
activity in a pVHL capture assay, PHD1 possesses less activity (91). However, in 
cellular systems PHDs are differentially expressed and therefore contribute differently 
to HIF-α hydroxylation depending on the enzyme abundance (92). Generally, the 
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hydroxylated prolyl residue for HIF-α resides in a strongly conserved LXXLAP motif 
(X stands for any amino acid) but only the hydroxylation target proline is absolutely 
mandatory for recognition (93), (94), (95). 
 
4.2.3 Tissue distribution and sub-cellular localization of PHDs 
PHD enzymes are differently expressed in tissues and organs. Using of monoclonal 
anti-PHD antibodies, a comprehensive overview about human PHD tissue distribution 
and sub-cellular localization has been done by Soilleux et al. (96). Most pronounced 
differences were observed in the heart with highest PHD3 expression and testis with 
strong PHD1 expression. PHD2 was widely found in most tissues (97), (83). 
On sub-cellular level, fluorescent-fusion or tagged PHD1 protein was exclusively 
localized in the nucleus whereas PHD2 was found in the cytosol. PHD3 was equally 
detected in both compartments (98), (93). 
In primary rat hepatocytes endogenous PHD1 was mainly found in the nucleus 
though at 1% O2 PHD1 was bound to cytoplasm membrane and translocated back to 
the nucleus during reoxygenation (99). Endogenous PHD2 and PHD3 were 
described in the cytoplasm as well as in the nucleus. In hypoxia, PHD2 remained in 
the cytoplasm. Interestingly, some peroxisomal associated pattern was observed for 
all of the PHDs and additional mitochondrial staining for PHD2 and PHD3. 
 
4.2.4 Genetic ablation of PHDs 
Genetic disruption of the PHD2 gene led to embryonic lethality between embryonic 
days E12.5 and E14.5 whereas PHD1 and PHD3 knockout did not affect embryonic 
viability (100). Phd2-/- mice display developmental defects in the heart and the 
placenta leading to embryonic death. The cardiac function is disturbed as evident by 
enlarged intraventricular lumen, not fully developed trabeculae and closed 
interventricular septum. The placenta structure appeared to be irregulary formed by 
improper distribution of spongiotropoblast and giant cells. The labyrinth of highly 
vascularized villi of the placenta based on the fetus-derived blood vessels and the 
chorionic ectoderm was completely disorganized. Defects of placental development 
were a result of increased HIF-α protein levels. However, HIF-1α protein amount was 
not elevated in Phd2-/- mice hearts suggesting either a partial compensatory effect of 
PHD1 or 3 or PHD2 has other function apart from HIF-α hydroxylation (100). Global 
conditional inactivation of the PHD2 gene in adult mice resulted in mature and 
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perfusable blood vessels and increased vascular density in a variety of organs like 
ear, heart, liver, lung and kidney. HIF-1α accumulation led to increased expression of 
serum VEGF-A, but not elevated VEGF-A, angiopoietin 1 (ANG1) and ANG2 mRNA 
levels in various organs. Interestingly, despite inefficient disruption of Phd2 in brain, 
excessive vascular growth was observed and might be a result of systemic effects 
(101). As expected, somatic inactivation of PHD2 enhanced serum EPO levels and 
subsequently increased red blood cell production. Long term induced EPO protein 
caused polycythemia and as a result of it, hyperviscosity and cardiac dysfunction.  
Subsequently, these mice died from venous congestion and dilated cardiomyopathy 
(102), (103). Interestingly, HIF-1α protein but not HIF-2α accumulated in liver and 
kidney but only serum as well as kidney erythropoietin was increased. Heterozygous 
Phd2 gene deletion did not facilitate erythrocytosis. Polycythemia did not arise from 
single Phd1-/- or Phd3-/- mice but double knockout mice showed induced elevated 
EPO levels by upregulating HIF-2α protein in the liver. Loss of Phd1 gene shifted 
glucose metabolism from aerobic glucose oxidation to anerobic glycolysis thereby 
lowering oxygen consumption in skeletal muscle fibers. Genetic ablation of PHD1 
enhanced PDK1 and PDK4 expression and therefore restricted the entry of pyruvate 
in the Krebs cycle. These mice showed a worse endurance performance. Muscle 
fibers were protected from ischemic necrosis after femoral artery ligation and loss of 
PHD1 induced hypoxic tolerance (104). Genetic ablation of PHD3 increased the 
number of superior cervical ganglion neurons in the sympathoadrenal system; 
however, the sympathoadrenal function seems to be disturbed and led to systemic 
low blood pressure (105). 
 
4.2.5 Regulation of PHD expression and degradation 
Proline hydroxylation is a non-reversible process and therefore PHDs itself are 
regulated on protein as well as on RNA levels. PHD2 and PHD3, but not PHD1 
mRNA expression is oxygen-dependently regulated by HIF. PHD2 contains a 
functional HBS in the CpG island promoter region that is located approximately 3.5 
kb upstream of the translation start codon (106). Interestingly, the hypoxia-responsive 
HBS of PHD3 is found in the first intron about 12 kb downstream of transcription 
initiation (107). Both proteins are direct HIF targets and induced under reduced 
oxygen tension (33). Enhanced hydroxylation activity due to increased PHD protein 
amount upon hypoxia accelerated HIF-1α protein degradation during reoxygenation 
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process (108), (109). Moreover, in long-term hypoxia increased PHD2 and PHD3 
protein levels can compensate for reduced pO2 and attenuate HIF-1α protein levels 
and it’s target genes limiting the hypoxic response (110). Apart from oxygen, 
stimulation of serum-starved cells with transforming growth factor β (TGFβ) lowered 
PHD2 mRNA as well as protein amount and consequently prolonged HIF-1α protein 
stability (111). Oestrogen stimulation of breast cancer cell lines enhanced PHD1 
mRNA (112), (92). Furthermore, PHD3 expression is modulated in different cell types 
by p53, by stimuli inducing smooth muscle cell differentiation and by nerve growth 
factor withdrawal (113), (114), (115), (116). Aging augmented specifically PHD3 
protein in rat heart, skeletal muscle and liver and it could be countervailed by caloric 
restriction (117), (118). 
PHDs display distinct mRNA and protein regulation as well as different degradation 
pathways. PHD1 and PHD3 have been reported to be targeted by E3 ubiquitin ligase 
Siah1/2 and subsequently proteasomal degraded (119). In Siah1/2-/- MEFs PHD3 
protein stability is prolonged and resulted in decreased HIF-1α stability and HIF-
dependent target gene expression. The lack of the N-terminal extension of PHD3 
compared to PHD1 and PHD2 governs the susceptibility to Siah1/2-dependent 
ubiquitinylation and degradation (120). PHD2 is neither ubiquitinylated and degraded 
by the proteasome pathway (manuscript in preparation). PHD2 specifically interacts 
with the peptidyl prolyl cis/trans isomerase FK506-binding protein 38 (FKBP38) (121). 
Knockdown of FKBP38 by RNA interference (RNAi) increased PHD2 protein amount 
and prolonged its stability. PHD2 protein half life might depend on FKBP38 sub-
cellular localization (manuscript in preparation). 
 
4.2.6 Modulation of PHD activity 
4.2.6.1 Oxygen 
Oxygen is the limiting factor in the prolyl hydroxylase reaction. Therefore, availability 
of oxygen modulates the prolyl-4-hydroxylases. The Km values of the three PHDs 
were determined by an in vitro hydroxylation-coupled decarboxylation assay. 
Radioactively labeled 2-oxo(1-14C)glutarate was converted to succinate and 14CO2 by 
using a 19-residue HIF-1α derived peptide as substrate. The Km values for the three 
PHDs range between 230-250 µM and correspond to the Km value for oxygen under 
normoxic conditions (30). Hence, changes in oxygen might easily limit prolyl 
hydroxylation and indicate the PHDs are effective oxygen sensors. However, Km 
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values of the PHDs for O2 decreases with increased peptide length and it is most 
likely that the Km value might be lower than previously determined (32). Interestingly, 
tissue pO2 is much lower (between 4-20 mm Hg) compared to 104-150 mm Hg in 
lungs. Clearly, the Km value is still higher than tissue pO2 and provides the basis for 
regulated PHD enzymatic reaction and HIF-α turnover (122). Furthermore, oxygen 
exchange of cells with its environment is not only governed by free diffusion but is 
also mediated by Aquaporin-1 (AQP-1) channels (123). AQP-1 overexpression 
accelerated HIF-1α accumulation and HIF target gene expression in hypoxia and 
downregulation of AQP-1 in normoxia promoted increased HIF-α levels. Thus, AQP-1 
governs the flux of oxygen across the membranes depending on oxygen content in 
the environment thereby modulating the oxygen sensing pathway. 
 
4.2.6.2 Energy metabolism intermediates 
Prolyl-4-hydroxylase reaction requires tricarboxylic cycle (TCA) intermediates and 
limitation as well as excess of the Krebs cycle metabolites might affect PHD activity. 
Addition of oxaloaccetate, pyruvate and lactate promotes HIF-1α accumulation 
independently of oxygen in tumor cell lines (124), (125), (126). Enhanced HIF-1α 
protein levels were reversed by addition of ascorbate, cysteine, histidine and ferrous 
iron (126). Pyruvate and oxaloaccetate directly bind to the 2-oxoglutarate binding site 
of PHDs and thereby these enzymes were inhibited in normoxia (126), (127). Other 
groups did not find a pyruvate or oxaloaccetate dependent PHD inhibition in vitro or 
in cellular assays (127), (128). Furthermore, fumarate and succinate inhibit HIF-prolyl 
hydroxylases in vitro and prolonged HIF-1α half-life in cell culture models (129). 
Individuals with germline mutations in fumarate hydratase (FH) that catalyzes the 
conversion of fumarate to malate in the Krebs cycle are more prone to leiomyomas 
and renal cell cancer (130). Mice with conditional knockout of Fh1 in the kidney 
developed renal cysts similar to human renal carcinomas (131). Mutations in the 
succinate dehydrogenase (SDH) are associated with high risk of developing 
paragangliomas and pheaochromocytomas (130). SDH converts succinate to 
fumarate. These tumors are characterized by accumulated HIF-1α and induced HIF 
target gene expression like VEGF leading to high microvessel density and tumor 
vascularization. Knockdown of SDH or FH by RNAi or succinate or fumarate addition 
in tumor cells stimulates HIF-1α accumulation and target gene expression by 
interfering with prolyl hydroxylase activity (132), (133), (129). Impaired PHD activity in 
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SDH-deficient cells was re-activated by treatment with cell permeating α-
ketoglutarate derivatives and therefore restored HIF-1α impaired protein degradation 
(134). It is important to note that lack of SDH or FH might not only compromise PHDs 
but also other 2-oxoglutarate-dependent oxygenases in cellular systems (135). 
 
4.2.6.3 Iron and divalent ions 
PHDs belong to the family of Fe(II)- and 2-oxoglutarate-dependent dioxygenases that 
have a common jelly-roll motif (85). The jelly-roll motif possesses an iron-binding site 
in the active center. Purification of PHD2 to homogeneity co-purified endogenous iron 
and surprisingly zinc. Iron is mainly in its low spin form (Fe2+) and only little ferric iron 
(Fe3+) was observed (136). Km values for iron for the three PHDs vary between 0.1 
and 0.03 µM and its high affinity is consistent with strong iron binding to PHDs that is 
only slightly competed by the iron chelator desferrioxamine (DFX) and a variety of 
metals like Cd2+, Ni2+, Mg2+, Mn2+ and Co2+ (137). But these compounds have been 
reported to have an impact on the HIF system. So it is most likely that other 
mechanisms in spite of competition exist to inactivate the HIF hydroxylases and 
thereby activating the HIF system. Interestingly, Cu2+ may attach to the active center 
and displace iron from its coordinated binding to histidine, aspartate/glutamate and 
histidine ligands (136).Therefore, it is able to stabilize HIF-1α under normoxia and 
increased reporter gene expression (138). 
Furthermore, Ca2+ has been found to be involved in HIF pathway regulation. Cells 
treated with the specific Ca2+ chelator BAPTA, but not with Ca2+ ionophore A23187, 
HIF-1α was stabilized and accumulated in the nucleus (139). It interfered with PHD2 
activity and addition of Fe2+ did not reverse the observed effect. Interestingly, rather 
changes in intracellular Ca2+ distribution than Ca2+ chelation contributed to PHD 
inhibition in an unknown manner.  
 
4.2.6.4 Nitric oxide (NO) 
Several groups suggested that nitric oxide derived from diverse NO donors or 
produced by iNOS provokes HIF-1α accumulation in normoxia (140), (141). NO-
mediated HIF-1α stabilization is mainly caused by lowered PHD activity and might be 
mediated by formation of inhibitory nitrosothiols in the PHD protein, competing with 
oxygen binding or leading to oxidation at the iron in the catalytic center is oxidized 
(126). Furthermore changes in protein translation by NO-induced changes in PI3K 
INTRODUCTION 
- 24 - 
and MAPK signaling pathways might contribute to enhanced HIF-1α protein levels 
(142), (143). Contrary, in hypoxia the opposite effect is observed. Wang et al. 
suggested that the inhibitory effect of NO donors on HIF-1α protein accumulation 
might be due to changes in PHD activity in hypoxia (144). NO is a well known 
inhibitor of cytochrome c (Cyt c) oxidase (complex IV in the respiratory chain) and 
inhibits oxygen consumption by mitochondria. Therefore, oxygen is redistributed 
towards PHDs and enhances their activity even under reduced pO2 and destabilizes 
HIF-α (145). 
 
4.2.6.5 Reactive oxygen species (ROS) and antioxidants 
Mitochondria have been implicated in regulating the oxygen sensing pathway. 
Inhibition of mitochondrial activity by mitochondrial inhibitors, deletion of 
mitochondrial DNA or genetic ablation of Cyt c impairs HIF-1α accumulation but the 
molecular mechanism is controversially discussed. Chandel et al. proposed that 
increased ROS under hypoxic conditions affected HIF-target gene expression (146). 
Complex III of the mitochondrial electron transfer chain (ETC) might serve as the 
ROS-generating protein complex (147), (148). However, different groups with 
different cellular models and conditions suggest different ROS levels and 
consequences for HIF-1α accumulation. 
The impact of antioxidants to influence the oxygen signaling pathway might point 
towards a functional role of ROS in the HIF system. In tumors derived from c-myc 
dependent cells, tumorigenesis was reduced after treatment with N-acetylcysteine 
and ascorbate by decreasing HIF-1α levels. Reduction of tumor volume was 
dependent on functional PHD2 as well as pVHL (149). Furthermore, ascorbate is 
suggested to prevent oxidation of catalytic ferrous iron in prolyl hydroxylases (126) 
and ascorbate enhanced hydroxylation of a fusion protein containing of  a GAL4 (β-
galactosidase) DNA-binding domain, an HA (hemagglutinin Ha1 fragment) peptide 
and human HIF-1α ODDD in vitro thereby changing the mobility in SDS-PAGE 
analysis (128). Jun D is a transcription factor involved in oxidative stress defense and 
hydrogen peroxide H2O2 metabolism. Genetic ablation of Jun D impaired prolyl 
hydroxylase activity by increasing H2O2 and consequently iron oxidation to Fe3+ 
possibly through the Fenton reaction (150). Of note, Mucin 1 (MUC1) suppresses 
hypoxia induced accumulation of ROS, induces PHD3 expression and subsequently 
attenuates HIF transcriptional activity (151). 
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Another proposed hypothesis is the redistribution of oxygen after mitochondrial 
inhibition. Mitochondria are the main oxygen consuming organelles and inhibition of 
its function results in decrease in oxygen usage. Therefore, more oxygen is present 
in the cytosol and might activate prolyl hydroxylases even under hypoxia (145). 
Consistent with these data, mild hypoxia (3% O2) prevented HIF-1α accumulation 
after mitochondrial inhibition in conventional dishes but not in gas-permable dishes 
where the oxygen gradient in the cell culture medium was eliminated. This effect was 
not observed under severe hypoxia (0.1% O2) (152). Additionally, in PC12 AQP-1 
overexpressing cells, HIF-2α was less stabilized after mitochondrial inhibition in 
hypoxia due to increased O2 permeability (123). 
 
4.2.7 Interactors and non-HIF-α hydroxylation substrates of PHDs 
PHDs are not only regulated by its activity however interaction with other proteins 
might influence as well their function. We found a specific interaction of PHD1 with 
the onconeural antigen cerebellar degeneration-related protein 2 (Cdr2) (Kuppusamy 
et al., manuscript in preparation). Forced expression of Cdr2 reduced the expression 
of hypoxically induced target genes due to changes in the HIF transcriptional activity 
and HIF-1α protein accumulation. 
PHD3 is suggested to be a target of the cytosolic chaperonin TCP1 ring complex 
polypeptide (TriC) (153). It is proposed that it plays a role in folding and specific 
complex formation because PHD3 tends to form aggregates (153), (154). The MAPK 
organizer 1 (Morg1) specifically interacts with PHD3 and supports PHD3 activity 
(155). Furthermore, it has been reported, that PHD3 is upregulated during C2C12 cell 
line skeletal muscle differentiation (156). Interestingly, downregulation of PHD3 by 
RNAi and antisense oligonucleotides decreased myogenin protein, a member of the 
MyoD family of myogenic regulatory factors that is involved in skeletal muscle 
differentiation. PHD3 interacted with myogenin and therefore facilitated myogenin 
stabilization. Association of myogenin with pVHL enhanced myogenin degradation. 
Thus, PHD3 might compete with pVHL for binding to myogenin and regulates 
myogenin protein stability.  
Apart from HIF-α subunits, only a few potential PHD hydroxylation targets have been 
described so far. The nuclear factor-kappa B (NFκB) controls cell survival, 
proliferation and inflammation and is activated in hypoxia. In an inactive state, NFκB 
is bound to inhibitors of NFkB (IκB) and sequestered in the cytosol by masking the 
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nuclear localization sequence. Activation and translocation of NFkB to the nucleus is 
mediated by phosphorylation-dependent degradation of IκB by IκB kinases (IKKs). 
Downregulation of PHD1 or PHD2 by siRNA or DMOG treatment enhanced NFκB 
activity under normoxia whereas PHD1 overexpression decreased cytokine-
stimulated NFκB activity. Interestingly, IKKβ expression is induced under hypoxia and 
it contains the conserved LXXLAP hydroxylation motif. Mutation of the proline within 
the LXXLAP motif in IKKβ yields in loss of NFκB activity inducibility. Hence, IKKβ 
stability might be determined by oxygen-dependent hydroxylation of PHD1 and 
therefore modulates NFkB activity under reduced oxygen tension (157). 
The hyperphosphorylated carboxyl-terminal domain (CTD) of subunit 1 of RNA 
polymerase II (RP1) interacts with pVHL after UV radiation and DNA damage (158), 
(159). RP1 is targeted for rapid ubiquitinylation and destruction in the 26S 
proteasome. It is suggested that the interaction is hydroxylation-dependent and 
involves the PHDs.  
PHD3 has been reported to modulate oxygen-dependently the activating transcription 
factor 4 (ATF-4) that is involved in cellular stress response (160). ATF-4 is transiently 
upregulated under severe hypoxia or stabilized after MG132 or DMOG treatment. 
PHD3 binds in the zipper II domain of ATF-4 and might modify prolines in this domain 
thereby regulating the half life of ATF-4 ubiquitin- but not pVHL-dependent. Until now, 
no PHD2 hydroxylation target apart from HIF-α has been characterized. 
 
4.2.8 PHD’s relevance in pathological disorders 
A tumor is characterized by uncontrolled cell growth and proliferation. At a size of a 
few millimeters solid tumors suffer from deprivation of oxygen and nutrients. This 
results in hypoxic regions and upregulation of HIF and HIF-induced target gene 
expression thereby ensuring survival and growth of tumor cells (161). Ectopic 
expression of mPHD1 in HCT116 cells decreased in HIF-1 protein levels as well as 
target gene expression. Injection of mPHD1 expressing HCT116 cells in nude mice 
led to smaller tumor size, decreased microvessel density and more necrotic areas 
compared to animals injected with wild-type control cells (162). PHD2 expression in 
head and neck squamous cell carcinomas (HNSCC) is greatly enhanced compared 
to non-cancerous tissues and might be due to tumor hypoxia (163). Interestingly, 
enhanced PHD2 expression correlates with increased aggressiveness of tumors and 
nuclear translocation of PHD2. Pheochromocytomas, tumors derived from neural 
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crest cells, are characterized by germline mutations in Sdh or Vhl gene. Normally, in 
developmental processes of the sympathetic nervous system these cells die upon 
apoptosis after nerve growth factor (NGF) deprivation. PHD3 has been linked to 
promote apoptosis after NGF withdrawal and functions downstream of c-Jun in an 
unknown manner (164). Therefore, inactivation of SDH might limit PHD3 activity and 
subsequently foster neural crest cell survival and promotion of pheochromocytoma 
tumorous development. 
PHD inhibition or activation might be an attractive tool to interfere with pathological 
features of disorders like stroke, anemia and ischemia. Administration of prolyl 
hydroxylase inhibitors increased EPO production by stabilization of HIF-α subunits 
and therefore increased red blood cell mass in rhesus macaques (165). However, 
long-term administration of PHD inhibitors in the treatment of anemia might promote 
tumorigenesis and angiogenesis in patients (166). Downregulation of PHD2 by RNAi 
in mice attenuated ischemia/reperfusion injury of the heart and decreased infarct size 
(167). PHD inhibition reduces cell death in neurons after transient global ischemia by 
bilateral carotid occlusion. Furthermore, in a permanent focal ischemia model where 
a filament is placed in the internal carotid artery to occlude the middle artery, 
administration of PHD inhibitors significantly reduced the infarct volume in the brain 
(168), (169). 
The inflammatory bowel diseases are caused by an overactive immune system in the 
gastrointestinal tract. In murine models, colitis can be induced by administration of 
dextran-sodium sulphate (DSS) and the addition of the prolyl-4-hydroxylase inhibitor 
DMOG attenuated the progression of colitis and lowered the inflammatory markers 
IL-1β, TNF-α, IL-6 and Il-12 (170). 
 
4.2.9 PHD2 
Epstein et al. identified the C.elegans prolyl hydroxylase EGL-9 as the main enzyme 
that oxygen-dependently regulates the HIF-α subunits. By data base analysis the 
three human prolyl hydroxylases PHD1-3 were discovered. In spite of there ability to 
hydroxylate HIF-α subunits in vitro, they differ in there expression pattern, sub-
cellular localization and tissue distribution. They might compensate each other and 
may have as well non-redundant functions.  
PHD2 has been proposed to be the main oxygen sensor (171). Downregulation of 
PHD2 by RNAi was sufficient to stabilize HIF-1α under normoxia in HeLa cells. 
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However, different PHD expression levels in different cell lines do contribute 
differently to the regulation of HIF-α protein (92). PHD protein alignment revealed 
similar amino acid sequences in the C-terminal region that contains the catalytic 
domain but the N-terminal part greatly differs between the different isoforms. 
 
Figure 5. Domain structure of PHD2 
PHD2 consists of a catalytic domain that consists of a prolyl hydroxylase catalytic 
subunit and a MYND (myeloid, nervy and DEAF-1) zinc finger domain (Fig. 5). MYND 
domain containing proteins are widely distributed among mammals, lower eukaryotic 
organisms and plants. MYND domain might function as a protein-protein interaction 
domain that provides the basis for negative transcriptional regulation. Deletion of the 
MYND-type zinc finger in PHD2 has been reported to enhance its activity and it is 
proposed that the PHD2 N-terminal region negatively modulates PHD2 catalytic 
activity (172). The zinc chelator N,N,N’,N’-tetrakis (2-pyridylmethyl) ethylendiamine 
(TPEN) enhanced PHD2 hydroxylation ability but HIF-1α protein regulation was 
impaired due to inhibition of other Zn2+ containing proteins like CBP or Rbx (173). 
Recently the crystal structure of PHD2 from aa 181 to aa 426 containing the catalytic 
subunit was described (174). PHD2, like other members of the family of 2-OG 
dioxygenases, has the typical double-stranded β-helix core fold. It crystallized as a 
homotrimer whereas it was found as a monomer in solution. The active site consists 
of a deep pocket between the major and minor β-sheets with a narrow opening. 
Defects in the Phd2 gene have been described to play a role in the development of 
polycythemia (erythrocytosis). Erythrocytosis is characterized by dramatically 
increased red blood cell mass due to genetic defects in erythroid progenitor cells or 
elevated EPO concentrations. A family was described that suffers from familiar 
erythrocytosis (175). Analysis revealed a C950G point mutation resulting in a amino 
acid exchange at position 317 from proline to arginine and complete loss of PHD2 
hydroxylation activity. In addition, a novel PHD2 missense mutation (R371H) was 
reported (176). This mutation abolished HIF binding to PHD2 and increased HIF-
dependent reporter gene activity. Interestingly, R371 mutation lies close to the 
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Pro317 mutation site and both sides may be part of the HIF-α substrate binding 
groove. Recently, also two frameshift mutations have been described (177). The 
base G at position 606 in exon was deleted resulting in a frameshift and a truncated 
154 aa long C-terminal version of PHD2. Moreover, insertion of adenine between 840 
and 841 bp created a frameshift and subsequently a truncated 143 aa PHD2 product. 
Heterozygous substitution of nucleotide 1129 caused a stop codon in the Phd2 gene. 
So far, only a few proteins were reported to interact specifically with PHD2 and alter 
the oxygen signaling pathway. Amplified in osteosarcoma (OS9) protein was 
described as an essential complex component that promotes HIF-1α prolyl 
hydroxylation by PHD2 and PHD3 by interacting with both components at non-
overlapping sites (178). Using yeast two-hybrid methology, the iron-only 
hydrogenase-like protein 1 (IOP1) was found to interact with PHD2. Downregulation 
of IOP1 enhanced HIF-1α protein amount and target gene expression by increasing 
HIF-1α mRNA levels however the role of PHD2 remained elusive (179). Furthermore, 
PHD2 was reported to bind to the tumor suppressor protein inhibitor of growth family 
member 4 (ING4) and might recruit it to HIF-1 complex and thereby modulating HIF 
transcriptional activity (180). Consistent with these data, PHD2 might interfere with its 
N-terminal transcriptional activity in hypoxia and limit HIF-mediated hypoxic response 
(181). 
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4.3 The peptidyl prolyl cis/trans isomerases (PPIases) 
The superfamily of PPIases comprises the cyclophilins (Cyps), FK506-binding 
proteins (FKBPs), parvulins and the recently found protein serine/threonine 
phosphatase 2A (PP2A). Cyps and FKBPs were previously identified as cellular 
receptors for the clinically used immunosupressive drugs cyclosporin A (CsA), FK506 
(tacrolimus) and rapamycin (sirolimus). These compounds greatly improved the 
treatment of graft rejection after organ transplantation and autoimmune diseases. 
They suppress the maturation and proliferation of native T-cells into effector cells. T-
cell activation occurs after binding of specific antigen associated with the major 
histocompatibility complex (MHC) to the T-cell receptor. Ligand-dependent activation 
of T-cell receptor activates a signal cascade resulting in cellular Ca2+ increase. Ca2+ 
activated calmodulin (CaM) interferes with the serine/threonine phosphatase 
calcineurin and dephosphorylates nuclear factor of activated T-cells (NFAT). 
Dephosphorylated NFAT translocates to the nucleus and induces NFAT-dependent 
target gene expression e.g. interleukin 2. Secreted interleukin 2 binds to its receptor 
on T-cells and activates the mTOR pathway to induce cell growth as well as 
proliferation. CsA forms a ternary complex with cyclophilin A (CypA) and FK506 
associates with FK506-binding protein 12 (FKBP12). Both complexes block 
calcineurin phosphatase activity (182). Furthermore, rapamycin binds to FKBP12 and 
suppresses mTOR kinase activity (183). 
Although structurally unrelated in their amino acid sequences, all members of the 
protein family of PPIases exhibit a potential PPIase activity and can be inhibited by 
different types of immunosuppressive compounds. The catalytic domain contains a 
central β-sheet (184). Interestingly, FK506, rapamycin and CsA do impair PPIase-
enzymatic activity in vitro due to binding in the catalytic pocket of the PPIase domain 
but the immunosuppressive action is rather due to the formation of a ternary complex 
with calcineurin or mTOR, respectively (185), (186), (187). 
The amino acid proline exists in distinct cis or trans conformations within a protein 
structure and provides the basis for a potential regulatory switch (Fig. 6). Though the 
trans state (torsion angle = 180º) is energetically more favorable than the cis 
conformation (torsion angle = 0 º), imide peptide bonds (X-Pro) are found only in 5 to 
6% of all protein structures in cis conformation (188), (189). 
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In fact, prolyl cis/trans isomerization process is a very slow reaction as a result of 
high-energy barrier in conjunction with torsion angle of 90º and is greatly accelerated 
by PPIase catalysis (191). However, the precise mechanism remains to be solved. 
PPIases are thought to be involved in protein folding but growing evidence supports 
their role in regulating cellular processes like cell cycle, signaling regulation and gene 
expression. 
Furthermore, PPIases are suggested to have a chaperone function distinct from the 
PPIase enzymatic activity (192), (193). Chaperones facilitate folding and unfolding as 
well as assembly and disassembly of macromolecular complexes and attenuate 
protein aggregation. The chaperone activity of FKBP51/52 was mapped in vitro in the 
C-terminal region including the tetratricopeptide repeats (TPR) that are well known 
for protein-protein interaction like Hsp90 and separates it from the PPIase domain 
(194). On the other hand, the chaperone function of cyclophilin 40 (Cyp40) was in 
vitro located in the linker region between PPIase domain and TPRs. Hence, the 
domain or required residues containing the chaperone activity remains to be 
identified. 
Cyclophilin prototype cyclophilin A (Cyp18) was first discovered by its high affinity to 
cyclosporin A (195). Subsequently, further cyclophilins were identified by its 
cyclosporine A binding ability. So far, 7 major cyclophilins are known in humans: 
CypA, B, C, D, E, 40, NK (196). Beside a common PPIase activity, they greatly differ 
in there sub-cellular localization and potential function. Cyclophilin A, 40 and NK are 
localized in the cytosol and function in the maturation of neuronal receptors as well 
as steroid-receptor complex formation. Cyclophilin B and C are endoplasmatic 
reticulum secretory pathway associated proteins (197), (198). Cyclophilin D protein is 
part of the mitochondrial permeability transition pore (MPTP) together with the 
 
Figure 6. Prolyl cis/trans isomerization (190) 
PPIases enzymes catalyze the cis /trans isomerization of prolyl bonds between cis and trans conformation.  
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voltage-dependent anion transporter (VDAC) and adenine nucleotide translocase 
(ANT) (199). Cyclophilin D might be inducing a conformal change in ANT by oxidative 
stress and Ca2+ overload thereby opening the pore and stimulating rather necrotic 
cell death than apoptosis (200), (201), (202).  
FKBP12 was isolated by it’s binding capability to FK506 in the cytosol of T-Jurkat 
cells (203). It belongs to a phylogenetic widely distributed family. New members were 
discovered by sequence homology comparison. So far, 7 human FKBPs are known 
which differ in size, structure, distribution and function (204). FKBP12, 13 and 25 are 
single domain proteins that function in receptor regulation and attached to 
erythrocyte membranes or nuclear proteins like casein II and nucleolin. The multi-
domain proteins like FKBP51 and 52 are required in the formation of Hsp90 
associated progesterone or steroid receptor complexes (205), (206). 
The most prominent and unique member of the parvulin family is Pin1. Neither FK506 
nor CsA interfere with the peptidyl prolyl cis/trans isomerase activity and Pin1 
specifically recognizes phosphorylated Pro-directed Ser/Thr (pSer/Thr-Pro) peptide 
sequences (207), (208). Phosphorylation of p53 after DNA damage enables Pin1 to 
interact with p53 thereby preventing interaction with Mdm2 and subsequent p53 
proteasomal destruction (209), (210). Hence, Pin1 enhances p53 stabilization and 
p53 target gene expression. Furthermore, Pin1 is required in proper processing of the 
amyloid precursor protein (APP) (211). Phosphorylated APP phosphorylation tends to 
be in cis conformation that forwards APP to the amyloidogenic processing pathway 
via β- and γ-secretase and results in insoluble Aβ42 peptides. Pin 1 converts APP in 
trans position thereby APP processing occurs via α- and γ-secretase pathway 
resulting in non-toxic APP fragments.  
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4.4 FKBP38 
4.4.1 Discovery and characterization of FKBP38 
FK506-binding protein 38 (FKBP38) is a member of the FKBP family that binds the 
immunosuppressive drug FK506. First, FKBP38 was described by Elsa Lam et al. in 
1995. They screened for cDNAs from Jurkat cells that contain the DNA sequence for 
the well conserved second β-sheet region of FKBP12 from amino acid 26 to 34 to 
identify novel FKBP homologs (212). A cDNA was found that encodes a 38 kDa 
protein, FKBP-related 38 kDa protein (FKBPr38) that is 33% identical to FKBP12. As 
a matter of fact, the 38 kDa form resulted from a truncated open reading frame. 
Nielsen at al. 2004 described a 47 amino acid encoded extended open reading frame 
of FKBP38 and named it FKBP8 (213), (214). It encodes for a 45 kDa protein in 
human and 44 and 46 kDa protein splice variants in mouse but no further known 
domains, signal sequences as well as glycosylation sites were discovered. 
The human FKBP38 (=FKBP8) gene is located on chromosome 19p12. FKBP38 
possesses a PPIase domain, three 34 amino acid long tetratricopeptide repeat 
domains (TPRs) similar to FKBP52, a CaM binding site and transmembrane domain 
(TM) at the C-terminus (Fig. 7). The second TPR overlaps with a consensus leucine 
zipper motif (212), (213). 
Highest levels of FKBP38 human mRNA expression are observed in the brain and 
moderate expression can be found in the heart, lung, skeletal muscle and pancreas 
and low expression in placenta and liver. In mice, FKBP38 is widely expressed in 
mouse brain tissues including neurons of the forebrain, striatum and thalamus and 
cells of Purkinje cell layer of the cerebellum. Transgenic mice expressing lacZ in front 
of a putative 4.4 kb FKBP38 promoter region showed an abundant expression in 
hippocampus, neocortex, striatum and cerebellum. NF-Y and SP1 binding sites were 
found in the promoter region of FKBP38 (213). On the protein level, FKBP38 is 
widely expressed in murine embryonic and adult tissues as well as in human cancer 
cell lines (215), (216). FKBP38 is an integral membrane protein located in 
Figure 7. Domain structure of FKBP38  
PPIase - peptidyl prolyl cis/trans isomerase activity domain; TPR - tetratricopeptide repeat domain; CaM - calmodulin binding 
domain; TM - transmembrane domain 
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mitochondria and ER membranes exposed to the cytosolic face. Furthermore, 
FKBP38 is suggested to be posttranslationally modified but not by glycosylation 
(215). 
Amino acid sequence analysis of the FKBP38 PPIase domain showed strong 
differences compared to other PPIases. It lacks the conserved amino acid tryptophan 
(W) at position 59 and has instead a Leucin (L). Tryptophan forms the basis of the 
hydrophobic FK506 drug-binding cavity that comprises the PPIase domain. 
Therefore, it was suggested that FKBP38 does not contain a PPIase activity (212). 
FKBP38 alone does not exhibit an enzymatic activity in an in vitro protease-coupled 
cis/trans isomerase activity assay. However, it absolutely requires Ca2+ and CaM as 
co-factors to function as an active enzyme (217). Inhibition of complex formation with 
CaM inhibitory myosine light chain kinases (MLCK) peptides, FKBP38 activity was 
completely abolished (217). CaM possesses two globular domains connected with a 
linker. The C-terminal part from aa 76 to 148 binds calcium-dependently to the CaM 
binding site in FKBP38 whereas the N-terminal aa 1 to 75 link the N-terminal region 
of FKBP38 (aa 35-153) to a so far unknown CaM binding site  in a Ca2+ independent 
manner (218). 
Genetic disruption of FKBP38 by deletion of FKBP38 exon 4-6 resulted in embryonic 
lethality at embryonic day E13.5 (215). Detailed analysis showed defects in the 
development of the central nervous system. The retina and pigmented epithelium 
was reduced and this results in failure of eye development. Ventral cell fates were 
remarkably increased on the expense of the dorsal fates. This phenotype seems to 
be similar to constitutively active sonic hedgehog signaling (SHH) pathway or 
inhibition of the SHH antagonist protein kinase A (PKA) (219). Indeed, in Fkbp38-/- 
mice the SHH pathway is constitutively activated. The SHH signaling pathway is 
crucial in embryonic pattering and cell fate determination. De-regulation of this 
signaling pathway supports tumor growth in skin, muscle and brain (220). As a 
secreted morphogen, SHH binds to its receptor patched (Ptch1) and suppresses the 
inhibitory effect of Ptch1 on Smoothened (Smo) (Fig. 8). Through a so far not 
completely understood signal cascade, the transcription factors Gli are not 
proteasomally cleaved and induce target gene expression. 
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In the absence of SHH receptor 
binding, Gli transcription factors 
are processed in the 
proteasome and the carboxy-
terminally truncated version 
suppresses Gli-mediated target 
gene expression. So, genetic 
ablation of FKBP38 resulted in 
induced expression of SHH 
signaling target genes like 
Ptch1 and Gli transcription 
factors. Double knockout of 
FKBP38 and SHH rescued the 
FKBP38 knockout phenotype. Therefore, FKBP38 may negatively regulate, most 
likely ligand-independently, the SHH signaling pathway during development of the 
central nervous system. 
Mice with homozygous disruption of exon 3 to 7 of Fkbp38 completed embryonic 
development however the mice died soon after birth (222). These mice suffered from 
defects in the closure in thoracico-lumbo-scaral region (spina bifida) and skeletal 
defects. Neural tube defects were furthermore observed in FKBP38 knockout mice 
generated by gene trap insertion (223). 
 
4.4.2 Physiological functions of FKBP38 
4.4.2.1 Impact of FKBP38 on calcineurin activity 
The best characterized FKBP member, FKBP12, forms a complex with FK506 and 
the FKBP12-FK506 complex interferes with calcineurin and its interaction with its 
substrates like NFAT, MEF2, Elk-1, NOS and PKA. FK506 binds in the PPIase 
domain and mimics endogenous ligands to block calcineurin phosphatase activity. 
Therefore, Shirane et al. proposed an intrinsic inhibitory effect of FKBP38 on 
calcineurin (224). Tagged isolated FKBP38 from HeLa cells reduced the 
dephosphorylation capacity of calcineurin on synthetic phosphopeptide of RII subunit 
of PKA. Increased Ca2+ influx by A23187 decreased phosphorylated NFAT4, a 
known calcineurin target and overexpressed FKBP38 lowered dephosphorylation of 
NFAT4. Furthermore, expression pattern of FKBP38 in mouse brain resembles that 
Figure 8. Sonic hedegehog signaling pathway (221) 
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of calcineurin (213). Contrary to Shirane et al., other groups did not observe neither 
an inhibitory effect on calcineurin phosphatase activity by FKBP38 in vitro nor 
changes in the NFAT-responsive reporter gene activity upon FKBP38 overexpression 
in SH-SY5Y cells and Jurkat cells (225), (216). Furthermore, FKBP38 does not 
physically interact with calcineurin and it does not influence the PPIase activity of 
FKBP38. Only, the complex of FKBP38 and FK506 inhibits calcineurin activity but to 
a much lesser extend than FKBP12-FK506 complex (226). 
 
4.4.2.2 Functional role of FKBP38 in apoptosis 
FKBP38 association with the anti-apoptotic protein Bcl-2 might have a functional role 
in apoptosis process but it is a matter of intense debate. Programmed cell death is 
essential to eliminate aged, injured or infected cells and supports correct 
development of multicellular organisms. In apoptotic cells, the DNA condensates and 
is degraded, the membrane starts to bleb and the cell breaks apart in vesicles that 
are absorbed by phagocytes without inducing an inflammatory response. 
Self destruction is induced by ligand-dependent binding to the death receptors of the 
tumor necrosis factor (TNF) family. This extrinsic pathway mediates the activation of 
caspase-8 (and caspase-10 in humans) and downstream caspases that provoke cell 
destruction. Independently, programmed cell death is also induced by diverse 
intracellular stresses including growth factor or cytokine deprivation, accumulation of 
unfolded proteins or genotoxic damage and triggers the release of Cyt c from 
mitochondria. Subsequently, Cyt c forms a complex with apoptotic protease 
activating factor-1 (Apaf-1) that activates the initiator caspase 9 and later on the 
executioner caspases 3, 6, 7 (Fig. 9). This pathway is mainly governed by the Bcl-2 
family. The Bcl-2 family comprises the pro-survival proteins like Bcl-2, Bcl-xL, Bcl-w, 
Mcl-1, the cell death promoters Bax-like apoptotic proteins Bax, Bad, Bak and the 
BH3-only proteins Bik, Bid, Bim, Noxa and Puma (227). The current model suggests 
that the pro-survival proteins engage with the anti- apoptotic proteins and prevent 
disturbance of mitochondrial membrane structure by pore formation in the outer 
mitochondrial membranes (228). 
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Intracellular stress and 
developmental cues trigger 
the BH3-only proteins as cell 
damage sensors to interact 
with the pro-survival proteins 
in the hydrophobic grove of 
the globular BH1, 2, 3 
domains and promote the 
translocation of pro-apoptotic 
proteins to mitochondria to 
induce Cyt c release. In HeLa 
cells, FKBP38 targets Bcl-2 
as well as Bcl-xL to 
mitochondrial membranes 
thereby facilitating Bcl-2 and 
Bcl-xL in their anti-apoptotic 
role (224). FKBP38 downregulation by RNAi strongly reduced HeLa cell viability and 
greatly enhanced caspase-3 activity as well as PARP cleavage, a caspase-3 
substrate (216). Protein stability of FKBP38 and Bcl-2 is determined by Presenilin 1/2 
where mutations cause early onset of familiar Alzheimer`s disease (FAD). Genetic 
ablation of Presenilin 1/2 increases FKBP38 and Bcl-2 protein abundance. So, cells 
were less susceptible to intrinsic apopotic stimuli due to increased Bcl-2 translocation 
to mitochondria (230). 
Additionally, Edlich et al. reported a Ca2+-CaM dependent interaction of FKBP38 with 
Bcl-2 that is blocked by Hsp90 binding to FKBP38. However, they propose that 
FKBP38 promotes cell death in SH-SY5Y neuroblastoma cells. Blockage of FKBP38 
by the FKBP inhibitor GPI1046 lowered the decrease in cell viability after induction of 
cell death by diverse inducers like etoposide, camptothecin and ionomycin and can 
be reversed by overexpression of Hsp90 in this cell line (217), (231). Furthermore, 
FKBP38 inhibitor DM-CHX reduced neuronal cell death in rats subjected to transient 
focal cerebral ischemia suggesting its pro-apoptotic function.(226). Interestingly, 
overexpression of FKBP38 reduced matrix metalloproteinase 9 (MMP9) and 
upregulated syndecan 1 (SDC1), proteins involved in invasion and metastasis of 
tumors suggesting anti-metastatic and anti-invasive functions (232). 
 
Figure 9. Apoptosis pathway (229) 
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4.4.2.3 FKBP38 as a chaperone 
FKBP38 may also function as a chaperone. Recombinant FKBP38 was able to 
reduce thermal denaturated citrate synthase aggregates in vitro, a chaperone activity 
measurement (216). Global cystic fibrosis transmembrane conductance regulator 
(CFTR) interactome protein analysis demonstrated FKBP38 as a co-chaperone. 
Cystic fibrosis is an inherited disease that results in the defective folding and export 
of the CFTR protein from ER due to deletion of aa F508. Expressed CFTR is 
expressed in apical epithelial cells like lung, liver, pancreas, skin and functions as a 
cAMP-regulated chloride channel that moves chloride ions to the covering mucus and 
regulates the fluidity of mucus and secretions. Patients with cystic fibrosis suffer from 
airway obstruction by thick mucus and chronic infection which eventually results in 
loss of pulmonary function (233). 
FKBP38 affects the stability of CFTR and seems to be tightly associated to the 
steady-state levels of Hsp90 to support the Hsp90-client pathway (234). Indeed, 
FKBP38 itself interacts with the chaperone Hsp90 (235). Furthermore, FKBP38 
associates with HERG, a voltage-dependent potassium channel supports the full 
maturation of HERG (236) as well as with Protrudin, a modulator of neurite formation 
and membrane trafficking (237). 
 
4.4.2.4 FKBP38 as an organelle linker 
FKBP38 has been reported to associate to the S4 subunit of the 19S proteasome via 
its TPRs (238). The 19S proteasome is the regulatory particle and forms with the 
proteolytic core (20S proteasome) the 26S proteasome. 
The 26S proteasome is an ATP-dependent macromolecular complex and regulates 
protein stability by its ubiquitin-dependent degradation. In primary FKBP38 knockout 
cells the 26S proteasome is more localized in the cytosol then to membrane fractions 
and a decrease in proteasomal activity was observed in the membrane compared to 
cytosolic fraction. Therefore, FKBP38 might link the proteasome to mitochondria as 
well as ER to increase proteasomal activity at these organelles. 
 
4.4.2.5 FKBP38 and its role in the mTOR pathway 
mTOR is the master regulator of cell growth, size and proliferation and integrates 
diverse signals e.g. nutrients, energy state and growth factors (Fig. 10). 
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Under growth conditions, the 
mTOR pathway is stimulated 
by diverse growth factors like 
insulin. Over a cascade of 
adaptor proteins the 
phosphoinositide-3 kinase 
(PI3K) is activated and 
phosphorylates PIP2 into PIP3. 
Only PIP3 is able to recruit 
PDK1 and AKT to the cell 
membrane. Activation of PDK1 
leads to activation of AKT. AKT 
is a serine/threonine kinase 
that blocks the activity of the 
TSC complex. The TSC 
complex is composed of the tumor suppressor proteins hamartin (TSC1) and tuberin 
(TSC2) that mediate the inhibition of mTOR by acting as a GTPase-activating (GAP) 
protein stimulating the GTPase activity of the ras homolog enriched in brain (Rheb) 
protein. In its active state, the GTP-bound form stimulates the serine/threonine kinase 
activity of mTOR. Activated mTOR phosphorylates the eukaryotic initiation factor 4E 
(eIF4E)-binding protein 1 (E4-BP1) that releases eIF4E which then increases cap-
dependent translation. The p70 ribosomal protein S6 kinase 1 (S6K1) is 
phosphorylated by mTOR, activates the 40S ribosomal protein S6 and enhances the 
translation of mRNA’s that contain repressive 5’-terminal oligopyrimidine (5’-TOP) 
tracts. These mRNAs encode elongation factors as well as ribosomal proteins 
reviewed by Li et al. (239). Under conditions that are adverse for proliferation, this 
pathway is inactivated by TSC1/2 whereas the TSC1/2 complex is blocked by AKT 
under growth favourable conditions. TSC1/2 overexpression slightly reduced the cell 
size but this effect was reversed by FKBP38 downregulation with antisense 
olignucleotides (240). Furthermore, FKBP38 mRNA levels were upregulated upon 
TSC1 overexpression. Recently, FKBP38 has been reported to compete with Rheb 
for mTOR binding (241). When sufficient nutrients and growth factors were present, 
GTP-Rheb accumulated and prevented FKBP38 binding to mTOR and activated the 
phosphorylation of mTOR targets S6K and 4E-BP. Nutrient and growth factor 
Figure 10. The mTOR signaling pathway 
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deprivation inactivated mTOR by enhanced FKBP38 binding. Therefore, FKBP38 
might function as an endogenous mTOR inhibitor by interfering with Rheb and 
modulating cell growth and size. 
In summary, accumulating data implicate a multifunctional role of FKBP38 in cell 
regulatory processes like cell signaling, apoptosis, cell proliferation and growth. 
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4.5 Working hypothesis 
Prolyl-4-hydroxylases are the key enzymes regulating the stability of the HIF-α 
subunits. PHD activity is attenuated by the availability of the substrate O2 but also by 
other factors like ROS, divalent cations, antioxidants or Krebs cycle intermediates. 
Due to the fact that there are at least three PHD isoforms capable of hydroxylating 
HIF-α subunits in vitro and differing in their tissue distribution and sub-cellular 
localization and in vivo function as determined by genetic knockout models, we 
hypothesize that PHDs have redundant as well as non-redundant functions and other 
hydroxylation targets besides HIF-α protein. PHD1 has been shown to regulate the 
stability of IKKβ whereas ATF4 protein stability was proposed to be determined by 
PHD3 (157), (160). 
Thus, we propose that there might exists further hydroxylation targets or factors that 
influence PHD2 and regulate its function in addition to pO2. To answer this question, 
we initiated a yeast two-hybrid screening using PHD2 as bait. Among the potential 
interactors we found the FKBP38 protein. FKBP38 is a peptidyl prolyl cis/trans 
isomerase and we speculated that it might function as a PHD2-co-factor to modulate 
HIF hydroxylation. The goal of this thesis was to investigate the functional role of the 
FKBP38:PHD2 interaction and its relevance in the PHD-dependent oxygen-sensing 
pathway. 
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The Peptidyl Prolyl cis/trans Isomerase FKBP38 Determines
Hypoxia-Inducible Transcription Factor Prolyl-4-Hydroxylase
PHD2 Protein Stability
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The heterodimeric hypoxia-inducible transcription factors (HIFs) are central regulators of the response to
low oxygenation. HIF- subunits are constitutively expressed but rapidly degraded under normoxic conditions.
Oxygen-dependent hydroxylation of two conserved prolyl residues by prolyl-4-hydroxylase domain-containing
enzymes (PHDs) targets HIF- for proteasomal destruction. We identified the peptidyl prolyl cis/trans isomer-
ase FK506-binding protein 38 (FKBP38) as a novel interactor of PHD2. Yeast two-hybrid, glutathione S-
transferase pull-down, coimmunoprecipitation, colocalization, and mammalian two-hybrid studies confirmed
specific FKBP38 interaction with PHD2, but not with PHD1 or PHD3. PHD2 and FKBP38 associated with their
N-terminal regions, which contain no known interaction motifs. Neither FKBP38 mRNA nor protein levels were
regulated under hypoxic conditions or after PHD inhibition, suggesting that FKBP38 is not a HIF/PHD target.
Stable RNA interference-mediated depletion of FKBP38 resulted in increased PHD hydroxylation activity and
decreased HIF protein levels and transcriptional activity. Reconstitution of FKBP38 expression abolished
these effects, which were independent of the peptidyl prolyl cis/trans isomerase activity. Downregulation of
FKBP38 did not affect PHD2 mRNA levels but prolonged PHD2 protein stability, suggesting that FKBP38 is
involved in PHD2 protein regulation.
The response to reduced tissue oxygenation (hypoxia) is
characterized by alterations in gene expression, allowing the
organism to adapt to hypoxia on the systemic, local, and cel-
lular levels (46). A large number of these target genes are
regulated by hypoxia-inducible factor 1 (HIF-1) and HIF-2, the
master regulators of oxygen homeostasis in physiological, as
well as in pathophysiological, processes (3, 34, 37). HIFs are
members of the basic helix-loop-helix/Per-ARNT-Sim (bHLH/
PAS) transcription factor family and bind as an / het-
erodimer to cis-regulatory hypoxia response elements (HREs)
(47). Oxygen-dependent regulation is mediated by the HIF-
subunits and involves novel enzymatic posttranslational mod-
ification pathways that hydroxylate specific amino acids, de-
pending on the oxygen partial pressure (36). A novel family of
oxygen-, ferrous iron-, and 2-oxoglutarate-dependent prolyl-4-
hydroxylase domain-containing enzymes (PHD1, PHD2, and
PHD3) mediate the proteolytic regulation of HIF- subunits
(4, 9, 15). Under normoxic conditions, two conserved prolyl
residues within the oxygen-dependent degradation (ODD) do-
main of HIF- are hydroxylated and recognized by the von
Hippel-Lindau (pVHL) tumor suppressor protein via trans-4-
hydroxyprolyl binding (16, 17, 25). pVHL serves as a substrate
recognition unit of an E3 ligase complex, targeting HIF- for
degradation by the ubiquitin-proteasome pathway. Because
PHDs depend on molecular oxygen as a cosubstrate, hydroxy-
lation is reduced in hypoxia, leading to HIF- stabilization and
accumulation. Thus, PHDs can serve as cellular oxygen sensors
and provide a direct link between oxygen availability and HIF-
dependent transcriptional regulation. In addition to the regu-
lation of protein stability, hydroxylation of a specific asparag-
inyl residue within the C-terminal transactivation domain of
HIF- by factor inhibiting HIF (FIH) prevents interaction with
the CH1 domains of the p300/CBP transcriptional coactiva-
tors, thus reducing the transcriptional activity of HIF- (13, 21,
22). FIH belongs to the same family as the PHDs, but its Km
for oxygen is lower (14, 20), providing an elegant way of fine
tuning HIF- stabilization and target gene induction by the
current tissue oxygenation.
All three PHD proteins are able to hydroxylate HIF- in
vitro, but they differ in their expression patterns, as well as in
their subcellular localization, at least when overexpressed (1,
26). However, recent analysis of endogenous localization
showed expression of all three PHD enzymes predominantly in
the cytoplasm (39). PHD2 is ubiquitously expressed and has
been shown to be the main hydroxylase responsible for HIF-
modification in normoxia (2). The recent description of a fam-
ily with erythrocytosis caused by an inherited PHD2 proline
point mutation confirmed these data (32). Interestingly, PHD2
and PHD3 are HIF-dependently regulated, constituting a neg-
ative feedback mechanism, whereas PHD1 is not regulated by
hypoxia (27, 33). In accordance with the complex functions of
HIF in various hypoxic adaptation processes, the PHD pro-
* Corresponding author. Mailing address: Institute of Physiology
and Center for Integrative Human Physiology, University of Zu¨rich,
Winterthurerstrasse 190, CH-8057 Zu¨rich, Switzerland. Phone: 41
(0)44 63 55075. Fax: 41 (0)44 63 56814. E-mail: gieri.camenisch@access
.uzh.ch.
† Present address: Microbiology, University of Konstanz, D-78457
Konstanz, Germany.
 Published ahead of print on 12 March 2007.
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teins also seem to be subjected to multilayer regulatory mech-
anisms, including modification of enzyme activity by posttrans-
lational modifications and protein associations (15, 24). To
screen for novel PHD interactors, we applied yeast two-hybrid
methodology using PHD2 as bait and identified the peptidyl
prolyl cis/trans isomerase FK506-binding protein 38 (FKBP38)
as prey.
MATERIALS AND METHODS
Plasmids. Unless otherwise indicated, cloning work was carried out using
Gateway technology (Invitrogen, Basel, Switzerland). Entry vectors were gener-
ated by cloning PCR fragments into BamHI/EcoRV-digested (all restriction
enzymes were purchased from MBI Fermentas, Labforce, Nunningen, Switzer-
land) pENTR4 or pENTR/D-TOPO vectors. Full-length PHD1 to -3 (accession
numbers NM_053046, NM_022051, and NM_022073, respectively) were ampli-
fied by PCR from plasmids pcDNA3.1/PHD1 (29), pcDNA3.1/HA-PHD2 (15),
and pcDNA3.1/PHD3 (29). pENTR/PHD2-170-426 was obtained by digesting
pENTR/PHD2 with SmaI and NotI, Klenow fill-in, and religation. To obtain
pDONR/FKBP38, as well as pDONR/FKBP3898-257, the BP Clonase recom-
bination enzyme mixture (Invitrogen) was used to transfer the corresponding
inserts from yeast two-hybrid library vectors into pDONR221. DNA fragments
corresponding to amino acids (aa) 3 to 97, aa 99 to 412, and aa 256 to 412 of
FKBP38 (accession number AY278607) were amplified by PCR from plasmid
pDONR-FKBP38 and cloned into pENTR4. The DNA fragment corresponding
to the HIF-2ODD-domain (aa 404 to 569) was amplified by PCR from plasmid
pcDNA3/hEPAS and cloned into pENTR/D-TOPO. The inserts of all entry and
donor vectors were verified by DNA sequencing (Microsynth, Balgach, Switzer-
land).
To generate fusion protein expression vectors, entry or donor vectors were
recombined in vitro with destination vectors using LR Clonase recombination
enzyme mix (Invitrogen). To generate expression plasmids for yeast two-hybrid
analysis, the destination vectors pDEST32 (Gal4 DNA-binding domain [Gal4-
DBD]) and pDEST22 (Gal4 activation domain [Gal4-AD]) were used. The
mammalian Matchmaker vectors pM and pVP16 (Clontech, BD Biosciences,
Heidelberg, Germany) were converted to destination vectors by ligation of the
Gateway vector conversion cassette reading frame B (Invitrogen) into the EcoRI
sites (blunted with Klenow polymerase) of pM and pVP16 to generate pMDEST
and pVP16DEST, respectively. Expression vectors for the Gal4-DBD (pM) and
VP16AD fusion proteins were obtained after in vitro recombination with the
corresponding entry vectors. The mammalian one-hybrid plasmid pM-HIF-1-
370-429-VP16AD was generated by cloning a PCR fragment (using primers
5-GTCAGAATTCAGAAAATGACTCAGCTATTCACCAA-3 and 5-CGAT
GAATTCGGAATGGTACTTCCTCAAGTTGCT-3) into the EcoRI site of
pM-VP16AD. Plasmids pDEST15 and pDEST17 were used to generate vectors
for glutathione S-transferase (GST) and His6 fusion protein expression in bac-
teria or in rabbit reticulocyte lysates. The plasmid used to generate recombinant
GST–HIF-1-530-826 was described previously (6). pDEST20 was used to gen-
erate expression vectors for GST fusion proteins in the baculovirus/Sf9 insect cell
system (Invitrogen). pcDNA3.1/nV5-DEST and pcDNA3.1/c-myc-DEST were
used to express N-terminal V5- and c-myc-tagged proteins in mammalian cells,
respectively. pcDNA3.1/c-myc-DEST was obtained by ligating c-myc oligonucle-
otides (synthesized by Microsynth) into pcDNA3.1/nV5-DEST digested with
EcoRV and HindIII.
Yeast two-hybrid analysis. Yeast two-hybrid analyses were performed using
the ProQuest system according to the manufacturer’s instructions (Invitrogen).
Full-length PHD2 fused to the Gal4-DBD was expressed from pDEST32-PHD2
in Saccharomyces cerevisiae strain MaV203 (Invitrogen). To test for self-activity,
cotransformants of pDEST32/PHD2 and pExpAD502, encoding the Gal4-AD,
were examined on selection plates. A Gateway-compatible ProQuest human
brain cDNA library was screened on synthetic dropout medium containing 10
mM 3-amino-1,2,4-triazole (Sigma, Buchs, Switzerland). The pExpAD502 plas-
mids encoding putative PHD2-interacting proteins were isolated, retested for
interaction, and tested for self-activity. Inserts of confirmed interactors were
sequenced to ensure in-frame coding sequence with the Gal4-AD.
Cell culture and transient transfection. Human Hep3B hepatoma, HeLa cer-
vical carcinoma, and HEK293 embryonic kidney carcinoma cell lines were cul-
tured in high-glucose Dulbecco’s modified Eagle’s medium (DMEM) (Sigma) as
described previously (6). Transient transfections were performed with the poly-
ethylenimine (Polysciences, Warrington, PA) method (42).
In vitro transcription/translation (IVTT) and GST pull-down. IVTT reactions
were carried out as described by the manufacturer (Promega, Madison, WI)
using recombined DEST vectors in the presence of [35S]Met (Hartmann Ana-
lytic, Braunschweig, Germany). GST and GST fusion proteins were expressed in
Escherichia coli BL21-AI by induction with 0.025% arabinose for 4 h and affinity
purified using glutathione-Sepharose columns (GSTrap FF; GE Healthcare,
Du¨bendorf, Switzerland) by liquid chromatography (BioLogic DuoFlow; Bio-
Rad, Reinach, Switzerland). Purified GST-tagged proteins (10 g) were diluted
in bead binding buffer (50 mM potassium phosphate, pH 7.5, 150 mM KCl, 1 mM
MgCl2, 10% glycerol, 1% TX-100) and incubated with glutathione-Sepharose
beads. For pull-down experiments, 20 l rabbit reticulocyte IVTT reaction mix-
ture was incubated for 2 h at 4°C with bound GST fusion proteins in coimmuno-
precipitation (co-IP) buffer (50 mM Tris-HCl, pH 7.6, 2 mM EDTA, 100 mM
NaCl, 0.1% TX-100), washed five times with co-IP buffer, boiled in sample buffer
(40 mM Tris-HCl, pH 6.8, 1% sodium dodecyl sulfate [SDS], 50 mM -mercap-
toethanol) for 5 min, and separated by SDS-polyacrylamide gel electrophoresis
(PAGE). The gels were stained with Coomassie blue and dried, and radioactively
labeled proteins were detected by phosphorimaging (Molecular Imager FX;
Bio-Rad).
Immunoblotting. Combined cytoplasmic and nuclear extracts of cultured cells
were prepared using 0.4 M NaCl and 0.1% NP-40 in extraction buffer as de-
scribed previously (23). Nuclear extracts were prepared from isolated nuclei
using 0.4 M NaCl. Protein concentrations were determined by the Bradford
method using bovine serum albumin as a standard. Immunoblot analyses were
performed as previously described (23). The following antibodies were used:
mouse monoclonal antibody (MAb) anti-V5 (Invitrogen), MAb anti-c-myc
(Roche Diagnostics, Rotkreuz, Switzerland), MAb anti--actin (Sigma), MAb
anti-HIF-1 (Transduction Laboratories, BD Biosciences), rabbit polyclonal
anti-PHD2 antibody (Novus, Abcam, Cambridge, United Kingdom), rabbit poly-
clonal anti-FKBP38 antibody (7), and secondary polyclonal goat anti-mouse and
anti-rabbit antibodies coupled to horseradish peroxidase (Pierce, Perbio, Lau-
sanne, Switzerland). Chemiluminescence detection was performed using Super-
signal West Dura (Pierce), and signals were recorded with a charge-coupled
device camera (FluorChem8900; AlphaInnotech, Witec, Littau, Switzerland) or
by exposure to X-ray film (Fujifilm, Dielsdorf, Switzerland).
Co-IP. HEK293 cells were transiently cotransfected with pcDNA3.1/V5-
FKBP38 and pcDNA3.1/c-myc-PHD2 using the polyethylenimine method. After
24 h, 107 cells were lysed with 1 ml nondenaturing lysis buffer (50 mM Tris-HCl,
pH 7.4, 300 mM NaCl, 5 mM EDTA, 1% TX-100, complete protease inhibitors
[Roche]). The lysates (500 l) were precleared with protein A agarose beads
(Roche) before incubation with protein A agarose beads bound to monoclonal
mouse anti-V5 (2 g; Invitrogen), anti-c-myc (2 g; Roche), or nonspecific
purified mouse immunoglobulin G (IgG) (2 g; Sigma) overnight at 4°C. Anti-
body-protein complexes were washed four times with wash buffer (50 mM Tris-
HCl, pH 7.4, 300 mM NaCl, 5 mM EDTA, 0.1% TX-100) and once with
phosphate-buffered saline (PBS) and eluted with SDS-PAGE sample buffer.
Immunofluorescence microscopy. Cells were cultivated on microscope slides,
washed twice with ice-cold PBS, and fixed on ice for 30 min with 4% parafor-
maldehyde. The cells were then permeabilized with 0.1% saponin in PBS. En-
dogenous FKBP38 was detected with rabbit anti-FKBP38 antibodies, and trans-
fected hemagglutinin (HA)-PHD2 was detected with mouse anti-HA antibodies
(Sigma). Immune complexes were visualized with goat anti-rabbit antibody–
Alexa 488 or goat anti-mouse antibody–Alexa 568 (Molecular Probes, Invitro-
gen), respectively. Finally, nuclei were stained with DAPI (4,6-diamidino-2-
phenylindole) (Sigma) for 30 min. After extensive washings with PBS, the slides
were mounted and analyzed by confocal laser scanning microscopy (SP1; Leica
Microsystems, Switzerland).
Reporter gene and mammalian one- and two-hybrid assays. Cloning of the
HIF-dependent firefly luciferase reporter gene construct pH3SVL was described
previously (45). Cells were cotransfected with 500 ng pH3SVL and 20 ng pRL-
SV40 Renilla luciferase reporter vector (Promega) to control for differences in
transfection efficiency and exposed to normoxic or hypoxic conditions for 16 h.
Mammalian one- and two-hybrid analyses were performed using the mammalian
Matchmaker system (Clontech, BD Biosciences). HeLa cells were transiently
cotransfected with one-hybrid or DBD and AD fusion protein vectors, together
with the firefly luciferase reporter vector pGRE5xE1b and pRL-SV40. Lucifer-
ase reporter gene activity was determined using the dual-luciferase reporter
assay system according to the manufacturer’s instructions (Promega).
RNAi. For silencing FKBP38 by RNA interference (RNAi), a pair of 63-
nucleotide oligonucleotides (Microsynth) targeting the sequence 5-AAGAGU
GGCUGGACAUUCUGG-3 were inserted into pSilencer2.1-U6 hygro di-
gested with BamHI and HindIII (Ambion, Huntingdon, United Kingdom) and
transfected into HeLa and Hep3B cells by calcium phosphate coprecipitation. A
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pool of clones were selected in medium containing 200 g/ml hygromycin B
(Calbiochem, VWR International, Lucerne, Switzerland), and single clones were
subsequently isolated by limited dilution. The downregulation of FKBP38 ex-
pression by RNAi was analyzed by real-time reverse transcriptase (RT) PCR and
immunoblotting and compared to cells containing the control oligonucleotide
harboring the vector pSilencer2.1-U6 hygro.
Pulse-chase experiment. HeLa cells were starved in DMEM (without fetal calf
serum [FCS]) lacking Met and Cys for 1 h. The cells were then incubated in the
same medium supplemented with 10% FCS (dialyzed against PBS) and [35S]Met/
Cys mixture (0.1 mCi/ml; Hartman Analytics, Braunschweig, Germany) for 2 h.
After the cells were washed twice with PBS, they were chased with DMEM-10%
FCS containing cold Met/Cys (3 mM each). During the chase period, cells were
harvested at different time points, and radioactively labeled PHD2 was immu-
noprecipitated and visualized by phosphorimaging.
In vitro prolyl-4-hydroxylation assay. HeLa cells were pelleted and Dounce
homogenized in cell lysis buffer (100 mM Tris-Cl, pH 7.5, 1.5 mM MgCl2, 8.75%
glycerol, 0.01% Tween 20) supplemented with complete protease inhibitors. The
lysates were centrifuged for 30 min at 4°C and 20,000  g, and pVHL-elongin
B-elongin C (VBC) binding was determined as previously described (23, 30).
RNA extraction and real-time RT-PCR quantification. Cells were grown in
15-cm plates under normoxic or hypoxic conditions, and total RNA was extracted
as described previously (23). First-strand cDNA synthesis was performed with 3
g of RNA using Superscript III Moloney murine leukemia virus RT according
to the manufacturer’s instructions (Invitrogen). Subsequently, mRNA expression
levels were quantified with 2 l of diluted cDNA reaction mixture by real-time
PCR using a SybrGreen Q-PCR reagent kit (Sigma) in combination with the
MX3000P light cycler (Stratagene, Amsterdam, The Netherlands). Initial tem-
plate concentrations of each sample were calculated by comparison with serial
dilutions of a calibrated standard. To verify RNA integrity and equal input levels,
ribosomal protein L28 mRNA was determined, and the data were expressed as
ratios relative to L28 levels. Primers were as follows: hL28 forward, 5-GCAAT
TCCTTCCGCTACAAC-3; hL28 reverse, 5-TGTTCTTGCGGATCATGTGT-
3; hGLUT1 forward, 5-TCACTGTGCTCCTGGTTCTG-3; hGLUT1 reverse,
5-CCTGTGCTCCTGAGAGATCC-3; hCAIX forward, 5-GGGTGTCATCT
GGACTGTGTT-3; hCAIX reverse, 5-CTTCTGTGCTGCCTTCTCACT-3;
hFKBP38 forward, 5-ACATGACGTTCGAGGAGGAG-3; hFKBP38 reverse,
5-GTTGGAAGGTTCCAGCTTCA-3; hPHD1 forward, 5-CTGGGCAGCTA
TGTCATCAA-3; hPHD1 reverse, 5-AAATGAGCAACCGGTCAAAG-3;
hPHD2 forward, 5-GAAAGCCATGGTTGCTTGTT-3; hPHD2 reverse, 5-T
TGCCTTCTGGAAAAATTCG-3; hPHD3 forward, 5-ATCGACAGGCTGG
TCCTCTA-3; and hPHD3 reverse, 5-CTTGGCATCCCAATTCTTGT-3.
RESULTS
Identification of FKBP38 as a specific PHD2 interactor. To
identify novel PHD2-interacting proteins, human PHD2 ex-
pressed as a fusion protein with the Gal4-DBD was used as bait
in a yeast two-hybrid screen of a human brain cDNA library. A
total of 2  106 individual transformants were screened, and
several independent cDNA clones encoding FKBP38 were
identified based on their abilities to activate the three reporter
genes His, Ura, and LacZ (data not shown). In order to confirm
these data in a yeast-independent interaction assay, GST pull-
down experiments were performed. PHD1, -2, and -3 were
subjected to IVTT in the presence of radioactive [35S]Met,
incubated with bacterially expressed and purified GST-
FKBP38, and precipitated by glutathione-Sepharose. As con-
trols, GST–HIF-1-530-826 and GST–HIF-2-404-569 were
also expressed and purified as GST fusion proteins. GST alone
was used as a noninteraction control. Whereas HIF- frag-
ments containing the ODD domain interacted with all three
PHDs, FKBP38 showed specific association with PHD2 only
(Fig. 1A), confirming the previous findings in yeast (data not
FIG. 1. FKBP38 interacts specifically with PHD2. (A) IVTT 35S-labeled PHD1, PHD2, and PHD3 were incubated with GST–HIF-1-530-826,
GST–HIF-2-404-569, GST-FKBP38, or GST alone. Bound proteins were pulled down and visualized by phosphorimaging. (B and C) Total cell
extracts from HEK293 cells transiently transfected with V5-FKBP38 and c-myc–PHD2 were incubated with anti-V5 (B) or anti-c-myc (C) anti-
bodies or with isotype-matched control IgG. The antibodies and bound proteins were immunoprecipitated and analyzed by immunoblotting (WB).
Coimmunoprecipitated PHD2 and FKBP38 were detected by specific antibodies. IP, immunoprecipitate. (D) Indirect immunofluorescence of
FKBP38 and PHD2. HeLa cells were transfected with a plasmid encoding HA-PHD2 and stained with antibodies to FKBP38 (green) and HA
(red), followed by fluorescently labeled secondary antibodies.
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shown). The stronger binding of PHD2 to HIF-2-404-569
than to HIF-1-530-603 might be due to the presence of both
hydroxylated proline residues in the recombinant HIF-2 pro-
tein (P405 and P531) versus just the C-terminal proline in
HIF-1 (P564).
To confirm the FKBP38:PHD2 interaction in a mammalian
system, we transiently transfected HEK293 cells with V5-
tagged FKBP38 and c-myc-tagged PHD2. Tag-specific anti-
bodies were then used for co-IPs. V5-FKBP38 interacted with
exogenous, as well as with endogenous, PHD2 (Fig. 1B), and
c-myc–PHD2 was found in a complex with both overexpressed
and cellular FKBP38 (Fig. 1C). Nonspecific isotype-matched
mouse IgG served as an immunoprecipitation control.
We next investigated whether FKBP38 colocalizes with
PHD2 in HeLa cells. Since the antibodies directed against
these two proteins were generated in rabbits, we transiently
transfected HA-PHD2 and used mouse anti-HA antibodies to
detect PHD2. Immunofluorescence analysis indicated that en-
dogenous FKBP38 colocalized with HA-PHD2 in the cyto-
plasm of HeLa cells (Fig. 1D).
Mapping of the PHD2 interaction site in FKBP38. FKBP38
belongs to the enzyme class of peptidyl prolyl cis/trans isomer-
ases (PPIases), and the amino-terminal region of FKBP38 con-
tains a PPIase domain of the FKBP type, harboring PPIase-
and FK506-binding activities. In addition, FKBP38 contains
three tetratricopeptide repeats, a calmodulin-binding site, and
a membrane anchor in its carboxy-terminal half (7, 38). Based
on the predicted domain architecture of FKBP38 (Fig. 2A), a
series of deletion mutants fused to GST were designed, ex-
pressed in bacteria, purified, and analyzed for PHD2 interac-
tion in GST pull-down experiments. Radioactively labeled
PHD2 was produced by IVTT, and the interaction of labeled
PHD2 with purified GST-FKBP38 deletion constructs, or GST
alone, was tested. The N-terminal FKBP38 fragment contain-
ing aa 3 to 97 was sufficient to maintain interaction with PHD2
(Fig. 2B). The PPIase domain was not required for PHD2
interaction. On the other hand, an N-terminally truncated
PHD2 protein (PHD2 aa 170 to 426) interacted with GST–
HIF-2-404-569 but not with GST-FKBP38 (Fig. 2C). Similar
results were obtained in yeast two-hybrid experiments (data
not shown). These data suggest that aa 3 to 97 of FKBP38 are
required for interaction with aa 1 to 169 of PHD2. The cata-
lytic domain of purified PHD2 is sufficient for HIF-2 ODD
domain binding and hydroxylation of HIF-1-derived peptides
(data not shown), suggesting that FKBP38 is not a PHD2
hydroxylation substrate.
FKBP38-PHD2 interaction and FKBP38 gene expression
are independent of the oxygen concentration. To investigate
whether the FKBP38-PHD2 interaction is oxygen-dependent,
we expressed PHD1, PHD2, or PHD3 fused to the Gal4-DBD,
together with the VP16AD fused to FKBP38, in a mammalian
two-hybrid system in HeLa cells. The activity of a cotransfected
luciferase reporter gene construct containing five Gal4-DBD
sites is greatly enhanced when the AD and DBD fusion pro-
teins interact with each other. As shown in Fig. 3A, luciferase
expression was significantly higher when the DBD-PHD2 and
AD-FKBP38 fusion constructs were cotransfected than in
transfection of either construct alone or AD-FKBP38 in com-
bination with DBD-PHD1 or DBD-PHD3, confirming specific
FKBP38-PHD2 interaction in mammalian cells. Cotransfec-
tion of DBD-PHD2 with the AD construct fused to FKBP38
deletions confirmed the findings in yeast, as well as the in vitro
interaction results mentioned above (data not shown). DBD-
p53, together with AD-CP (polyomavirus coat protein), served
as a negative control. In contrast to the significantly increased
luciferase activity under hypoxic conditions following cotrans-
fection of DBD-PHD2 with AD–HIF-2-404-569 (HIF-
2ODD), luciferase expression remained unchanged following
cotransfection of DBD-PHD2 with AD-FKBP38 under hy-
poxic and normoxic conditions.
FIG. 2. Mapping of the FKBP38 and PHD2 interaction sites. (A) Schematic representation of the predicted FKBP38 domain architecture and
the FKBP38 constructs used. TPR, tetratricopeptide repeats; CaM, calmodulin-binding site; TM, transmembrane domain. (B) IVTT 35S-labeled PHD2
was allowed to interact with GST-FKBP38, GST–FKBP3898-257, GST–FKBP38-3-97, GST–FKBP38-99-412, GST–FKBP38-256-412, or GST alone;
the protein complexes were precipitated by glutathione-Sepharose, separated by SDS-PAGE, and visualized by phosphorimaging. (C) IVTT 35S-labeled
PHD2-170-426 was tested for interaction with GST-FKBP38, GST–HIF-2-404-569, or GST alone and analyzed as described above.
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We next determined mRNA levels in cultured HeLa cells
exposed to normoxic or hypoxic conditions by real-time RT-
PCR. The known oxygen-regulated HIF target genes PHD2,
PHD3, GLUT1, and CAIX, but not FKBP38, PHD1, or L28
control mRNA, were induced by hypoxia (Fig. 3B). FKBP38
protein levels were not regulated by inhibition of PHDs with
dimethyloxalylglycine or by hypoxia, whereas HIF-1, as
well as PHD2, protein expression was increased following
PHD inhibition or hypoxic exposure (Fig. 3C). In summary,
these data demonstrate an oxygen-independent interaction
of FKBP38 with PHD2, suggesting that FKBP38 is not a
PHD2 substrate but might rather act as a cofactor.
RNAi-mediated FKBP38 silencing increases PHD-depen-
dent HIF-1 hydroxylation. To investigate the functional
consequences of the FKBP38-PHD2 interaction with regard
to the regulation of PHD activity, FKBP38 mRNA was
downregulated by RNAi. HeLa and Hep3B cells were trans-
fected with a FKBP38-silencing construct or with a control
plasmid harboring nonspecific oligonucleotides. Pools of clones
were generated by hygromycin B selection, and single clones
were isolated by limited dilution. As shown in Fig. 4A and B,
respectively, FKBP38 RNAi expression resulted in de-
creased endogenous FKBP38 mRNA, as well as protein
levels, in HeLa cells. Similar data were obtained in Hep3B
cells (data not shown). The ability of cell lysates derived
from FKBP38 RNAi clones to hydroxylate HIF-1 was in-
vestigated in an in vitro prolyl-4-hydroxylation assay. PHD
hydroxylation activity was measured by binding of the VBC
complex to HIF-1-derived peptides. Decreased FKBP38
resulted in a concomitant significant increase in hydroxyla-
tion activity (Fig. 4C). Reconstitution of FKBP38 gene ex-
pression using transiently transfected expression vectors
normalized prolyl hydroxylation (Fig. 4D), whereas trans-
fection with a lacZ expression vector had no effect (data not
shown).
Expression of a functional mutant FKBP38PPIase (FKBP
3898-257) resulted in normalized prolyl hydroxylation compara-
ble to transfection with FKBP38 (data not shown).
FIG. 3. FKBP38-PHD2 interaction and FKBP38 gene expression are not regulated by oxygen. (A) HeLa cells were transiently transfected with
Gal4-DBD and VP16AD fusion protein vectors and Gal4 response element-driven firefly luciferase reporter, as well as a Renilla luciferase control
vector. Following transfection, the cells were incubated under normoxic (20% O2) or hypoxic (0.2% O2) conditions, and luciferase reporter gene
activities were determined 16 h later. Firefly/Renilla luciferase activity ratios were normalized to the normoxic negative control DBD-p53/AD-CP
cotransfection, which was arbitrarily defined as 1. Mean values plus standard errors of the mean are shown for three independent experiments
performed in triplicate. (B and C) HeLa cells were cultured under normoxic (20% O2) or hypoxic (0.2% O2) conditions or treated with the PHD
inhibitor dimethyloxalylglycine (DMOG) (2 mM). (B) Total RNA was extracted after 8 h of incubation, and mRNA levels of FKBP38, PHD1 to
-3, GLUT1, CAIX, and ribosomal protein L28 were quantified by real-time RT-PCR. The transcript levels of these genes were normalized to L28,
and hypoxic inductions were calculated (mean, n  2). (C) Cellular proteins were extracted and separated by SDS-PAGE, and endogenous
FKBP38, PHD2, HIF-1, and -actin levels were analyzed by immunoblotting.
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FKBP38 silencing reduces HIF-1-dependent reporter gene
activity. To further investigate whether increased hydroxyla-
tion activity due to FKBP38 depletion affects HIF-dependent
reporter gene expression, wild-type HeLa, as well as FKBP38,
small interfering RNA (siRNA) cell clones were transiently
cotransfected with pH3SVL, containing six HIF-binding sites
from the transferrin HRE and a Renilla luciferase control
plasmid. Luciferase activity was reduced under hypoxic condi-
tions in FKBP38-depleted cell clones compared with control
cells (Fig. 5A). It has recently been reported that PHD2 is
able to modulate HIF-1 transcriptional activity (44), and
therefore, we established a mammalian one-hybrid assay to
investigate HIF-1 protein stability directly. FKBP38
siRNA cell clones were transiently cotransfected with HIF-
1-370-429 fused at the N-terminal end with Gal4-DBD and
at the C-terminal end with VP16AD, a firefly luciferase
reporter gene construct containing five Gal4-DBDs, and a
Renilla luciferase control plasmid. As shown in Fig. 5B,
luciferase activity was significantly reduced under normoxic
as well as hypoxic conditions in FKBP38-depleted cell
clones compared with control cells. Reconstitution of V5-
FKBP38 with a FKBP38 expression vector, but not with a
lacZ control vector, rescued luciferase activity (Fig. 5C).
Overexpression of a functional FKBP38 mutant that does
not bind PHD2 (FKBP38-99-412) resulted in luciferase ac-
tivities comparable to the lacZ control transfections (Fig.
5C). The nonimmunosuppressive small molecule GPI1046
[3-(3-pyridyl)-1-propyl (2S)-1-(3,3-dimethyl-1,2-dioxopen-
tyl)-2-pyrrolidine carboxylate] mimics the FK506 residues
interacting with FKBP38. GPI1046 has been shown to pref-
erentially bind FKBP38 and to inhibit the PPIase activity
with a Ki of 48 nM (7, 40). Addition of GPI1046, to inhibit
FKBP38 PPIase activity, to V5-FKBP38 reconstituted cells
had no effect, indicating a PPIase-independent function of
FKBP38 in the regulation of HIF-1 hydroxylation (data not
shown). Note that relative luciferase activities were gener-
ally higher in functional FKBP38 reconstituted clones than
in cells transfected with FKBP38, mutant for PHD2 binding,
or lacZ, suggesting that overexpression of FKBP38 reduces
PHD-dependent degradation of the HIF one-hybrid con-
struct.
Reduced FKBP38 gene expression leads to increased PHD2
protein levels and attenuates HIF-dependent gene expression.
The enhanced hydroxylation and reduced HIF-1-dependent
one-hybrid reporter gene activity found in FKBP38-depleted
cells could be based on modification of the enzymatic activity
itself and/or on elevated enzyme abundance. However, incu-
bation of active GST-PHD2 fusion protein purified from bac-
ulovirus-infected Sf9 cells with recombinant GST-FKBP38 did
not influence PHD2 hydroxylation activity as measured by the
FIG. 4. Enhanced hydroxylation activity by RNAi-mediated FKBP38 depletion. HeLa cells were transfected with vectors containing FKBP38
RNAi or control oligonucleotides, and stable clones were selected (3A5, 3D6, and 2G8). (A) Total RNA was extracted, and FKBP38 transcript
levels were determined by real-time RT-PCR and normalized to L28 mRNA levels (mean, n  2). (B) Total cell extracts were prepared and
analyzed by immunoblotting for FKBP38 and -actin expression. Total cell extracts of untransfected (C) and FKBP38-reconstituted (D) stable
RNAi clones were prepared, and hydroxylation activity was measured using the VBC-binding assay. Shown are mean values of relative VBC
binding plus standard errors of the mean of three independent experiments performed in triplicate. P values were obtained by paired t tests (*,
P 	 0.05). Subsequently, cell extracts were analyzed by immunoblotting for endogenous FKBP38, transfected V5-FKBP38, and -actin expression.
wt, wild type; ctrl, control.
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VBC capture assay (data not shown). Therefore, we analyzed
PHD2 protein levels in FKBP38 RNAi cell clones and ob-
served enhanced PHD2 levels inversely related to FKBP38
(Fig. 6A, left). Transient transfection of these FKBP38 RNAi
cells with V5-FKBP38 restored the low constitutive PHD2 pro-
tein levels, comparable to those of wild-type HeLa cells (Fig. 6A,
middle). Addition of GPI1046 did not influence PHD2 protein
levels in wild-type HeLa or FKBP38 RNAi cell clones, again
indicating a PPIase-independent effect (Fig. 6A, right). The same
results were obtained by treating cells with N-(N,N-dimethylcar-
boxamidomethyl)-cycloheximide, another FKBP38 PPIase inhib-
itor (reference 8 and data not shown).
PHD1, PHD2, and PHD3 mRNA levels were not affected by
downregulation of FKBP38, indicating that PHD2 is posttran-
scriptionally regulated by FKBP38 (Fig. 6B). To analyze
whether FKBP38 is able to attenuate endogenous HIF-1 pro-
tein expression by modification of PHD2 abundance, HeLa
control cells and FKBP38 RNAi cell clones were cultured
under hypoxic conditions and analyzed by immunoblotting.
PHD2 protein levels were inversely related to FKBP38 expres-
sion even under hypoxic conditions (Fig. 6C). Note that ele-
vated PHD2 protein levels in FKBP38-silenced cells compared
to control cells are less pronounced, because hypoxia upregu-
lated PHD2 expression in the control cells. HIF-1 protein was
not detectable under normoxic conditions but strongly in-
creased in hypoxic control cells. Strikingly, HIF-1 protein
levels markedly decreased in hypoxic FKBP38-depleted cells,
suggesting that elevated PHD2 levels lead to increased proteo-
lytic destruction of HIF-1, even under hypoxic conditions
(Fig. 6C).
Reduced HIF-1 protein levels might explain the less pro-
nounced increase in PHD2 levels under hypoxic conditions.
Indeed, hypoxia-inducible transcripts of HIF target genes, in-
cluding PHD2, PHD3, and GLUT-1 but not PHD1, were at-
tenuated two- to threefold in FKBP38 knockdown cell clones
(Fig. 6D). These results indicate that increased PHD2 abun-
dance in FKBP38 RNAi cell clones led to elevated HIF-
substrate hydroxylation and subsequent degradation, finally
resulting in decreased HIF function in the cell.
PHD2 protein stability is increased in FKBP38-downregu-
lated cells. Increased PHD2 protein levels in FKBP38-de-
pleted cells could be due to increased translation or protein
stability. To analyze PHD2 protein stability, we performed
pulse-chase experiments in wild-type HeLa and FKBP38-si-
lenced HeLa 2G8 cells (Fig. 7A). Whereas the measured half-
life of PHD2 was about 20 h in wild-type cells, it was ex-
trapolated to approximately twice as long when FKBP38 was
downregulated. In addition, cycloheximide treatment and
subsequent analysis of PHD2 protein levels showed a half-
FIG. 5. FKBP38 regulates HIF-dependent reporter gene activity.
(A) HeLa wild-type (wt) as well as FKBP38 siRNA cell clones were
cotransfected with pH3SVL and pRL-SV40 Renilla luciferase reporter
vectors and cultivated for 16 h under normoxic (20% O2) or hypoxic
(0.2% O2) conditions before relative luciferase activities were deter-
mined. The results are mean values plus standard errors of the mean
of five independent experiments performed in triplicate. ctrl, control.
(B) Stable FKBP38 RNAi HeLa clones were transiently transfected
with Gal4-DBD–HIF-1-370-429–VP16AD expression vectors (sche-
matically represented) and Gal4 response element-driven firefly lucif-
erase reporter, as well as a Renilla luciferase control vector. (C) HeLa
clones were cotransfected with the one-hybrid reporter gene vectors
and FKBP38, FKBP38-99-412, or lacZ control expression vectors.
Eight hours posttransfection, the cells were cultured under either nor-
moxic or hypoxic conditions for an additional 16 h, and firefly lucifer-
ase activities were determined and corrected for Renilla luciferase
activity. The results are mean values of relative luciferase activities plus
standard errors of the mean of at least three independent experiments
performed in triplicate. P values were obtained by paired t tests (**,
P	 0.01; *, P	 0.05). Expression of the transfected V5-tagged vectors
was verified by immunoblotting against V5 and -actin.
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life in the same range, as determined by pulse-chase in
control HeLa cells, whereas PHD2 protein stability was
markedly elevated in FKBP38-downregulated cell clones
(Fig. 7B). These experiments suggest a function of FKBP38
in the proteolytic regulation of PHD2. FKBP38 protein lev-
els remained constant for up to 32 h during cycloheximide
treatment (Fig. 7C). PHD2 is induced in HeLa cells by
incubation under hypoxic conditions for 24 h. After reoxy-
genation, PHD2 levels remain increased for up to 24 h and
afterwards slowly decline. In contrast, in FKBP38-down-
regulated HeLa cells, PHD2 remained elevated even after
72 h of reoxygenation (Fig. 7D), indicating that FKBP38 is
FIG. 6. Increased PHD2 protein stability in FKBP38-depleted cells. (A) Wild-type HeLa cells (wt), stable FKBP38-silenced HeLa clones,
V5-FKBP38 reconstituted HeLa cells, or FKBP38-silenced HeLa cells treated with the FKBP38 inhibitor GPI1046 (10 M) were cultivated under
normoxic (20% O2) conditions, and FKBP38, V5-FKBP38, PHD2, or -actin was detected by immunoblotting. (B) Total RNA was extracted and
reverse transcribed into cDNA, and mRNA levels of PHD1, PHD2, and PHD3 were normalized to ribosomal L28 mRNA levels as quantified by
real-time RT-PCR (n  2). ctrl, control. (C) Total hypoxic FKBP38 RNAi cell clone lysates were separated by SDS-PAGE and analyzed for
FKBP38, PHD2, HIF-1, and -actin protein levels by immunoblotting. (D) Total RNA was extracted after 8 h of incubation in normoxia or
hypoxia, and mRNA levels of FKBP38, PHD1 to -3, GLUT1, and ribosomal L28 were quantified by real-time RT-PCR. The transcript levels of
these genes were normalized to L28 mRNA, and hypoxic inductions were calculated (n  2).
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also required for the regulation of PHD2 protein levels
under reoxygenation conditions.
DISCUSSION
Although oxygen-dependent hydroxylation directly links ox-
ygen availability to HIF- protein stabilization and transcrip-
tional activity, both HIF and PHD hydroxylase activities are
likely to be subjected to additional levels of regulation. Indeed,
a HIF-dependent regulatory feedback mechanism has been
shown to increase PHD2 and PHD3 protein abundance under
hypoxic conditions, suggesting a role during reoxygenation (9).
We recently found that inducible PHD2 and PHD3 mRNA
levels remain upregulated under prolonged hypoxic exposure
and that PHDs maintain a functional HIF- hydroxylation
activity even under severe hypoxic conditions (42). Biochemi-
cal analysis of a PHD2 protein complex, consisting of approx-
imately 15 proteins with an apparent molecular mass of 320 to
440 kDa, indicated that PHD2 might be part of a large het-
eromeric complex (15). The formation of stable complexes
with other proteins raises the possibility that such proteins
might be involved in the regulation of PHD2 function, e.g.,
through chaperones; modulation of access to the cosubstrates
oxygen, ferrous iron, 2-oxoglutarate, and probably ascorbate;
and target protein recognition. Because HIF prolyl hydroxyla-
tion is a nonreversible process, differences in PHD protein
abundance would also be a means of regulating hydroxylation
activity.
We identified FKBP38 as a PHD2-associated nonsubstrate
protein and showed that silencing of FKBP38 results in in-
creased PHD2 stability, leading to enhanced hydroxylation and
attenuated HIF-dependent transcription. Conversely, FKBP38
overexpression resulted in elevated HIF reporter gene activity
in transient transfections (data not shown), as well as in one-
hybrid assays (Fig. 5C). Whereas PHD1 and PHD3 are tar-
geted for proteasomal degradation by the E3 ubiquitin ligases
Siah1a and Siah2 under hypoxic conditions, it is so far un-
known how PHD2 is posttranslationally regulated (28). Al-
though the molecular mechanism remains elusive, FKBP38-
dependent decreased PHD2 protein stability provides the first
data concerning the proteolytic regulation of PHD2 and at-
tributes a novel function to FKBP38.
The enzyme class of PPIases encompasses the immunophilin
families of cyclophilins and FKBPs, which were originally dis-
covered as cellular receptors of the immunosuppressive drugs
cyclosporine A and FK506, respectively (11, 43). Although
structurally unrelated, the two subfamilies share the common
enzymatic activity to catalyze the isomerization of the cis and
trans conformers of peptide bonds preceding prolines (10).
The singularity of peptidyl-prolyl bonds in peptide chains is
caused by the formation of an imidic peptide bond at the N
FIG. 7. Increased PHD2 protein stability in FKBP38-silenced cells. (A) The half-lives of PHD2 protein in wild-type HeLa (wt) and FKBP38-
depleted (2G8) cells were monitored by a pulse-chase experiment. Cells were metabolically labeled with [35S]Met/Cys for 2 h, followed by chase
for the indicated times. PHD2 was immunoprecipitated from the cell lysates with anti-PHD2 antibodies, and signals were detected by autora-
diography. Translation was blocked in FKBP38 RNAi HeLa clones by addition of 100 M cycloheximide and PHD2 (B), as well as FKBP38
(C), and protein levels were determined after the indicated time periods by immunoblotting. Subsequent detection of -actin served as a
loading control. (D) Total lysates of HeLa cells were prepared at the indicated periods of hypoxia or hypoxia followed by reoxygenation, and
PHD2 as well as -actin levels were detected by immunoblotting.
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terminus of the N-alkylated amino acid proline that is unique
among amino acids. The rate of the uncatalyzed interconver-
sion between the prolyl cis/trans isomers is low, pointing to an
involvement of PPIases in protein folding. It has been shown
for collagen that proline hydroxylation occurs on the nascent
polypeptide chain during translation, and subsequent cyclophi-
lin-assisted cis/trans isomerization is the rate-limiting step for
collagen helix formation. Procollagen folding is slowed down
by the addition of cyclosporine A (41).
Because VHL binds to HIF- trans-4-hydroxyprolyl residues
(16, 17), we speculated that the PPIase FKBP38 might act as a
PHD2 cofactor, influencing the conformation of HIF- prolyl
residues and/or the activity of PHD2. However, FKBP38 did
not physically interact with HIF- in yeast or mammalian two-
hybrid assays (data not shown), suggesting that FKBP38 does
not influence the conformation of the HIF- ODD domain.
On the other hand, the PPIase domain of FKBP38 was not
required for PHD2 interaction (Fig. 2), Ca2/calmodulin-me-
diated activation of recombinant FKBP38 did not modulate
the hydroxylation capacity of PHD2 (data not shown), and the
small-molecule FKBP38 PPIase inhibitor GPI1046, as well as
N-(N,N-dimethylcarboxamidomethyl)-cycloheximide, did not
influence PHD2 protein abundance (Fig. 6A and data not
shown, respectively). These data provide evidence that the
effect of FKBP38 on PHD2 abundance is PPIase independent.
FKBP38 is widely expressed in both adult and embryonic
tissues, as well as in different cancer cell lines (5, 18). Recently,
knockout mice showed that FKBP38 plays an essential role
during development. FKBP38 acts as a negative regulator of
the sonic hedgehog (SHH) pathway, and its loss leads to ec-
topic and ligand-independent activation of SHH signaling, re-
sulting in disturbed cell fate determination and embryonic
lethality (5). However, the molecular function of FKBP38 in
the SHH pathway remains elusive, and it will be interesting to
determine whether PHD2 is involved.
An interaction of FKBP38 with Bcl-2 has also been de-
scribed (38), but the functional consequences of this associa-
tion remain controversial. Antiapoptotic (38), as well as pro-
apoptotic (7), effects have been reported, probably depending
on the cellular context. The two proteins interacted only upon
Ca2 influx and subsequent FKBP38 activation. However, we
did not observe a cofactor-dependent interaction of FKBP38
with PHD2, nor did the addition of Ca2 to cell lysates alter
the hydroxylation activity, and cell viability was not affected
by RNAi-mediated downregulation of FKBP38 as measured
by MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium
bromide] assays (data not shown). Further potential functions
of FKBP38 include antitumor effects by regulation of anti-
invasive syndecan 1 and suppression of proinvasive MMP9 and
regulation of cell size via the tuberous sclerosis complex (12,
35). Clearly, the increasing amount of data about potential
FKBP38 functions suggests that FKBP38 is a multifunctional
protein involved in the regulation of many cellular processes,
but further studies are required for a better comprehension of
the biochemical functions of FKBP38.
In addition to FKBP38, the candidate tumor suppressor
ING4 was shown to associate with PHD2, suppressing HIF
activity and thereby possibly attenuating HIF target genes in-
volved in tumor growth and angiogenesis (31). It has been
proposed that ING4 retains PHD2 in the nucleus in order to
degrade HIF upon reoxygenation. However, recent data
showed predominant cytoplasmic localization of PHD2 (39).
PHD2 has a calculated molecular mass of 46 kDa, enabling it
to pass through nuclear pores, and it might be actively ex-
cluded from the nucleus by interaction with FKBP38. FKBP38
contains a C-terminal transmembrane domain that anchors the
protein in the mitochondrial and endoplasmic reticulum mem-
branes, and our immunofluorescence data also show a patchy
cytoplasmic staining for PHD2, indicating an association with
subcellular cytoplasmic structures (Fig. 1D). Additionally, it
has recently been demonstrated that PHD2 interacts with the
HIF-1 C-terminal ODD domain (aa 498 to 603) and thereby
reduces the transcriptional activity of this fragment (44). Al-
though we cannot exclude the possibility that attenuation of
HIF-1 transcriptional activity by PHD2 is involved in reduced
hypoxic HIF-dependent reporter gene (Fig. 5A) as well as HIF
target gene (Fig. 6D) induction in FKBP38 siRNA clones, our
data suggest that elevated PHD2 protein levels attenuate hy-
poxic HIF-1 stabilization (Fig. 5B and 6C).
PHDs represent attractive new therapeutic targets to mod-
ulate HIF activity, and thus functional understanding of PHD
function and regulation is crucial. Recently, it has been re-
ported that an inherited mutation in the active site of PHD2
leads to decreased hydroxylation activity and is associated with
familial erythrocytosis (32). These data confirm previous stud-
ies with cultured cells implicating PHD2 as the primary PHD
isoform responsible for HIF regulation under physiological
conditions (2). Interestingly, a screen for genetic mutations in
endometrial cancer cells identified PHD2 as being mutated at
significantly higher frequencies (19). Expression of wild-type
PHD2 in mutated cells induced senescence by negatively reg-
ulating HIF-1 expression, suggesting that PHD2 might be a
candidate tumor suppressor. Specific upregulation of PHD2 in
a FKBP38-dependent manner opens novel possibilities for in-
terfering with one PHD family member specifically, thereby
attenuating HIF signaling in cancer cells.
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Abstract
The prolyl-4-hydroxylase domain (PHD) oxygen sensor proteins hydroxylate
hypoxia-inducible transcription factor (HIF)-alpha (a) subunits, leading to their
subsequent ubiquitinylation and degradation. Since oxygen is a necessary
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cosubstrate, a reduction in oxygen availability (hypoxia) decreases PHD activity
and, subsequently, HIF-a hydroxylation. Non-hydroxylated HIF-a cannot be
bound by the ubiquitin ligase von Hippel-Lindau tumor suppressor protein
(pVHL), and HIF-a proteins thus become stabilized. HIF-a then heterodimerizes
with HIF-beta (b) to form the functionally active HIF transcription factor com-
plex, which targets approximately 200 genes involved in adaptation to hypoxia.
The three HIF-a PHDs are of a different nature compared with the prototype
collagen prolyl-4-hydroxylase, which hydroxylates a mass protein rather than a
rare transcription factor. Thus, novel assays had to be developed to express and
purify functionally active PHDs and to measure PHD activity in vitro. A need also
exists for such assays to functionally distinguish the three different PHDs in
terms of substrate specificity and drug function. We provide a detailed descrip-
tion of the expression and purification of the PHDs as well as of an HIF-a–
dependent and a HIF-a–independent PHD assay.
1. Introduction
Cells sense changes in environmental oxygen availability by a group of
enzymes that directly control the cellular response to low oxygen by destabi-
lizing HIF-a subunits, the master transcriptional regulators of the hypoxic
response. These oxygen-sensing enzymes have alternatively been termed
PHD, HIF prolyl hydroxylase (HPH), or egg-laying defective nine homolog
(EGLN). Up to date, three family members are known: PHD1/HPH3/
EGLN2, PHD2/HPH2/EGLN1, and PHD3/HPH1/EGLN3 (Bruick,
2000; Epstein et al., 2001; Ivan et al., 2002). PHDs hydroxylate HIF-1a and
HIF-2a at two distinct proline residues within the HIF-a oxygen-dependent
degradation (ODD) domain (Fig. 3.1A). Under normoxic conditions, prolyl-
4-hydroxylase allows binding of pVHL, leading to polyubiquitinylation and
proteasomal destruction (Schofield and Ratcliffe, 2004; Wenger, 2002).
Under hypoxic conditions, prolyl-4-hydroxylase is reduced, and HIF-1a
and HIF-2a become stabilized, heterodimerize with the constitutively
expressed HIF-1b subunit aryl hydrocarbon receptor nuclear translocator
(ARNT), and regulate the expression of a large number of effector genes
involved in adaptation to low oxygen (Wenger et al., 2005). In addition,
factor-inhibiting HIF (FIH) hydroxylates an asparagine residue within the
C-terminal transactivation domain. Oxygen-dependent asparagine hydroxyl-
ation blocks the recruitment of the CREB-binding protein (CBP)/p300
transcriptional coactivators and thereby regulates the transcriptional activity
of HIFs (Hewitson et al., 2002; Lando et al., 2002; Mahon et al., 2001).
Prolyl-4-hydroxylase domain proteins do not represent static oxygen
sensor molecules, but rather are highly regulated themselves. Importantly,
PHD2 and PHD3, but not PHD1, have been reported to be hypoxically
induced at both the messenger RNA (mRNA) and protein levels (Epstein
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Figure 3.1 (A) Reaction mechanism of prolyl-4-hydroxylase domain (PHD)-
mediated oxygen-dependent prolyl-4-hydroxylation by oxidative decarboxylation of
the cosubstrate 2-oxoglutarate. Inhibitors of this reaction are indicated. N-OG,
N-oxalylglycine; DMOG, dimethyloxalylglycine. (B) Purification of glutathione
S-transferase (GST)-tagged PHD1, PHD2, and PHD3 expressed in baculovirus-
infected Spodoptera frugiperda (Sf) 9 insect cells by glutathione affinity chromatography.
The purified GST-PHD proteins were analyzed by sodium dodecyl sulfate polyacryl-
amide gel electrophoresis (SDS-PAGE) andCoomassie blue staining (CBS) or immuno-
blotting (IB) using anti-GST antibodies for the detection of GST-PHD1 and
GST-PHD2 or anti-PHD3 antibodies for the detection of PHD3. (C) Hydroxylation
activities of GST-PHDpreparations determined byavonHippel-Lindautumor suppres-
sor protein (pVHL)/elongin B/elongin C (VBC)-binding assay, as described in the text.
Wild-type (Pro) and P564A mutant (Ala) hypoxia-inducible transcription factor
(HIF)-1a oxygen-dependent degradation (ODD) domain-derived peptides were used
as hydroxylation substrates.
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et al., 2001). Accordingly, elevated PHD2 and PHD3 levels have been
demonstrated in a broad panel of established cancer cell lines (Appelhoff
et al., 2004). Functional hypoxia response elements (HREs) are located in the
promoter region of the human PHD2 gene as well as in the first intron of the
human PHD3 gene, demonstrating that PHD2 and PHD3 are HIF target
genes themselves (Metzen et al., 2005; Pescador et al., 2005). Because the
essential cofactor oxygen is basically lacking under hypoxic conditions, the
HIF-dependent hypoxic increase in PHD abundance is somehow paradoxi-
cal; it has been suggested that PHD induction plays a role in accelerating the
termination of the HIF response following reoxygenation (Appelhoff et al.,
2004; Aprelikova et al., 2004; Epstein et al., 2001; Marxsen et al., 2004).
Indeed, biochemical in vitro studies revealed Km values of purified PHDs for
oxygen close to the oxygen partial pressure (pO2) in air, suggesting that the
kinetics of specific HIF-a hydroxylation under hypoxic conditions are rather
slow (Ehrismann et al., 2006;Hirsila¨ et al., 2003).Of note, theseKm values are
critically dependent on the length of the target peptide (Koivunen et al.,
2006). However, tissues in situ have to deal with a great variability of
generally very low pO2 values, even when the inspiratory pO2 is considered
to be ‘‘normoxic.’’ We recently showed that HIF-dependent regulation of
PHD levels adapts the PHD-HIF oxygen sensing system to a given tissue pO2
rather than simply accelerating HIF-a destruction following reoxygenation
(Stiehl et al., 2006). Such a self-regulatory loop might define a tissue-specific
threshold for HIF-a activation as a function of local pO2.
In addition to transcriptional regulation, PHD levels are also regulated by
protein–protein interactions: the ubiquitin ligase Siah2 regulates PHD1 and
PHD3, but not PHD2, protein stability (Nakayama et al., 2004); PHD3, but
not PHD1 or PHD2, appears to be a substrate for the TRiC chaperonin
(Masson et al., 2004); OS-9 apparently is simultaneously interacting with
both HIF-a and PHD2 or PHD3, but not PHD1, thereby enhancing HIF-a
hydroxylation and degradation (Baek et al., 2005); andMorg1might provide
the molecular scaffold for HIF-a interaction specifically with PHD3 (Hopfer
et al., 2006). On the other hand, PHD2 has been shown to inhibit the
transactivation function of HIF-1a in VHL-deficient cells (To and Huang,
2005), a process that might involve PHD2-dependent recruitment of ING4,
a likely component of a chromatin-remodeling complex (Ozer et al., 2005).
These findings suggest two additional layers in oxygen signaling: first,
abundance and function of PHDs actually can be regulated; and second, the
three different PHDs are regulated in nonidentical ways, further supporting
their non-redundant roles in oxygen sensing. In fact, while all three PHDs
can hydroxylate HIF-a with similar efficiency in vitro, PHD2 has been
suggested to play the main role for normoxic HIF-a turnover in cultured
cells (Berra et al., 2003). Consistent with these findings, PHD2, but neither
PHD1 nor PHD3, knockout mice die during embryonic development
(Takeda et al., 2006). Interestingly, a family with erythrocytosis due to a
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mutation in the gene encoding PHD2 has recently been reported (Percy
et al., 2006). The three PHDs are expressed in most organs; however,
strikingly high levels of PHD3 and PHD1 mRNA are expressed in the
heart and testis, respectively (Stiehl et al., 2006; Willam et al., 2006).
PHD function can also be regulated by a number of endogenous small
molecules as well as by a number of clinically relevant drugs; ascorbate
(Knowles et al., 2003), transition metals (Hirsila¨ et al., 2005; Martin et al.,
2005), Krebs cycle intermediates (Dalgard et al., 2004; Lu et al., 2005; Selak
et al., 2005), and reactive oxygen species (ROS), including NO (Berchner-
Pfannschmidt et al., 2006; Gerald et al., 2004; Metzen et al., 2003), have
been shown to influence or completely block the activity of the PHDs.
Thus, molecular cross-talks appear to exist between oxygen homeostasis and
transition metal homeostasis as well as cellular metabolism. However, it is
not completely understood how various transition metals and ascorbate
interfere with PHD and FIH function. The transition metals do not simply
replace or oxidize the ferrous iron in the active center of the hydroxylases
(Hirsila¨ et al., 2005; Martin et al., 2005); at least cobalt and nickel might
deplete intracellular ascorbate (Karaczyn et al., 2006; Salnikow et al., 2004).
As known for collagen hydroxylation, ascorbate is essential in reducing
ferric iron in the active center of PHDs and FIH, which occurs when
oxidative decarboxylation of 2-oxoglutarate is uncoupled from target
hydroxylation (McNeill et al., 2005; Myllyla¨ et al., 1984).
In addition to kinase signaling pathways, numerous reports appeared about
an involvement of ROS in HIF-a protein stabilization by either growth
stimuli or hypoxia. Inconclusive data were obtained about the source(s) of
the ROS and whether hypoxia leads to an increase or decrease in ROS levels
(Wenger, 2000). However, ROS do have the potential to interfere with the
complex process of protein hydroxylation. Indeed, the increase in ROS in
junD/ cells leads to a decrease in PHD activity and hence to HIF-1 a
accumulation (Gerald et al., 2004). Apart from direct interference of
ROS with the active center of oxygen sensing protein hydroxylases, the
redirection of oxygen from mitochondria towards the protein hydroxylases
might contribute to these effects (Hagen et al., 2003; Wenger, 2006).
Due to the large therapeutic potential of PHD inhibitors in the treatment
of anemic and ischemic diseases, several attempts to develop PHD antagonists
are in progress. Currently, N-oxyalylglycine (N-OG) and its cell-permeable
derivative dimethyloxalylglycine (DMOG) are the commercially available
PHD inhibitors of choice for experimental purposes. Apart from these cosub-
strate competitive inhibitors, iron chelators are verywell known to induceHIF
by PHD inhibition. These include deferoxamine (DFX) and ciclopirox
olamine (CPX), two clinically relevant hydroxamic acid iron chelators
(Linden et al., 2003). In order to functionally investigate the potency and
mechanisms of available and future PHD inhibitors, a need exists for reliable
methods to generate PHD proteins and to determine their activity.
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2. Production of Functionally Active PHDs
Since bacterially expressed PHDs retain only little hydroxylase activity,
PHDs were expressed and purified from baculovirally infected insect cells.
To facilitate purification, the PHDs were tagged with either glutathione
S-transferase (GST), maltose-binding protein (MBP), or His6. According to
our experience, best results were obtained with GST-tagged PHD proteins.
Thus, GST-tagged expression vectors were prepared by LR clonase-
mediated homologous recombination of the corresponding pENTR vector
containing PHD1, PHD2, or PHD3 complementary DNA (cDNA) inserts,
with the pDEST20 vector (Invitrogen, Carlsbad, CA). Recombined plas-
mids were transfected into the Escherichia coli strain DH10BAC, and the
resulting bacmid plasmids were used to generate baculovirus stocks accord-
ing to themanufacturer’s instructions (Invitrogen). Spodoptera frugiperda (Sf) 9
cells were infected with baculovirus and cultured in Grace’s insect medium
(Invitrogen) at 27 in a humidified incubator. Infected cells were grown for
80 to 110 h, collected by centrifugation at 700g for 10 min at 4, and
washed with ice-cold phosphate buffered saline (PBS). Lysis was performed
on ice for 10 min with 0.1%NP-40 in a buffer containing 10 mMTris-HCl,
pH 7.4, 100 mMNaCl, 100 mM glycine, 100 mM dithiothreitol (DTT), and
ethylenediaminetetraacetic acid (EDTA)-free complete protease inhibitor
cocktail (Roche Applied Science, Indianapolis, IN). Crude lysate was
cleared by centrifugation at 20,000g for 20 min at 4, and the supernatant
was incubated with glutathione-Sepharose beads (previously washed with
PBS) for at least 2 h at 4 with gentle agitation. After washing three times
with PBS, the protein was eluted with 15 mM reduced glutathione (GSH) in
50 mM Tris-HCl, pH 8.0, and 2 mM FeSO4. Eluted proteins were supple-
mented with 5% glycerol and stored in aliquots at –80. Purity was checked
by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE)
followed by Coomassie staining or immunoblotting (see Fig. 3.1B). Activity
was routinely determined by the VHL binding assay described later (see
Fig. 3.1C).
3. Determination of PHD Activity by VHL Binding
to Peptides Derived from the HIF-1a
ODD Domain
Enzymatic activities of recombinant PHD proteins were determined
by an in vitro hydroxylation assay based on a 96-well format, as de-
scribed previously (Oehme et al., 2004). Briefly, biotinylated
synthetic peptides derived from human HIF-1a amino acids 556 to 574
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(biotin-DLDLEALAPYIPADDDFQL), either wild-type, P564A mutant,
or hydroxylated (Hyp564), were bound to NeutrAvidin-coated 96-well
plates (Pierce, Rockford, IL). All methionine residues were mutated to
alanine residues in these peptides (M561A, M568A). Hydroxylase reactions
using purified recombinant GST-tagged PHDs or cellular extracts were
carried out for 1 h at room temperature. A polycistronic bacterial expression
vector for His6-tagged and thioredoxin-tagged pVHL/elongin B/elongin C
(VBC) complex (kindly provided by S. Tan, Pennsylvania State University,
University Park, PA) was used to express VBC in E. coli strain BL21AI,
followed by purification using nickel affinity chromatography (GE Health-
care, Buckinghamshire, UK), followed by anion exchange chromatography
using a Hi Trap Q FF column (GE Healthcare) and gel filtration Hi Prep
26/10 desalting column; GE Healthcare). The VBC complex was allowed
to bind to the hydroxylated peptides for 15 min, anti-thioredoxin antibo-
dies were added for 30 min, and horseradish peroxidase-coupled anti-rabbit
antibodies (Sigma, St. Louis, MO) were added for 30 min. Bound VBC
complex was detected using the 3,30,5,50-tetramethylbenzidine (TMB)
substrate kit (Pierce). The peroxidase reaction was stopped by adding one
volume 2 M H2SO4, and absorbance was determined at 450 nm in a
microplate photometer. This assay is routinely used to determine the activity
of the three GST-tagged PHD enzymes purified from Sf 9 insect cells (see
Fig. 3.1C). Interassay comparability was guaranteed by calibration of each
experiment to an internal standard curve using increasing fractions of synthetic
hydroxyproline–containing peptides (Fig. 3.2A). When performed with
pre-equilibrated solutions in a hypoxic glove box (Inviv02 400; Ruskinn
Technology, Pencoed, UK), this assay demonstrates that PHD2 and
PHD3 hydroxylase activities are functional over a wide range of physiologi-
cally relevant oxygen concentrations (see Fig. 3.2B). Furthermore, this assay is
strictly dependent on the presence of P564 within the substrate peptide,
and the iron chelator DFX as well as the substrate analog N-OG inhibit
PHD-dependent prolyl-4-hydroxylation (see Fig. 3.2C).
Apart from purified recombinant PHDs, crude cellular extracts also are
suitable sources of PHD activity for the VBC-binding assay. Therefore,
Hep3B cells were lysed by dounce homogenization in 100 mM Tris-HCl,
pH 7.5, 1.5 mM MgCl2, 8.75% glycerol, 0.01% Tween20, and EDTA-free
complete protease inhibitor cocktail (Roche Applied Science, Indianapolis,
IN). Cell lysates were cleared by centrifugation at 20,000g for 30 min at 4.
These extracts stimulated VBC binding to wild-type, but not P564A mutant,
HIF-1aODD-derived peptides (see Fig. 3.2D). The specificity of the PHD
activity was further demonstrated by inhibition with 2 mM N-OG and by
culturing the Hep3B cells under hypoxic conditions (0.4% O2 for 16 h).
Consistent with the known hypoxic induction of PHD2 and PHD3, extracts
derived from hypoxic Hep3B cells showed an increased PHD activity (see
Fig. 3.2D). Similar results were obtained with HeLa cells (data not shown).
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Figure 3.2 (A) Von Hippel-Lindau tumor suppressor protein (pVHL)/elongin
B/elonginC (VBC) complexbinding toprolyl-4-hydroxylated hypoxia-inducible tran-
scription factor (HIF)-1a oxygen-dependent degradation (ODD) domain-derived
peptides. Biotinylated peptides containing increasing proportions of synthetically gen-
erated hydroxyproline peptides were allowed to bind to NeutrAvidin-coated 96-well
enzyme-linked immunosorbent assay (ELISA) plates. Immunodetection of bound
VBC complex was performed, as described in the text. (B) Oxygen-dependent activity
of recombinant glutathione S-transferase (GST) prolyl-4-hydroxylase domain (PHD)
2 and GST-PHD3. Purified PHD proteins were used to hydroxylate HIF-1a ODD
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4. Determination of Prolyl-4-Hydroxylation by
Oxidative Decarboxylation of 2-Oxoglutarate
While the VHL binding assay is well suited to investigate PHD
function, it is strictly dependent on VBC binding and hence unlikely to
investigate the hydroxylation of potential novel non–HIF-a targets. To
overcome this problem, a 2-oxoglutarate to succinate conversion assay,
originally developed to study collagen hydroxylation (Kaule and Gu¨nzler,
1990), was adapted to HIF-a hydroxylation. There are basically two possi-
bilities to label the 2-oxoglutarate cosubstrate: when [5-14C]2-oxoglutarate
is used, the resulting [14C]succinate can be measured (Kaule and Gu¨nzler,
1990); when [1-14C]2-oxoglutarate is used, the resulting [14C]CO2 must be
captured and quantified (Hirsila¨ et al., 2003). Because it is technically less
demanding, the former technique is used in our laboratory. This assay was
first applied for PHD measurements by Frelin and coworkers using ‘‘light
mitochondrial rat kidney fractions’’ (D’Angelo et al., 2003a,b). We measured
oxidative decarboxylation of 2-oxoglutarate by purified PHDs because
kidney extracts prepared according to Frelin and coworkers solely showed
high background activities, but did not contain measurable quantities of
specific PHD activity (described later). Peptide (5–50 mM) or protein sub-
strates (5 mM) were incubated with 0.1 mg GST-tagged PHD enzymes
in 100 ml 50 mM Tris-HCl, pH 7.4, 10 mM 2-oxoglutarate, 2 mM
ascorbate, 100 mM DTT, 1 mg/ml BSA, 0.6 mg/ml catalase, 5 mM freshly
prepared FeSO4, and 50,000 to 100,000 dpm [5-
14C] 2-oxoglutarate with a
specific activity of 50 mCi/mmol (Hartmann-Analytic, Braunschweig, Ger-
many). The 2-oxoglutarate concentration can be varied from 10 to 100 mM,
depending on the peptide/protein target concentration and the desired
specific radioactivity. Generally, a two-fold molar excess over the target
concentration was used. Hydroxylation reactions were carried out for 24 h
at 37. To separate 2-oxoglutarate from succinate, 25 ml 20 mM succinate and
20 mM 2-oxoglutarate were added and mixed by vortexing. Subsequently,
25 ml 0.16M 2,4-dinitrophenyl hydrazine in 30% HClO4 were added. After
incubation at room temperature for 30 min, 50 ml of 1M 2-oxoglutarate was
added to remove residual 2,4-dinitrophenyl hydrazine, and the reaction was
domain-derived peptides under the indicated oxygen concentrations (%vol/vol in the
gas phase). The extent of prolyl-4-hydroxylation was quantitated, as previously
described. (C) PHD3 and the wild-type peptide substrate (Pro) are required for VBC
binding.The lack of peptide (), a P564A mutation (Ala), iron chelation by deferroxa-
mine (DFX), or N-oxalylglycine (N-OG) all completely inhibited VBC binding.
(A^C) Shown aremeanvaluesSEMof triplicates. (D)Hypoxia stimulates PHDactiv-
ity in Hep3B cells. Crude cellular lysates were used to hydroxylate HIF-1a ODD
domain-derived peptides, as previously described. Shown are mean values  SEM of
triplicates normalized to protein content.
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allowed to proceed for another 30 min at room temperature. Following
centrifugation at 20,000g for 15 min at 4, 150 ml supernatant was carefully
removed, mixed with 3 ml scintillation cocktail (PerkinElmer, Waltham,
MA), and the amount of [14C]succinate was determined by liquid scintillation
counting in a b-counter (TRI-CARB 2900TR, Packard).
As depicted in Fig. 3.3A, recombinant GST-PHD2 shows a linear
relationship between the availability of an HIF-1a ODD domain-derived
synthetic peptide substrate and [14C]succinate production in the range from
8- to 50-mM peptide. Below 5 mM, however, only background values were
obtained. This assay is strictly dependent on the presence of 1 mM ascorbate
as well as a peptide substrate containing the wild-type P564 (see Fig. 3.3B).
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Figure 3.3 (A) Determination of prolyl-4-hydroxylation by oxidative decarboxyl-
ation of [5-14C]2-oxoglutarate. Recombinant glutathione S-transferase (GST) prolyl-
4-hydroxylase domain (PHD) 2 was incubated with increasing concentrations of a
hypoxia-inducible transcription factor (HIF)-1a oxygen-dependent degradation
(ODD) domain-derived peptide, as indicated. PHD-dependent generation of [14C]
succinatewas determined, as described in the text. Background activitywas determined
in control reactions without substrate peptide and the obtained value subtracted from
the peptide-containing reactions. (B) Recombinant GST-PHD2 was incubated with
increasing concentrations of ascorbate (as indicated) and either a wild-type, P564A
mutant, or no peptide substrate.
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The lack of a substrate peptide or the mutation of the critical proline
(P564A) results in background 2-oxoglutarate conversion.
5. Crude Tissue Extracts are not a Suitable
Source of PHD Activity for the
2-Oxoglutarate Conversion Assay
Earlier reports suggested the use of ‘‘light mitochondrial rat kidney
fractions’’ as a source for PHD activity in this type of assay (D’Angelo et al.,
2003a,b). We therefore prepared rat kidney extracts according to this proto-
col and tested them for PHD activity. As shown in Fig. 3.4A, 2-oxoglutarate
conversion was indeed stimulated by these extracts. However, a very high
background activity was also observed in the absence of the HIF-1a
ODD domain-derived peptide, and the presence of the wild-type peptide
stimulated 2-oxoglutarate conversion only moderately. To ensure PHD-
dependent 2-oxoglutarate conversion, ample amounts of the known PHD
inhibitors DFX and N-OG (see Fig. 3.2C) or CuCl2 (Martin et al., 2005)
were added to the reaction mix. Surprisingly, none of these PHD inhibitors
blocked 2-oxoglutarate conversion, whether the substrate peptide was pres-
ent or not (see Fig. 3.4A, left panel). Moreover, the presence of a P564A
mutant peptide stimulated 2-oxoglutarate conversion as well as the wild-
type peptide (see Fig. 3.4A, right panel). The P564A mutant peptide cannot
be hydroxylated and shows no VBC complex binding after incubation with
purified PHDs (see Figs. 3.2C and 3.3B). Therefore, these experiments
demonstrate that ‘‘light mitochondrial rat kidney fractions’’ do not represent
a source of specific PHD activity, but rather contain high levels of enzymes
not specifically metabolizing 2-oxoglutarate. A similar lack of specific (i.e.,
PHD-dependent) 2-oxoglutarate conversion was observed with crude
extracts derived from HeLa, Hep3B, and Sf 9 cells (data not shown).
6. Thin Layer Chromatography to Assess the
Purity of [5-14C]2-Oxoglutarate
Amajor problem in the optimization of the 2-oxoglutarate conversion
method is the high proportion of background activity when non-purified
PHD preparations are used as a source of the enzymatic activity. Indeed,
cellular extracts usually contain too high background activities to be
suitable as PHD sources, even when the PHDs are exogenously overex-
pressed. Another background-causing problem was the quality of the
radioactively labelled [5-14C]2-oxoglutarate. To analyze the [5-14C]2-
oxoglutarate preparations for impurities, it was diluted in 1.5 mM unlabeled
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2-oxoglutarate and spotted onto thin layer chromatography (TLC) plates
(Silica gel 60 F254, Merck, Whitehouse Station, NJ). Following drying, the
TLC plate was placed in a chromatography chamber containing a 120:70:15
mixture of diethyl ether/hexane/formic acid. When the eluent reached
the top of the TLC plate, it was dried and the radioactivity quantitated by
phosphorimaging (BioRad, Hercules, CA). Unlabeled 2-oxoglutarate and
succinate were used as standards. They were visualized as bright yellow
spots by immersing the TLC plates in a 0.04% bromcresol purple solution
in a 1:1 mixture of ethanol and water (adjusted to pH 10.0 with NaOH)
and dried with a hairdryer. Rf values for succinate and 2-oxoglutarate
were 0.45 and 0.12, respectively. Considerable differences exist in the
quality of the available [5-14C]2-oxoglutarate preparations (see Fig. 3.4B).
While some batches were of acceptable purity (Fig. 3.4B, left panel),
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Figure 3.4 (A) Lack of specific 2-oxoglutarate-to-succinate conversion by ‘‘light
mitochondrial rat kidney fractions.’’ (Left panel) Peptide-stimulated activity in these
extracts could not be inhibited by DFX, CuCl2, or N-OG. (Right panel) A P564A
mutant (Ala) hypoxia-inducible transcription factor (HIF)-1a oxygen-dependent
degradation (ODD) domain-derived peptide stimulated 2-oxoglutarate conversion
and the wild-type (Pro) peptide. (B) Quality control of [5-14C]2-oxoglutarate by thin
layer chromatography. The amount of [5-14C]2-oxoglutarate spotted corresponded to
30, 15, 7.5, and 3.8 kdpm, respectively (from left to right). Two [5-14C]2-oxoglutarate
batches of different quality are shown. Pure 2-oxoglutarate and succinate served as
migrationmarkers (positions indicated in rightmargin).
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others contained up to 30% of an impurity that co-migrated with the
succinate standard (Fig. 3.4B, right panel). Regarding the relatively low
specific PHD activities and the rather high unspecific background
2-oxoglutarate conversion, such high impurities are not acceptable in this
type of assay.
7. Application of the 2-Oxoglutarate
Conversion Assay to Protein Targets
In order to be useful for putative novel PHD substrate proteins
without prior knowledge of the actual target prolyl residue, the
2-oxoglutarate conversion assay needs to work also with proteins rather
than only with synthetic peptides. To demonstrate the feasibility of this
approach, wild-type GST-HIF-2aODD (aa 404–569, MW ¼ 46 kDa) and
P405A/P531A double-mutant GST-HIF-2aODD protein fragments were
expressed in E. coli BL21AI by induction with 0.2% arabinose for 4 h at 37.
After harvesting by centrifugation, the bacteria were lysed with a high-
pressure cell disrupter (Basic-Z, Constant Systems Ltd, Sanford, NC) in the
presence of EDTA-free complete protease inhibitor cocktail (Roche
Applied Science, Indianapolis, IN). Purification of the GST-tagged protein
was carried out using affinity chromatography on glutathione Sepharose
beads (GE Healthcare, Buckinghamshire, UK), as previously described
(see Fig. 3.1B). Purity of the recombinant protein fragments was checked
by SDS-PAGE followed by Coomassie staining or immunoblotting
(Fig. 3.5A). When compared with an HIF-1aODD–derived wild-type
peptide, equimolar concentrations of the HIF-2aODD protein fragment
also stimulated PHD1-dependent 2-oxoglutarate conversion, albeit to a
somewhat lower extent (see Fig. 3.5B).
8. Conclusions
The PHD-dependent hydroxylation assay presented here works inde-
pendently of already known peptide sequences or VHL binding. It should
thus be possible to use this assay for the investigation of putative novel, non–
HIF-a PHD substrates as well. In addition, even if not shown here, the same
assay should principally be applicable to novel FIH substrates and might
become useful for screening for novel hydroxylation targets. Whereas no
non–HIF-a PHD hydroxylation targets have been reported thus far, FIH
has recently been shown to hydroxylate a number of proteins containing
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ankyrin repeats, including NF-kB and IkBa (Cockman et al., 2006). We
expect a similar widening of the spectrum of PHD targets. In addition,
PHD-dependent hydroxylation assays will be required to study novel drugs
that modulate PHD activity and hence will become important for the
treatment of anemic and ischemic disease.
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Figure 3.5 (A) Purification of wild-type and P405/531A double-mutant glutathione
S-transferase (GST) hypoxia-inducible transcription factor (HIF)-2a oxygen-dependent
degradation (ODD human HIF-2a amino acids 404^569) protein fragments expressed
in bacteria and purified by glutathione affinity chromatography.The purified proteins
were analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) and Coomassie blue staining (CBS) or immunoblotting (IB) using anti-GST
antibodies. (B) Determination of prolyl-4-hydroxylation byoxidative decarboxylation
of [5-14C]2-oxoglutarate. Recombinant GST-PHD1^dependent generation of [14C]
succinate was promoted by HIF-1a ODD-derived wild-type (wt), but not by P564A
mutant (mt) peptides (human HIF-1a amino acids 556^574). Generation of [14C]succi-
nate was also promoted by wild-type GST-HIF-2aODD protein, but not by GSTalone
and to a much lower extent by the GST-HIF-2aODD P405/531A double mutant. Equi-
molar concentrations (5 mM) of the substrate peptides and protein fragments were used.
Where indicated, the reactions could be blocked by 5 mM N-oxalylglycine (N-OG).
Shown are mean values  SEM of three independent experiments performed in
duplicates.
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Prolyl-4-hydroxylases (PHDs) are oxygen-dependent enzymes that mediate the 
rapid destruction of the hypoxia-inducible factor (HIF)-α subunits. Three PHD 
isoforms (PHD1-3) are known to regulate HIF-α and they differ in their cellular 
and tissue distribution as well as in their in vivo functions as determined by 
genetic mouse models. PHD1 and PHD3 protein stability is regulated by the 
binding of the Siah1/2 ubiquitin ligase, followed by degradation in the 26S 
proteasome. However, little is known about PHD2 protein regulation. Recently, 
we reported that the FK506-binding protein 38 (FKBP38) specifically interacts 
with PHD2 and thereby modulates PHD2 protein stability in a peptidyl prolyl 
cis/trans isomerase (PPIase) independent manner. Here, we show that PHD2 
protein regulation is independent of ubiquitinylation and proteasomal 
degradation but the FKBP38 transmembrane domain and therefore FKBP38 
sub-cellular localization is essential for the interaction with PHD2 and required 
to determine PHD2 protein abundance. 
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Introduction 
HIFs are central regulators of the cellular, local and systemic response to reduced 
oxygen partial pressure (pO2). The HIF protein complex consists of a HIF-α and HIF-
1β subunit (1), (2). HIF-α is constitutively expressed but under normoxic conditions 
rapidly degraded by the ubiquitin-proteasome pathway. HIF-α protein stability is 
determined by specific hydroxylation of prolines in the oxygen-dependent 
degradation domain (ODDD) by the oxygen-dependent PHDs and subsequent 
binding of the von Hippel-Lindau tumor suppressor protein (pVHL) (3), (4), (5), (5), 
(6). VHL is the recognition component of an E3 ubiquitin ligase complex and targets 
HIF-α for proteasomal destruction. So far, three PHD isoforms (PHD1-3) have been 
identified that mediate HIF-α protein stability in an oxygen-dependent manner (7), 
(8), (9). Additionally, the asparaginyl hydroxylase factor inhibiting HIF (FIH) regulates 
oxygen-dependently the transcriptional activity of HIF (10). 
In hypoxia, PHDs and FIH are inactive and hence HIF-α accumulates, translocates 
to the nucleus and forms a heterodimeric complex with the constitutively expressed 
HIF-1β subunit. As a transcription factor, HIF regulates the expression of more than 
70 target genes that allow the organism to adapt to hypoxia on the systemic, local 
and cellular level (11). 
PHDs belong to the non-heme, Fe2+- and 2-oxoglutarate-dependent family of 
dioxygenases. They require di-oxygen, Fe2+ and 2-oxoglutarate for their enzymatic 
reaction and therefore PHD activity correlates with the availability of oxygen. 
However, PHD2, PHD3 but not PHD1 are induced under hypoxia and are able to 
restrict hypoxic HIF response by compensating the lack of oxygen due to increased 
PHD protein levels and activity (12), (13). Besides HIF-α subunits, only a few other 
PHD hydroxylation targets have been described so far (14), (15), (16). 
Interestingly, genetic ablation of PHD2 resulted in embryonic lethality between E12.5 
to E14.5 due to defects in the developing placenta whereas Phd1-/- and Phd3-/- 
mice were viable (17). In adult mice, PHD2 somatic inactivation led to severe 
erythrocytosis as a result of increased erythropoietin (EPO) serum levels and EPO 
mRNA in the kidney whereas PHD1 and PHD3 single knockout mice showed no 
severe phenotype (18), (19). PHD1 and PHD3 double knockout animals 
demonstrated moderate erythrocytosis. Phd1-/- mice had a lowered oxygen 
consumption in skeletal muscle by shifting the glucose metabolism to anerobic 
glycolysis and preserved the muscle myofibers against ischemic necrosis (20). 
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Despite genetic ablation of PHD3 increased the number of superior cervical ganglion 
neurons in the sympathoadrenal system, the sympathoadrenal function was 
disturbed leading to low systemic blood pressure (21). 
These genetic in vivo models suggest that PHDs might have redundant as well as 
non-redundant functions and seems conceivable that PHDs are itself a subject of 
regulatory mechanisms to limit their activity and/or stability. 
Recently, we demonstrated that the FK506-binding protein 38 (FKBP38) specifically 
interacts with PHD2 but neither with PHD1 nor PHD3 (22). Stable downregulation of 
FKBP38 by RNAi in HeLa cells increased PHD2 protein abundance and therefore 
enhanced PHD hydroxylation activity and lowered HIF-1α accumulation under 
hypoxic conditions. Increased PHD2 protein levels resulted from enhanced PHD2 
protein stability in a PPIase independent manner. Here, we report that the sub-
cellular localization of FKBP38 is required for the regulation of PHD2 protein levels. 
 
Experimental Procedures 
Plasmids 
If not indicated otherwise, cloning work was carried out using Gateway technology 
(Invitrogen, Basel, Switzerland). Cloning of PCR fragments into entry vectors and 
recombination in destination vectors was described previously (22). All restriction 
enzymes were purchased from MBI Fermentas, Labforce, Nunnigen, Switzerland 
and New England Biolabs, United Kingdom. pENTR4-PHD2 from amino acid (aa) 1 
to 162 (pENTR4-PHD2_1-162), pENTR4-PHD2_1-31, pENTR4-PHD2_1-58, 
pENTR4-PHD2_1-114 was obtained by amplifying PHD2_1-162, 1-31, 1-58, 1-114 
from plasmid pENTR/D-PHD2 by PCR and subsequent cloning in XhoI/NcoI 
digested pENTR4-vector. pENTR/D-PHD2_21-426 and pENTR/D-PHD2_63-426 
were obtained by digesting with MscI/ScaI and MscI/KasI followed by Klenow fill-in 
and re-ligation. pENTR4-FKBP38_1-389 (∆TM) was generated by insertion of a stop 
codon in pENTR4-FKBP38_1-412 by site-directed mutagenesis. The inserts of all 
entry vectors were verified by DNA sequencing (Microsynth, Balgach, Switzerland). 
To generate fusion protein expression vectors, entry vectors were recombined in 
vitro with destination vectors using LR Clonase recombination enzyme mix 
(Invitrogen). The mammalian Matchmaker vectors pM and pVP16 (Clontech, BD 
Biosciences, Heidelberg, Germany) were converted to destination vectors by ligation 
of the Gateway vector conversion cassette reading frame B (Invitrogen) into the 
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EcoRI sites of pM and pVP16 to generate pM-DEST and pVP16-DEST, respectively. 
Expression vectors for Gal4 DNA-binding domain (pM) or VP16 activation domain 
(VP16) fusion proteins were obtained after in vitro recombination with the 
corresponding entry vectors. The mammalian one-hybrid plasmid pM-HIF-1α_370-
429-VP16AD was generated described previously (22). Plasmids pDEST15 and 
pDEST17 were used to generate vectors for GST- and His6-fusion protein 
expression in bacteria or in rabbit reticulocyte lysates. The plasmid used to generate 
recombinant GST-HIF-1α_530-826 was described previously (23). pDEST20 was 
used to generate expression vectors for GST-fusion proteins in the baculovirus/Sf9 
insect cell system (Invitrogen). pcDNA3.1/nV5-DEST were used to express N-
terminal V5-tagged proteins in mammalian cells, respectively. The mammalian 
fluorescent vectors pECFP-C1 and pEYFP-C1 (Clontech, BD Biosciences, 
Heidelberg, Germany) were converted to destination vectors by ligation of the 
Gateway vector conversion cassette reading frame B (Invitrogen) into the SmaI sites 
of pECFP-C1 and pEYFP-C1 to generate pECFP-C1-DEST and pEYFP-C1-DEST, 
respectively. 
Chemicals 
Chemicals were purchased from the following companies: CHX (Sigma Aldrich, 
Switzerland), E64 (Alexis Biochemicals), AEBSF (Alexis Biochemicals), MG132 
(Sigma Aldrich, Switzerland), ALLM (Calbiochem), Pepstatin A (Alexis 
Biochemicals). 
Peptide array synthesis 
Using the standard SPOT synthesis protocol (24), the peptides were synthesized 
stepwise by an Abimed Asp 222 synthesizer on a cellulose membrane derivatized 
with two β-Ala residues as linker. 9H-fluoren-9-ylmethoxycarbonyl (Fmoc) protective 
groups were cleaved with 20% piperidine in dimethylformamide (DMF). After 
washing, the Fmoc amino acids (preactivated as pentafluorophenyl esters) were 
coupled. The side-chains of the amino acids were protected as follows: Pbf 
(arginine), Trt (asparagine, glutamine, histidine, cysteine), tBu (threonine, tyrosine, 
serine), OtBu (aspartic acid, glutamic acid), Boc (lysine, tryptophan). After coupling, 
all unreacted amino groups were blocked with acetic anhydride. In the final cycle, the 
deprotection with piperidine was performed before acetylation and thus N-terminal 
acetylated peptides were obtained. All protective groups were cleaved for 3 h with 30 
ml 50% trifluoroacetic acid (TFA) / dichlormethane (DCM) containing 1 ml 
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triisopropylsilane (TIPS). 
Western blot analysis of PHD2 interaction with the peptide array 
Before Western blot screening, the dry peptide-array membranes were rinsed for 10 
min in methanol and for 3x20 min in TBS buffer (30 mM Tris/HCl, pH 7.6, 170 mM 
NaCl, 6.4 mM KCl). PHD2 variant solutions (100 nM) in TBS buffer were allowed to 
react with peptide-array membranes for 4 h at 4°C under gentle shaking. The 
membrane was subsequently washed 3 times with TBS buffer, before bound protein 
was blotted onto nitrocellulose membranes and analyzed using polyclonal rabbit anti-
PHD2 antibodies (Abcam, Cambridge, United Kingdom). 
Peptide synthesis 
The peptides were produced by solid-phase peptide synthesis with the robot Syro II 
(MultiSynTech, Witten, Germany) using 0.15 mmol pre-loaded Fmoc-Asn(Trt)-Wang 
resin from NovaBiochem (Läufelfingen, Switzerland). The synthesis was performed 
by Fmoc strategy and standard protocol, with Fmoc amino acids as building blocks, 
as well as benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate 
(PyBOP), (NovaBiochem) and N-methyl-morpholine as coupling reagents in 
dimethylformamide (DMF). Piperidine (20%)/DMF was the standard cleavage 
cocktail used for Fmoc detachment. The resin was treated twice for 10 minutes. All 
couplings were performed using a 4-fold excess of Fmoc amino acid derivative, 
PyBOP and N-methyl-morpholine in DMF. A double coupling protocol was used. The 
coupling of biotin at the N-terminal position of the protected peptide was carried out 
in N-methyl-pyrrolidone/DMSO (1:1 v/v). After detachment of the peptides from the 
resins and side-chain deprotection with TFA/TIPS/thioanisol/N-(methyl) 
mercaptoacetamide/ water (80/7.5/5/2.5/2.5/2.5 v/v) at room temperature for 12 h, 
the crude peptides were precipitated with diethylether and purified by RP-HPLC 
using Gilson 306 equipment with a SP 250/10 Nucleosil 100-7 C8 column 
(Macherey-Nagel, Düren, Germany) by applying a water (0.1% TFA/acetonitrile) 
gradient. The purified peptides were lyophilized. The purity of the peptides was 
evaluated by analytical HPLC and the correct molecular masses were confirmed by 
MALDI-TOF mass spectrometry. 
Protein binding assay 
Streptavin agarose (Sigma, Deisenhofen, Germany) was saturated with Biotin-
EEEEEEEEEEDDLSELPPLE-NH2 peptide and washed three times with incubation 
buffer (25 mM Tris/HCl, 200 mM NaCl, 1 mM DTT, pH 7.5). PHD2 variants (1 µM) 
MANUSCRIPT 
- 59 - 
were incubated either in presence or absence of Ac-EEEEEEEEEEDDLSELPPLE-
NH2 peptide (20 µM) and FKBP38 (10 µM) with the affinity matrix for 1 h at 4 °C. 
Subsequently, the samples were washed three times with incubation buffer, boiled in 
Laemmli buffer and subjected to SDS-PAGE. Binding of PHD2 was analyzed using 
polyclonal rabbit anti-PHD2 antibodies (Abcam, Cambridge, United Kingdom). 
For incubation with endogenous rat proteins, rat liver was decomposed in 50 mM 
Hepes buffer (4% Chaps, 1% DTT, 100 mM NaCl, 0.1% NaN3, pH 7,5) and 
centrifuged at 14’000 x g for 10 min at 4°C. The supernatant was applied to the 
affinity matrix in analogy to the PHD2 proteins. 
Fluorescence spectroscopy 
Steady-state fluorescence spectra were recorded on a Perkin Elmer FluoroMax2 
fluorescence spectrometer, using a 1 × 1 cm cuvette with an excitation wavelength of 
280 nm and excitation and emission slit widths of 5 and 3 nm, respectively. To 
compensate for inner filter effects, the samples for fluorescence measurements were 
diluted to an optical density at 280 nm of 0.15. Protein samples were applied in 
25 mM Tris/HCl buffer (200 mM NaCl, 1 mM DTT, pH 7.5). The binding constant (KD) 
was calculated from the fluorescence intensity by using the equation: 
n
K
n
CP D−−
⋅=⋅
)1(
0
0 α
αα  
where P0 = total protein concentration, α = (Fmax - F)/(Fmax - F0), Fmax = fluorescence 
intensity at saturation, and F0 = initial fluorescence intensity, n = number of 
independent binding sites, C0 = total PHD2 concentration at each addition, and KD = 
dissociation constant. 
Protein expression and purification 
GST and GST-fusion proteins were expressed in E. coli BL21-AI by induction with 
0.02% arabinose for 4 h and purified using glutathione sepharose beads (Amersham 
Biosciences). Purification of GST-PHD2 from Sf9 insect cells was previously 
described (25). 
In vitro transcription/translation (IVTT) and GST pull-down 
IVTT reactions were carried out as described by the manufacturer instructions 
(Promega, Madison, WI, USA) using recombined destination vectors in the presence 
of 35S-Met (Hartmann Analytic, Braunschweig, Germany). Purified GST-tagged 
proteins (10 µg) were diluted in bead binding buffer (50 mM potassium phosphate pH 
7.5, 150 mM KCl, 1 mM MgCl2, 10% glycerol, 1% TX-100) and incubated with 
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glutathione sepharose beads. For pull-down experiments, 20 µl rabbit reticulocyte 
IVTT reaction were incubated for 2 h at 4ºC with bound GST-fusion proteins in Co-IP 
buffer containing 50 mM Tris-HCl pH 7.6, 2 mM EDTA, 100 mM NaCl, 0.1% TX-100, 
washed 4 times with Co-IP buffer, boiled in sample buffer (40 mM Tris-HCl pH 6.8, 
1% SDS, 50 mM β-mercaptoethanol) for 5 min and separated by SDS-PAGE. Gels 
were stained with coomassie blue, dried and radioactively labeled proteins detected 
by phosphorimaging (Molecular Imager FX, BioRad). 
Cell culture and transient transfection 
The mouse E1-ubiquitin-activating enzyme temperature sensitive ts20 cells and the 
ts20 cell line reconstituted with wild-type E1 gene (H38-5) were kindly provided by 
Prof. C. Borner (Insitute for Molecular Medicine and Cell research, University of 
Freiburg, Freiburg, Germany). The mouse primary FKBP38 knockout and wild-type 
embryonic fibroblasts (MEFs) were a kind gift of M. Shirane (Medical Institute of 
Bioregulation, Kyushu University, Fukuoka, Japan). HeLa cervical carcinoma, 
HEK293 embryonic kidney carcinoma, MCF-7 breast cancer, mouse ts20, H38-5, 
wild-type and MEF FKBP38 knockout cell lines were cultured in high glucose 
Dulbecco's modified Eagle's medium (DMEM, Sigma) as described previously (15). 
Transient transfections were performed with the polyethylenimine (PEI; 
Polysciences, Warrington, PA, USA) method (12). 
Western Blot analysis 
Total cell extracts of cultured cells were prepared using RIPA buffer containing 50 
mM Tris Cl pH 8.0, 1 mM EDTA pH 8.0, 150 mM NaCl, 1% Triton X-100, 0.5% Na-
deoxycholate, 0.1% SDS. Protein concentration was determined using the BCA 
assay (Pierce, Perbio Science, Lausanne/Switzerland). Immunoblotting was 
performed as described previously (26). Briefly, protein was separated by SDS-
PAGE, electro-transferred onto nitrocellulose membranes (Amersham Biosciences) 
and incubated with antibodies. The following antibodies were used: rabbit anti-PHD2 
(Novus, Abcam, Cambridge. United Kingdom), rabbit anti-mouse PHD2 (Novus 
Biological), rabbit anti-FKBP38 (27), mouse anti-β-actin (Sigma Aldrich, Switzerland), 
mouse anti-PDI (Novus Biological), rabbit anti-Mitofilin (Novus Biological), mouse 
anti-p53 (Santa Cruz Biotechnology) and mouse anti-V5 antibody (Invitrogen). 
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Fluorescence microscopy and fluorescence resonance energy transfer (FRET) 
analysis 
Cells were cultivated on microscope slides, washed twice with ice-cold PBS, fixed on 
ice for 30 min with 4% paraformaldehyde and permeabilized with 0.1% saponine in 
PBS. Endogenous as well as transfected proteins were detected using the indicated 
antibodies. Cellular organelles were stained with Mitotracker (Molecular Probes, 
Invitrogen), WGA-Alexa 594 (Molecular Probes, Invitrogen) and with antibodies 
against PDI or Calreticulin (Novus Biologicals). Immune complexes were visualized 
with goat anti-rabbit Alexa 488, goat anti-mouse Alexa 488, goat anti-rabbit Alexa 
568 or goat anti-mouse Alexa 568 (Molecular Probes, Invitrogen), respectively. 
Nuclei were stained with DAPI (Sigma Aldrich, Switzerland) for 30 min. After 
extensive washings with PBS, the microscope slides were embedded in Mowiol and 
analyzed by confocal laser scanning microscopy (SP1, Leica Microsystems, 
Switzerland). For FRET analysis, HEK293 cells were transfected with indicated 
plasmids and FRET was monitored as described previously (28). 
Mammalian one- and two-hybrid assays 
Mammalian one- and two-hybrid analyses were performed using the mammalian 
Matchmaker system (Clontech, BD Biosciences) described previously (22). HeLa 
cells were transiently co-transfected with 10 ng one-hybrid or 1.5 µg Gal4 DNA 
binding domain (DBD) and 1.5 µg Gal4 activation domain (AD) fusion protein 
vectors, together with 500 ng of firefly luciferase reporter vector pGRE5xE1b and 20 
ng pRL-SV40. Luciferase reporter gene activity was determined using the dual 
luciferase reporter assay system according to the manufacturer’s instructions 
(Promega). 
Sub-cellular fractionation 
Cells were incubated in hypotonic buffer (10 mM HEPES pH 7.5, 1 mM EGTA, 25 
mM KCl) on ice for 20 min and afterwards dounce homogenized in homogenization 
buffer (10 mM HEPES pH 7.5, 1 mM EDTA, 250 mM sucrose). Cell lysates were 
centrifuged for 15 min at 4ºC at 3’000 x g to pellet nuclei and non lysed cells. To 
separate the membrane from the cytosolic fraction the supernatant was centrifuged 
for 1 h at 4ºC at 100’000 x g. The cytosolic fraction was stored for immunoblotting. 
The membrane fraction was resuspended in homogenization buffer and overlayered 
above a 10 to 30% iodixanol gradient and centrifuged for 18 h at 150’000 x g to 
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separate the membrane fractions. By punctuation of the centrifugation tubes, 1 ml 
fractions were obtained and analyzed by immunoblotting. 
In vitro VBC-dependent prolyl-4-hydroxylation assay 
1x108 HeLa cells were pelleted and dounce homogenized in 1 ml cell lysis buffer 
(100 mM Tris-Cl pH 7.5, 1.5 mM MgCl2, 8.75% glycerol, 0.01% Tween 20) 
supplemented with EDTA free complete protease inhibitors (Roche). Lysates were 
centrifuged for 30 min at 4°C at 20’000 x g and VBC-binding was determined as 
previously described (29), (25). 
RNA extraction and real-time RT-qPCR quantification 
Cells were grown in 15 cm plates under normoxic or hypoxic conditions and total 
RNA was extracted as described previously (26). First strand cDNA synthesis was 
performed with 3 µg of RNA using AffinityScriptTM multiple temperature reverse 
transcriptase (RT) according to the manufacturer’s instructions (Stratagene). 
Subsequently, mRNA expression levels were quantified with 2 µl of diluted cDNA 
reaction by real-time PCR using a SybrGreen Q-PCR reagent kit (Sigma) and the 
MX3000P light cycler (Stratagene, Amsterdam, The Netherlands). Initial template 
concentrations of each sample were calculated by comparison with serial dilutions of 
a calibrated standard. To verify RNA integrity and equal input levels, mouse 
ribosomal protein S12 mRNA was determined and data expressed as ratios relative 
to mS12 levels. Primers were used as follows: mS12 forward 5’-
gaagctgccaaagccttaga-3’, mS12 reverse 5’- aactgcaaccaaccaccttc-3’ mFKBP38 
forward 5’-attgctggcaggaactgact-3’, mFKBP38 reverse 5’-cagtccttcctgcttcttgg-3’ 
mPHD1 forward 5’-ttgcctgggtagaaggtcac-3’, mPHD1 reverse 5’-
gctcgatgttggctaccact-3’; mPHD2 forward 5’-gcaacggaacagg6ctatgtc-3’, mPHD2 
reverse 5’-ctcgctcatctgcatcaaaa-3’; mPHD3 forward 5’-caacttcctcctgtccctca-3’, 
mPHD3 reverse 5’-ggctggacttcatgtggatt-3’. 
 
Results 
Biochemical characterization of the PHD2:FKBP38 interaction. 
Recently, we reported that FKBP38 interacts with PHD2 but neither with PHD1 nor 
PHD3 (22). To further characterize the interacting domains of both proteins, we 
performed a peptide scan. A peptide array of 13mer peptides covering the entire 
protein sequence of FKBP38 was incubated with purified PHD2. PHD2 bound to 
peptides corresponding to FKBP38 from aa 37 to 56 to the N-terminal extension of 
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FKBP38, preceding the catalytic domain (Fig. 1A upper panel). PHD2 did not bind 
the reverse sequence of this motif in the peptide array demonstrating the stereo 
specificity of the interaction between PHD2 and the FKBP38_37-56 motif (Fig. 1B 
lower panel). In contrast, an N-terminal truncated PHD2 protein from aa 170 to 426 
did not bind to the peptide array, demonstrating the requirement of the N-terminal 
PHD2 domain for the interaction with FKBP38 (data not shown). 
Based on these results, the peptide biotinyl-EEEEEEEEEEDDLSELPPLE-NH2, 
which corresponds to the PHD2-interacting FKBP38 motif, was immobilized on 
streptavidin beads and subsequently analyzed for binding to purified PHD2 protein. 
PHD2 bound to the affinity matrix and this binding was diminished in the presence of 
a peptide corresponding to PHD2-binding motif of FKBP38 or FKBP38 itself, 
indicating competition between matrix and soluble FKBP38 variants for PHD2 
binding (Fig. 1B). In contrast, no binding of PHD2 170-426 to the affinity matrix was 
observed. These results suggest that the N-terminal PHD2 domain binds specifically 
to the identified motif in the FKBP38 N-terminus. In a further attempt, rat liver lysate 
was applied to either the affinity matrix or streptavidin beads done to test whether 
endogenous PHD2 interacts with the binding motif in FKBP38. Endogenous rat 
PHD2 bound only to the affinity matrix (Fig. 1C). 
To further analyze the interaction between FKBP38 and PHD2, measurements of the 
protein fluorescence of both interaction partners were performed. Upon the 
interaction between the N-terminal domains of FKBP38 and PHD2 the fluorescence 
spectrum was blue-shifted by 2 nm and the amplitude was increased by 12% 
compared to the sum of the fluorescence spectra of the separated proteins (Fig. 2A). 
In comparison, no changes in the protein fluorescence were observed, when the 
PHD2_170-426 was added to FKBP38 (Fig. 2B), again demonstrating the 
requirement of the N-terminal PHD2 domain for the interaction with FKBP38. 
Interestingly, the increase in the fluorescence signal, which occurs upon 
FKBP38:PHD2 interaction of the full-length proteins, was reduced in presence of the 
peptide corresponding to the PHD2-binding site in FKBP38 in a concentration 
dependent manner (Fig. 2C). The measurements resulted in a KD value of 1.48 ± 
0.15 µM for the interaction between FKBP38-37-56 peptide and PHD2. 
Furthermore, we performed isothermal titration calorimetry (ITC) measurements to 
characterize the interaction between PHD2 and the N-terminal extension of FKBP38 
(data not shown). The titration curve revealed a 1:1 complex and a dissociation 
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constant (KD) of 895 ± 148 nM for this interaction. For interactions between PHD2 
and FKBP38_37-56 ITC measurements showed as well a 1:1 stoichiometry and a KD 
= 1.28 ± 0.19 µM, which is similar to the result of the fluorescence titration curve. 
Mapping PHD2 interaction domain in FKBP38. 
PHD2 consists of a N-terminal MYND-type Zn2+ finger domain from aa 21 to 58 and 
a prolyl-4-hydroxylase catalytic subunit from aa 205 to 391 (Fig. 3A). Previously, we 
have shown that FKBP38 bound to the N-terminal region of PHD2 from aa 1 to 170. 
To further investigate the detailed interaction domain, we generated several PHD2 
N-terminal deletion constructs and analyzed the interaction in GST pull-down 
experiments (Fig. 3A). GST-FKBP38 strongly interacted with in vitro transcribed and 
translated (IVTT) 35S-labeled full-length PHD2 and PHD2_1-162 but no interaction 
was observed when GST-FKBP38 was incubated with any of the N-terminal 
deletions PHD2_21-426, 63-426 and 170-426 (Fig. 3B). GST alone did not bind to 
the different PHD2 fragments. We then generated several PHD2 C-terminal deletion 
fragments tested them for in vitro interaction. Surprisingly, IVTT 35S-labeled FKBP38 
only bound to GST-PHD2_1-114 but not to GST-PHD2_1-31, GST-PHD2_1-58 (Fig. 
3C and D). Therefore, we propose an interaction of FKBP38 with the N-terminal 
region of PHD2 from aa 1 to 114 containing the MYND-type Zn2+ finger domain. In 
addition, experiments investigating the binding of recombinant FKBP38 to a PHD2 
13mer peptide array did not lead to the identification of a distinct binding domain, 
suggesting a non-linear FKBP38 binding region in PHD2 (data not shown). 
PHD2 protein abundance is elevated in Fkbp38-/- cells. 
FKBP38 knockout mice die around embryonic day E13.5 due to defects in the 
development of the central nervous system (30). However, in another genetic 
background knockout of FKBP38 did not affect the viability of the mice but these 
mice displayed severe bone and cartilage deformation, probably due to increased 
cell death in the posterior neural tube (31). In HeLa FKBP38 knockdown cells, PHD2 
protein abundance was increased and PHD2 half life was prolonged whereas PHD2 
mRNA was not affected (22). We measured PHD2 protein and mRNA levels in 
primary Fkbp38+/+ and Fkbp38-/- MEF cells. Comparable to FKBP38 
downregulation in HeLa cells, PHD2 protein levels were slightly increased in 
normoxia (Fig. 4A). Under hypoxic conditions PHD2 protein was less induced 
compared to Fkbp38 wild-type MEFs (Fig. 4A). Neither PHD1 nor PHD2 and PHD3 
mRNA levels were affected in Fkbp38 knockout MEFs compared to wild-type MEFs 
MANUSCRIPT 
- 65 - 
in normoxia (Fig. 4B). 
PHD2 protein stability is regulated in an ubiquitin-independent manner. 
To explore the molecular mechanism of FKBP38 mediated PHD2 protein regulation, 
we investigated the proteolytic destruction of PHD2. MCF-7 cells were incubated in 
normoxia with protease inhibitor E64 (cysteine protease inhibitor), AEBSF (serine 
protease inhibitor), Pepstatin A (aspartyl protease inhibitor), ALLM (calpain inhibitor, 
catepsin L, B and neutral cysteine protease inhibitor) and MG132 (proteasomal 
inhibitor). Additionally, MCF-7 cells were pre-incubated for 24 h under hypoxic 
conditions and re-oxygenated in the presence of the described protease inhibitors 
above. Neither under normoxic conditions (Fig. 5A) nor during re-oxygenation (Fig. 
5B) PHD2 protein levels were affected by the incubation with these protease 
inhibitors. PHDs have been described to interact with the ubiquitin ligase Siah1/2 
(32). However, the functional consequence of the PHD2:Siah1/2 interaction 
remained unknown. To completely exclude the possibility of ubiquitin-mediated 
PHD2 proteasomal destruction we made use of mouse ts20 cells that possess a 
temperature sensitive E1-ubiquitin activating enzyme (33). Mouse PHD2 protein 
abundance was not affected in ts20 cells incubated under 34ºC or 39ºC for up to 48 
h (Fig. 5C). Additionally, no changes were observed for FKBP38. However, p53 a 
known protein target to be degraded by the ubiquitin-proteasome system, strongly 
accumulated under 39ºC incubation. As control, incubation of a ts20 cell line stably 
transfected with a wild-type E1 gene (H38-5) under 34ºC or 39ºC did not result in the 
accumulation of PHD2, FKBP38 and p53 (Fig. 5D). Furthermore, we questioned if 
different oxygen concentrations might influence PHD2 protein half-life. Hence, HeLa 
cells were treated with 100 µM CHX for 24, 48 and 72 h and cultivated either at 20% 
O2 or under 0.2% O2 (Fig. 5E). PHD2 protein stability was not significantly affected 
by the different oxygen concentration. Additionally, FKBP38 also did not show any 
oxygen-dependent differences in the protein stability. 
FKBP38 transmembrane domain determines PHD2 protein abundance. 
FKBP38 has been described to localize to the mitochondria and endoplasmatic 
reticulum (ER) (30) and we questioned whether the sub-cellular localization of 
FKBP38 might be important for PHD2 protein regulation. Hence, we generated a 
FKBP38 expression plasmid where the C-terminal transmembrane domain of 
FKBP38 (FKBP38_1-389) was deleted. Transiently transfected full length V5-tagged 
FKBP38_1-412 and FKBP38∆98-257 lacking the PPIase domain localized to 
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mitochondria (mitotracker) and endoplasmatic reticulum (calreticulin) (Fig.6A and B). 
FKBP38_1-389 was expressed diffusively throughout the cytosol and did not co-
localize either with Mitotracker or with calreticulin (Fig.6A and B). All V5-FKBP38 
fusion proteins did not localize to the golgi apparatus stained with WGA (Fig. 6C). 
Changes in the PHD2 protein levels directly influence the stability of HIF-α subunits. 
To investigate the stability of HIF-1α we co-transfected MCF-7 cells with HIF-
1α_370-429 flanked at the N-terminal end with Gal4-DBD and at the C-terminal end 
with VP16AD, a firefly luciferase reporter gene construct containing five Gal4-DBD 
responsive elements and a Renilla luciferase control plasmid. As shown in figure 6D 
expression of V5-tagged FKBP38_1-412 and FKBP38∆98-257 enhanced greatly 
HIF-1α one-hybrid stability compared to mock transfected MCF-7 cells, but the effect 
was not observed by FKBP38_1-1389 (∆TM) expression in normoxia and hypoxia. 
All expression plasmids were equally expressed as shown in figure 6D. Similar 
results were obtained in HeLa cells stably transfected either with a control plasmid 
harboring nonspecific oligonucleotides (ctrl) or a FKBP38-silencing construct (3D6, 
2G8). Expression of full length FKBP38 strongly increased the HIF-1α 370-429 one 
hybrid stability and it was comparable to mock transfected cells when FKBP38 1-389 
was overexpressed (Fig. 6E). Of note, in the FKBP38 knockdown cells the HIF-1α 
one hybrid construct is less stabilized than to control cell line due to increased PHD2 
protein stability under normoxic and hypoxic conditions. Furthermore, PHD2 protein 
levels were increased in HeLa FKBP38 depleted cell lines 3D6 and 2G8 compared 
to control and wild-type HeLa cells (Fig. 6F). Overexpression of full length V5-tagged 
FKBP38 in HeLa 3D6 and 2G8 reduced PHD2 protein levels comparable to control 
and wild-type HeLa cells wheras overexpression of V5-FKBP38_1-389 did not affect 
PHD2 protein levels (Fig. 6F), suggesting that the transmembrane domain of 
FKBP38 might be required in regulating PHD2 protein abundance. Consistent with 
these data, increased hydroxylation activity was observed in the FKBP38-depleted 
cells by using the VBC-dependent prolyl-4-hydroxylase assay (34), (25) and only 
expression of V5-tagged FKBP38_1-412 but not FKBP38_1-389 normalized prolyl 
hydroxylation (Fig. 6G). 
Correct FKBP38 sub-cellular localization is required for interaction with PHD2. 
To investigate whether the interaction of FKBP38 with PHD2 depends on the sub-
cellular localization of FKBP38, we applied FRET technology. We observed a FRET 
signal when CFP-FKBP38 and YFP-PHD2 were expressed in HEK293 cells. As 
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control, no signal was detected when the interaction domain of FKBP38 (CFP-
FKBP38_99-412) was deleted (Fig. 7A). Surprisingly, no FRET signal was observed 
when CFP-FKBP38_1-389 (∆TM) was co-expressed with YFP-PHD2 despite of the 
presence of the interaction domain of FKBP38 (Fig. 7A). However, in in vitro GST 
pull-down experiments GST-tagged FKBP38_1-412 and GST-FKBP38_1-389 
interacted with 35S-labeled PHD2 (Fig. 7B). To confirm the requirement of the 
FKBP38 transmembrane domain for the interaction with PHD2 in cells, we applied 
mammalian two-hybrid technology. The activity of a co-transfected luciferase 
reporter gene construct is greatly enhanced when DBD-PHD2 and AD-FKBP38_1-
412 were co-transfected in HeLa cells (Fig. 7C). Consistent with the FRET data, low 
luciferase reporter gene activity was measured when DBD-PHD2 was co-expressed 
with AD-FKBP38 1-389. Co-transfection of DBD-p53 with AD-CP or with AD-LT 
served as a positive and negative control, respectively. These data suggest that the 
transmembrane domain of FKBP38 is required for the binding to PHD2 in a cellular 
context. 
PHD2 co-localizes with FKBP38 in the cellular membrane fraction. 
By overexpression studies, PHD2 has been reported to be localized mainly in the 
cytosol (35). However, detailed sub-cellular localization of PHD2 has not been 
described so far. FKBP38 has been reported to be a membrane associated protein 
localized in the ER and in mitochondria (30). Since the localization of FKBP38 
seems to be important for regulation of PHD2 protein amount, we investigated the 
sub-cellular localization of PHD2 in more detail. By biochemical fractionation we 
analyzed PHD2 protein levels in the membrane and cytosolic fractions of wild-type 
HeLa cells and the FKBP38-knockdown cell line 2G8 (Fig. 8A and B). We observed 
an increase in PHD2 protein amount with decreased FKBP38 protein levels in the 
FKBP38 depleted cells but no shift of PHD2 protein in dependency of FKBP38 
availability from the membrane to cytosolic fraction was seen (Fig. 8B). Furthermore, 
cells were incubated for 16 h in hypoxia and PHD2 protein amount was detected in 
the membrane as well as cytosolic fraction in both cell lines, however to a higher 
extend in the FKBP38-depleted cells (Fig. 8C-E). 
 
Discussion 
HIF-α protein stability is tightly controlled by hydroxylation of specific prolines in the 
ODDD by the oxygen-sensing prolyl-4-hydroxylases PHDs. PHDs are not only 
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regulated by the availability of oxygen, as PHD2 and PHD3 expression is 
transcriptionally induced by HIF under hypoxic conditions and thereby compensating 
reduced oxygen partial pressure (pO2) (12), (13). PHD1 and PHD3 protein 
abundance are regulated by binding to the E3 ubiquitin ligase Siah1/2 and both 
proteins are targeted for proteasome-dependent degradation (32). Additionally, 
PHD2 interacted with Siah1/2 though the functional consequence remained elusive. 
Recently, we reported that PHD2 protein abundance is regulated by the peptidyl 
prolyl cis/trans isomerase FKBP38 in a peptidyl prolyl cis/trans isomerase-
independent manner (22). In this present study, we characterized in more detail the 
functional consequence of the FKBP38:PHD2 interaction. We discovered that the 
PHD2:FKBP38 interaction did not only require the N-terminal binding motif of 
FKBP38 but in addition the transmembrane domain of FKBP38 was essential for the 
interaction with PHD2. Moreover, the FKBP38 transmembrane domain and therefore 
FKBP38 sub-cellular localization was crucial for PHD2 protein regulation. 
FKBP38 binds with a minimal linear glutamate-rich binding motif from aa 37 to 56 to 
PHD2, a so far unknown interaction domain. PHD2 interacts with a non-linear motif 
from aa 1 to 114 to FKBP38. This region contains a MYND-type Zn2+ finger domain. 
A large group of proteins among the vertebrates have a MYND-type Zn2+ finger 
domain, mainly functioning as an interaction domain to recruit transcriptional co- and 
repressor complexes. PHD2 has been reported to have a potential transcriptional 
activity (36). Additionally, PHD2 has been demonstrated to interact with ING4 to 
recruit transcriptional repressors to limit the HIF response (37). We found a specific 
interaction of the N-terminal region of PHD2 with FKBP38. FKBP38 localization has 
been described to mitochondria and endoplasmatic reticulum and therefore this 
interaction might be important to keep PHD2 in the cytosol to regulate its function 
(30). Consistent with this assumption, FRET analysis and ITC measurements 
provide evidence for a tight interaction comparable to HIF-1α:HIF-1β interaction (28). 
However, a partial fraction of PHD2 was attached to ER and mitochondria. 
Additionally, PHD2 was found in the cytosol. Of note, neither PHD1 nor PHD3 
contain a MYND-type Zn2+ finger domain suggesting a different protein regulation. N-
terminal deletion of PHD2 renders PHD2 susceptible to degradation by Siah1/2 like 
PHD1 and PHD3 (38). 
We identified the transmembrane domain of FKBP38 to be crucial for the interaction 
with PHD2. FKBP38 was described to be targeted to mitochondria and to ER and 
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moreover we observed binding of PHD2 to these organelles. Previously, 
mitochondrial pattern of PHD2 was already observed in rat tissues (39). The 
interaction domain containing the MYND-type Zn2+ finger domain of PHD2 in 
FKBP38 was suggested to be an anchor to organelles and thereby modulating PHD2 
protein activity (40). We found that FKBP38 mediates the binding of PHD2 to ER and 
mitochondria and is required for PHD2 protein regulation. We explored the 
mechanism of PHD2 protein degradation. So far, we could not identify a specific 
protease or the ubiquitin-proteasome pathway to be involved in the degradation of 
PHD2. These data might suggest that a unique protease or a FKBP38-dependent 
degradation pathway is involved in the degradation of PHD2. Moreover, FKBP38 
might be directly involved in regulation of PHD2 protein steady state levels by a so 
far unknown mechanism.  
Interestingly, the PPIase Pin1 regulates the steady state levels of a variety of 
proteins to mediate proteasome-dependent and non-dependent proteasomal protein 
degradation (41), (42). Therefore, it might be most likely that PPIases may have 
additional functions to regulate the steady state levels of proteins. FKBP38 was also 
reported to have a chaperone activity monitored by in vitro refolding assays (43), 
(44). It remains open if this activity is involved in PHD2 regulation. 
In summary, our results suggest that the transmembrane domain of FKBP38 is 
crucial for the FKBP38:PHD2 interaction and for the regulation of the PHD2 protein 
levels. Specific pharmacological disruption of FKBP38:PHD2 might be an interesting 
approach to modulate PHD2 protein abundance thereby influencing HIF-1α protein 
stability. 
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Figure Legends 
Figure 1. Detailed analysis of FKBP38 interaction domain. 
(A) An array of 13mer peptides spanning the FKBP38 sequence was synthesized 
with forward-shifts by one amino acid. PHD2 interaction with the peptide array of the 
FKBP38 sequence forward (upper panel) and reverse (lower panel) was analyzed by 
Western blot. The respective binding motif comprised the peptides b13-24, which 
correspond to FKBP38 aa 37 to 56. The reverse sequence comprised of the same 
amino acids was not found to interact with PHD2 (lower panel). (B) Western blot 
analysis of the interaction between different PHD2 and a biotin-labeled FKBP38_37-
56 peptide bound streptavidin matrix using anti-PHD2 antibodies. The streptavidin 
matrix alone served as control. (C) Co-IP analysis of endogenous proteins from rat 
liver lysate interacting with a FKBP38_37-56 affinity matrix using anti-PHD2 
antibodies. The streptavidin matrix served as binding control. 
 
Figure 2. Biochemical characterization of the FKBP38:PHD2 interaction. 
(A) Fluorescence measurements at an excitation wavelength of 278 nm with 1 µM 
FKBP38 (__), 1 µM PHD2 (…) and a 1:1 mixture of both proteins (---). In addition, 
the calculated spectrum (__ __) represents the sum of the individual protein spectra, 
as it should appear when the components do not interact. (B) Fluorescence spectra 
of 1 µM FKBP38 (__), 1.25 µM PHD2_170-426 (…) and a 1:1 mixture of both 
proteins (---) at an excitation wavelength of 278 nm. In addition, the calculated 
spectrum (__ __) represents the sum of the individual protein spectra, as it should 
appear when the fluorescence of the proteins is not affected by the addition of a 
potential interaction partner. (C) Titration curve resulting from fluorescence 
measurements at 340 nm (excitation at 278 nm) of a sample containing 1 µM 
FKBP38/PHD2 and various concentrations of a peptide corresponding to 
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FKBP38_37-56. The straight line represents the fit according to the equation in the 
Materials and Methods section. 
 
Figure 3. Mapping of the PHD2 interaction domain. 
(A) Schematic representation of the PHD2 domain architecture and the used PHD2 
constructs. (B) IVTT 35S-labeled PHD2 variants were allowed to bind to GST-
FKBP38 or GST alone; protein complexes were pulled-down by glutathione 
sepharose, separated by SDS-PAGE and visualized by phosphorimaging. (C and D) 
IVTT 35S-labeled FKBP38 was allowed to interact with GST-PHD2_1-426, GST-
PHD2_170-426, GST-PHD2_1-31, GST-PHD2_1-58, GST-PHD2_1-114 or GST 
alone. GST pull-down was done described above. 
 
Figure 4. FKBP38 regulates PHD2 protein abundance. 
(A) Cellular extracts from FKBP38 wild-type or knockout MEFs incubated for 8 h at 
20% O2 or 0.2% O2 were extracted with RIPA buffer, separated by SDS-PAGE and 
endogenous FKBP38, PHD2 and β-actin were detected by immunoblotting. (B) Total 
RNA was extracted from Fkbp38+/+ and Fkbp38-/- MEFS cultivated at normoxia and 
mRNA levels of mPHD1, mPHD2 and mPHD3 and mS12 were quantified by real-
time RT-qPCR. Transcript levels of these genes were normalized to mS12 (mean of 
n = 2). 
 
Figure 5. Proteolytic regulation of PHD2. 
Cellular extracts were prepared, separated by SDS-PAGE and analyzed by Western 
blotting. (A) MCF-7 cells were incubated at 20% O2 with indicated protease 
inhibitors: E64 (50 µM), AEBSF (300 µM), MG132 (10 µM), ALLM (10 µM), Pepstatin 
(10 µM). DMSO and EtOH served as solvent control. (B) MCF-7 cells were pre-
incubated for 24 h at 0.2% O2 and then re-oxygenated in the presence of indicated 
protease inhibitors described under A. (C) Mouse ts20 cell line was incubated either 
under 34ºC or 39ºC for 24, 48, 72 h and cellular extracts were analyzed by 
immunoblotting. (D) Mouse ts20 cell line reconstituted with a wild-type E1 gene 
(H38-5) were incubated under the same conditions described in (C) and cellular 
proteins were analyzed by Western blotting. (E) HeLa cells were treated with 100 µM 
CHX and incubated for 24, 48, 72 h at 20% O2 or 0.2% O2. Cellular extracts were 
analyzed by immunoblotting. (F) HeLa cells were treated with 100 µM CHX and 
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incubated for 24, 48, 72 h at 20% O2 or 0.2% O2. PHD2 protein levels were 
quantified by densitometry and results are mean values of relative intensity 
normalized to time point 0 ± SEM of three independent experiments. 
 
Figure 6. FKBP38 transmembrane domain determines PHD2 protein stability. 
(A-C) HeLa cells were transiently transfected with pcDNA3.1-nV5-FKBP38, 
FKBP38∆98-257, FKBP38_1-389. After fixation, cells were stained with V5, DAPI 
and either with mitotracker (mitochondria marker), calreticulin (ER marker) or with 
WGA (golgi marker). (D) MCF-7 cells were transiently transfected with Gal4-
DBD_HIF-1α-370-429_VP16-AD expression vector (schematically represented), 
Gal4 response element-driven firefly luciferase reporter, renilla luciferase control 
vector and either co-transfected with V5-FKBP38, V5-FKBP38∆98-357, V5-
FKBP38_1-389 or mock (pcDNA3.1-nV5-LacZ) transfected. 24 h post-transfection, 
cells were either cultured under normoxic or hypoxic conditions for additional 16 h 
and firefly luciferase activities were determined and corrected for renilla luciferase 
activity. Results are mean values of relative luciferase activities ± SEM of 4 
independent experiments performed in triplicates. P values were obtained by paired t 
tests (** p<0.01; * p<0.05). Expression of the transfected V5-tagged vectors was 
verified by immunoblotting against V5 and β-actin. (E) HeLa FKBP38 RNAi control 
cells (ctr, 3A5) and FKBP38 RNAi depleted cells (3D6, 2G8) were transiently 
transfected with HIF-1α one-hybrid construct, Gal4 response element-driven firefly 
luciferase reporter, renilla luciferase control vector and with indicated FKBP38 
expression plasmids. 24 h post-transfection, cells were cultivated for 16 h under 
normoxic (20% O2) or hypoxic (0.2% O2) conditions before relative luciferase 
activities were determined. Results are mean values ± SEM of 7 independent 
experiments performed in triplicates. (F) HeLa wild-type, control or FKBP38-depleted 
cells (3D6, 2G8) were transiently transfected with indicated plasmids and PHD2, V5 
and β-actin were detected by immunoblotting. (G) HeLa wild-type, control or FKBP38 
depleted cells (3D6, 2G8) were transiently transfected with indicated plasmids and 
hydroxylation activity was measured using a VBC-binding assay. Shown are mean 
values of relative VBC binding ± SEM of 2 independent experiments performed in 
triplicates. 
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Figure 7. Requirement of FKBP38 localization for PHD2 interaction. 
(A) HEK293 cells were transiently transfected with indicated ECFP and EYFP 
vectors and FRET was monitored. (B) Recombinant GST, GST-FKBP38 or GST-
FKBP38_1-389 were incubated with radioactive labeled 35S-PHD2 and protein 
complexes were pulled-down by glutathione sepharose, separated by SDS-PAGE 
and visualized by phosphorimaging. (C) HeLa cells were transiently transfected with 
Gal4-DBD and VP16-AD fusion protein vectors, Gal4 response element-driven firefly 
luciferase reporter as well as a renilla luciferase control vector. Following 
transfection, the cells were incubated under normoxic (20% O2) or hypoxic (0.2% O2) 
conditions and luciferase reporter gene activities were determined 16 h later. Firefly 
to renilla luciferase activity ratios were normalized to the normoxic negative control 
DBD-p53/AD-CP co-transfection which was arbitrarily defined as 1. Mean values ± 
SEM are shown of 3 independent experiments performed in triplicates. 
 
Figure 8. Sub-cellular localization of FKBP38 and PHD2. 
HeLa wild-type cells or FKBP38-silenced cells (2G8) were incubated at 20% O2 (A), 
(B) or at 0.2% O2 (C), (D) and cellular membranes were separated from cytosolic 
fractions by differential centrifugation and then separated in a 10% to 30% iodixanol 
(Opti-prep) gradient. 1 ml fractions were collected and analyzed by immunoblotting. 
Mitofilin served as mitochondria and protein disulfide isomerase (PDI) as 
endoplasmatic reticulum (ER) marker. (E) Cytosolic fractions of HeLa wt and 2G8 
incubated at 20% O2 or 0.2% O2 were analyzed by immunoblotting. 
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7 List and contributions to the publications and manuscript 
This thesis consists of the following original publications and manuscript and I 
contributed to it as indicated: 
 
Publications: 
Barth S., Nesper J., Hasgall P.A., Wirthner R., Nytko K.J., Edlich F., Katschinski 
D.M., Stiehl D.P., Wenger R.H. and Camenisch G. (2007) The peptidyl prolyl 
cis/trans isomerase determines hypoxia-inducible transcription factor prolyl-4-
hydroxylase PHD2 protein stability. Mol Cell Biol; 27(10):3758-68 
 
• Everything, except yeast-two hybrid screening, figure 1A-C, figure 2 and 
figure 5A 
 
Wirthner R., Kuppusamy B., Stiehl D.P., Barth S., Spielmann P., Oehme F., 
Flamme I., Katschinski D.M., Wenger R.H., Camenisch G. (2007) Determination 
and modulation of prolyl-4-hydroxylase domain (PHD) oxygen sensor activity. 
Methods Enzymol; 435:43-60 
 
• Establishment of VBC-dependent hydroxylation assay for cell extracts 
• Figure 3.2 (D) 
 
Manuscript: 
Barth S., Edlich F., Berchner-Pfannschmidt U., Gneuss S., Shirane M., Wenger 
R.H. and Camenisch G. HIF prolyl-4-hydroxylase PHD2 protein stability depends 
on FKBP38 sub-cellular localization. 
 
• Everything except figure 1, 2 and FRET analysis (Fig. 7A) 
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8 Unpublished data 
Functional relevance of the FKBP38:PHD2 interaction in cell growth, 
proliferation and cell death 
Sandra Barth1, Roland H. Wenger1 and Gieri Camenisch1 
1Institute of Physiology and Zürich Center of Integrative Human Physiology (ZIHP), 
University of Zürich, CH-8057 Zürich, Switzerland 
 
Introduction 
Oxygen is an essential regulator of cellular metabolism and cell survival or death. 
Adaptation to oxygen deprivation is mainly governed by the transcription factor HIF 
and the stability of HIF-α subunits is oxygen-dependently regulated by prolyl-4-
hydroxylases (PHDs). PHDs require oxygen as a substrate and therefore HIF-α 
degradation is a function of oxygen availability. In addition to the function of PHDs as 
cellular oxygen sensors, the functional homologue of PHD in Drosophila (Hph) has 
been implicated in the regulation of cell growth (cell size), suggesting a link between 
growth signals, mitochondrial activity and oxygen sensing (1). Drosophila cyclin-
dependent protein kinase complex cyclin D/Cdk4 requires Hph to promote cell growth 
but not for cell proliferation. Adaptive mechanisms to O2 deprivation include inhibition 
of energy-consuming mRNA translation and it has been shown that hypoxia inhibits 
multiple key regulators of the PI3K/TSC/mTOR pathway (2). Interestingly, cell size 
regulation has been shown to depend also on FKBP38 (3). Overexpression of TSC1 
resulted in upregulation of FKBP38 expression and reduced cell size by down-
regulating mTOR activity, and this effect was reverted by downregulation of FKBP38 
by anti-sense oligonucleotides. 
In addition, FKBP38 has been linked to cell death. An interaction of FKBP38 with Bcl-
2 has been described, but the functional consequence of this association remains 
controversial. Pro- as well as anti-apoptotic effects have been reported depending on 
the used cell model (4), (5). Shirane et al. reported that in HeLa cells FKBP38 
recruits Bcl-2 to mitochondria and promotes cell survival. In SH-SY5Y neuroblastoma 
cells down-regulation of FKBP38 by RNAi reduced cell death after induction of 
apoptosis with etoposide, staurosporine and camptothecin (4). Interestingly, a 
function of PHDs in apoptosis is supported by the observation that Egl9-/- (C. 
elegans PHD homolog) worms are resistant to certain neurotoxins (6). A pro-
apoptotic function of human PHD3 has been shown in adrenal medullary tumors or 
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after nerve growth factor withdrawal (7), (8). Similar to PHD3, the rat homolog SM-20 
which is located to mitochondria is a mediator of caspase-dependent cell death after 
NGF deprivation (9). Interestingly, forced expression of PHD3 promotes aggregation 
of proteasomal components leading to cell death (10). 
Hence, we wanted to explore the role of FKBP38 in cell death and analyze FKBP38-
dependent regulation of PHD2 protein levels in relation to cell growth, proliferation 
and death or survival. 
 
Methods and materials 
Cell lines and cell culture 
Wild-type and stable control RNAi or FKBP38 RNAi transfected human HeLa cervical 
carcinoma cells were cultured in high-glucose Dulbecco`s modified Eagle`s medium 
(DMEM) (Sigma) supplemented with 10% FCS (Gibco) and Penicillin/Streptomycin 
(Sigma) and incubated at 20% O2, 5% CO2, 37ºC. For serum starvation experiments, 
cells were cultured with DMEM and 0.1% FCS for indicated periods of time. 
Western Blot analysis 
Total cell extracts of cultured cells were prepared using RIPA buffer containing 50 
mM Tris Cl pH 8.0, 1 mM EDTA pH 8.0, 150 mM NaCl, 1% Triton X-100, 0.5% Na-
deoxycholate, 0.1% SDS. Protein concentration was determined by detergent- 
insensitive BCA assay (Pierce, Perbio Science, Lausanne, Switzerland) using bovine 
serum albumin as a standard. Immunoblot analysis were performed as described 
previously (11). Briefly, proteins were separated by SDS-PAGE, electro-transferred 
onto nitrocellulose membranes (Amersham Biosciences) and incubated with anti-
PHD2 (Novus, Abcam, Camridge. United Kingdom), anti-FKBP38 (4), anti-phospho-
S6-kinase (Cell signaling technology, Bioconcept, Allschwil, Switzerland) and anti-S6 
kinase (Cell signaling technology, Bioconcept, Allschwil, Switzerland) antibodies. 
Cell analysis and 5-bromo-2-deoxyuridine (BrdU) proliferation assay 
HeLa cells were seeded in cell culture dishes and counted at different time points. 
Cell number, viability and size were determined using a Vi-Cell cell counter 
(Beckman Coulter, Switzerland). To measure the incorporation of BrdU in place of 
thymidine into the DNA, the cell proliferation BrdU assay from Roche was used 
according to the manufactures instructions. Briefly, HeLa cells were seeded at a 
concentration of 3000 cells/well in a 96 well luminometer plate. The cells were 
incubated with 10 µM BrdU for 2 h. To detect the incorporated BrdU, the fixed cells 
UNPUBLISHED DATA 
- 79 - 
were incubated with anti-BrdU-POD antibody and the chemiluminescence was 
monitored by a Centro LB 960 Luminometer (Berthold, Regensdorf, Switzerland). 
Caspase 3 activity assay with DEVD-AMC fluorogenic substrate 
HeLa cells were exposed to 44ºC for 4 h and further incubated at 37ºC for 4 h. Cells 
were pelleted after washing by centrifugation and resuspended in lysis buffer 
containing 100 mM HEPES, 0.1% CHAPS, 10% sucrose, 1 mM EDTA, 1 mM  
phenylmethylsuflonyl fluoride (PMSF). 60 µg of cellular proteins were incubated with 
3 mM of the fluorogenic substrate DEVD-AMC (Biomol) in a 96-well microtiter plate. 
The cleavage of the DEVD-AMC was immediately monitored by the release of AMC 
in a fluoroscan plate reader (Tecan) using 360 nm for excitation and 465 nm for 
emission. Fluorescence was measured for 18 min. 
 
Results and discussion 
Loss of function mutations of Drosophila prolyl-4-hydroxylase Hph suppresses cyclin 
D/Cdk4 induced cell growth but not cell proliferation suggesting that Hph is a positive 
regulator of cell growth (1). Cell growth is mainly controlled by the activity of the 
mTOR pathway. Recently, FKBP38 has been reported to limit the activity of mTOR 
by binding directly to mTOR. FKBP38:mTOR interaction is competed by Rheb-GTP 
binding to FKBP38. Rheb-GTP accumulates under growth supporting conditions 
whereas under growth factor withdrawal or nutrient deprivation Rheb-GDP can be 
found (12). We hypothesized that in our HeLa FKBP38 RNAi cell model, we will 
observe an increase in cell size as a result of increased PHD2 protein levels and 
increased mTOR target phosphorylation due to loss of FKBP38. 
Hence, we monitored the cell size of the FKBP38-downregulated cells 3D6 and 2G8 
compared to the parental (HeLa wt) and control (HeLa ctrl) cells (previously 
described (11)). We did not observe a significant change in the cell size which was 
dependent on the loss of FKBP38 (Fig. 1A). The same results were observed by 
FACS analysis (data not shown). 
UNPUBLISHED DATA 
- 80 - 
 
Figure 1. Depletion of FKBP38 does not significantly influence mTOR activity. 
(A) HeLa cell lines were cultured for the indicated time and the cell size was determined by Via-Cell counter. Shown are mean 
values ± SEM of 4 independent experiments. (B) HeLa cells were incubated for 16 h either with 10% FCS or 0.1% FCS and 
afterwards re-stimulated with 10% FCS. Cellular extracts were prepared and PHD2, FKBP38, phospho-SK6 and S6K were 
detected by immunoblotting. Total S6K protein levels served as loading control.  
Furthermore, HeLa cells were incubated with 10% fetal calf serum (FCS) or 0.1% 
FCS for 16 h. Additionally, HeLa cells were serum starved with 0.1% FCS and re-
stimulated with 10% FCS for 30 min. Cellular extracts were prepared and FKBP38, 
PHD2, phospho-SK6 and total S6K were detected. We observed an increase of 
PHD2 protein abundance in the FKBP38-depleted cells which was not affected by 
serum starvation and re-stimulation with 10% FCS (Fig. 1B). FKBP38 protein levels 
were not affected. Because of the proposed inhibitory function of FKBP38 on the 
mTOR activity, we expected to see an increase in phospho-S6K in the FKBP38 
depleted cells because S6K is a known phosphorylation target of mTOR. However, in 
our hands we did not detected differences in the phosphorylation state of S6K in 
dependency of FKBP38. We observed a general increase in the phosphorylation 
state of S6K after serum starvation and re-stimulation with FCS.  
Next, we examined the cell proliferation of wild-type HeLa cells compared to stably 
control transfected HeLa cells (HeLa ctrl) and stably transfected HeLa cells with a 
FKBP38 RNAi expressing plasmid (HeLa 3D6, 2G8). 
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Figure 2. The proliferation is decreased in HeLa FKBP38-silenced cells. 
HeLa cells were seeded with a cell density of 300’000/10 cm dish. Cells were counted after 24 h which was defined as time 
point t0. Cells were grown for further 24, 48 h and the number of cells were counted. Results are mean values of relative cell 
numbers normalized to t0 ± SEM of 4 independent experiments. P values were obtained by paired t tests (** p<0.01; * p<0.05). 
Interestingly, we observed a significant slower proliferation of the FKBP38 RNAi cells 
3D6, 2G8 after 24 h and 48 h compared to wild-type HeLa cells and HeLa ctrl cells 
(Fig. 2). The HeLa ctrl cell line proliferated slightly slower compared to the HeLa wild-
type cells which is most likely due to the incubation of the HeLa ctrl, 3D6, 2G8 with 
hygromycin B containing DMEM medium. In hypoxia, the proliferation rates did not 
significantly differ between the FKBP38 RNAi cells 3D6, 2G8 and the control cell 
lines HeLa wt and ctrl after 24 h (Fig. 3). However, when we tried to determine the 
changes in the DNA synthesis rate in these cells by the 5-bromo-2-deoxyuridine 
(BrdU) assay we did not see a significant difference in the uptake of BrdU between 
the ctrl and the FKBP38-silenced cell lines (Fig. 4). A slight difference was observed 
between the parental cell line and the ctrl and FKBP38 silenced cells which was most 
likely due to incubation of the cells with the antibiotic hygromycin B which functions 
as a selection marker. To confirm these changes in cell proliferation FKBP38 
reconstitution or PHD2 RNAi experiments should be done to investigate the 
dependency of cell proliferation on FKBP38 and/or PHD2. 
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Figure 3. The influence of hypoxia on the 
proliferation rate on HeLa wt, ctrl and FKBP38-
depleted cells. 
HeLa cells were seeded at a cell density of 300’000 cells/10 
cm dish and incubated under 0.2% O2. Cells were counted 
after 24 h which was defined as time point t0. Cells were 
grown for further 24, 48 h and the number of cells was 
counted. Results are mean values of one experiment. 
 Figure 4. DNA synthesis rate was not affected 
by loss of FKBP38. 
HeLa cells were seeded at a cell density of 300’000 
cells/10 cm dish and incubated under 0.2% O2. Cells 
were counted after 24 h which was defined as time point 
t0. Cells were grown for further 24, 48 h and the number 
of cells was counted. Results are mean values of relative 
cell luciferase counts normalized HeLa wt ± SEM of 4 
independent experiments. 
Because the variations in cell proliferation were not caused by alterations in the DNA 
synthesis, we analyzed the influence of FKBP38 on cell viability and cell death. 
Hence, we monitored the number of dead cells by trypan blue staining in relation to 
total counted cells. In FKBP38 down-regulated cells the cell viability tended to be 
lower in the FKBP38-silenced cells (Fig. 5A). The decrease in cell viability might 
explain the lower cell number counted in the FKBP38 RNAi cells. 
 
Figure 5. Analysis of cell death by trypan blue staining and apoptosis by measurement of caspase-3 
activity in FKBP38-down-regulated cells. 
(A) Cell viability was monitored by trypan blue exclusion and the number of viable cells was normalized to total number of cells 
(in %). Shown are mean values ± SEM of 4 independent experiments. (B) HeLa cells were cultivated for the indicated time 
periods at 37°C or 44°C and caspase-3 activity of total cellular lysates was measured. 
Cells may die by an induced intracellular program (apoptosis) after death stimuli or by 
necrosis caused from acute tissue injury which provokes an inflammory response. 
Inhibition of FKBP38 reduces etoposide-induced apoptosis in neuroblastoma cells 
and has neuroprotective effects in a rat brain ischemia model, suggesting a pro-
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apoptotic function of FKBP38 (4), (13). To investigate a possible role of PHD2 and 
FKBP38 in apoptosis, we cultivated HeLa wild-type and FKBP38-silenced HeLa 2G8 
cells under 37°C or 44°C. Whereas no significant difference was observed at 37°C, 
2G8 cells showed reduced apoptosis compared to wild-type cells after heat shock 
treatment (Fig. 5B). 
Our initial data indicate a reduced caspase-3 activity after heat-induced apoptosis in 
our stable FKBP38 siRNA HeLa cell clones, supporting a pro-apoptotic function for 
FKBP38. Contrary, cell viability was decreased at the early time points. It might be as 
well that the cells were more prone to stress resulting in increased necrotic cell 
death. However, this has to be confirmed by additional assays like staining for HMG-
1 which is a marker for necrotic cell death. 
To investigate the role of FKBP38 in apoptosis, similar experiments should be 
performed with alternative apoptosis inducers (e.g. etoposide, irradiation) and 
apoptosis assessed by measuring caspase-3 activity as well as by propidium 
iodide/annexin V staining and FACS analysis. To investigate the influence of 
hydroxylase activity, the experiment might be done under low-oxygen conditions or in 
the presence of PHD inhibitors. To investigate whether differences in apoptosis can 
be affected by PHD2 expression, we would transiently down-regulate PHD2 by 
siRNA in FKBP38-depleted clones and vice-versa overexpress PHD2 in wild-type 
HeLa cells, respectively. In addition, we would generate stable PHD2 down-regulated 
HeLa as well as HEK293 cell clones and apoptosis would be measured in these 
clones as mentioned above. Accordingly, to verify a direct function of FKBP38 in 
apoptosis, FKBP38 expression in siRNA clones will be reconstituted by transient 
transfections. 
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9 Conclusions 
Cells developed a variety of strategies to respond to diverse stress stimuli. Oxygen 
deprivation results in the stabilization of the HIF transcription factor that allows the 
expression of so far more then 70 proven target genes and more than 200 potential 
target genes involved in the regulation of cellular energy metabolism, cell growth and 
cell survival or cell death and cellular, local and systemic oxygen supply (1). 
However, the stability of the HIF-α subunits is tightly regulated by the oxygen-
dependently regulated prolyl-4-hydroxylases PHDs. So far, at least three isoforms 
(PHD1-3) are known to modulate HIF-α subunits in vitro and PHD2 has been 
suggested to be the main oxygen sensor in cellulo (2). Moreover, PHD2 is the main 
enzyme required during embryonic development and PHD2 adult knockout mice 
suffer from severe polycythemia whereas PHD1 and PHD3 knockout mice were 
apparent healthy (3), (4). However, PHD1 knockout mice show changes in their 
cellular energy metabolism and PHD3 knockout mice have lower systemic blood 
pressure (4), (5). These observations may suggest that PHDs have redundant as well 
as non-redundant functions. 
We wanted to explore the hypothesis if PHD2 has further hydroxylation substrates 
than HIF-α or if other regulatory mechanisms might be involved in the regulation of 
PHD2. We used yeast two-hybrid methology to identify novel PHD2 interacting 
proteins. We discovered that the FKBP38 protein binds specifically to PHD2 but not 
to PHD1 or PHD3. We performed a variety of interaction assays including yeast 
interaction analysis, GST pull-down and co-immunoprecipitation experiments, 
mammalian two-hybrid experiments and FRET analysis to confirm this interaction. 
The dissociation constant KD determined by ITC measurements with about 0.9 µM 
suggests a relative strong interaction. Consistent with these data, calculations from 
FRET analysis with expressed fluorescent-tagged FKBP38 and PHD2 in HEK293 
cells determined a distance between both proteins of about 5 nm which is even lower 
compared to the interaction of the hypoxically stabilized HIF-1α subunit and the 
constitutively expressed HIF-1β subunit with roughly 7 nm (6). Furthermore, we 
mapped the detailed interaction domain of FKBP38 with PHD2 and vice versa. 
FKBP38 binds with a linear binding motif from aa 37 to 56 to PHD2. The FKBP38 
binding site is a so far unknown interaction motif containing a glutamate rich stretch. 
A shorter version of this motif can be found in mouse and rat. 
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PHD2 interacts with its N-terminal region from aa 1 to 114 with FKBP38. As a result 
of the peptide array and N-terminal deletion interaction analysis of PHD2 with 
FKBP38, we suggest that PHD2 binds with a non-linear binding region to FKBP38. 
The region from aa 1 to 114 contains the MYND-type Zn2+ finger domain named after 
its general structure in MTG8 and drosophila proteins nervy and DEAF-1 (7). It 
composes a cluster of cysteine and histidine residues arranged with an invariant 
spacing to form the potential zinc-binding motif. Currently it is believed that the 
MYND-type Zn2+ finger domain is a protein-protein interaction domain that provides a 
platform to recruit transcriptional repressors. Recent reports have suggested that 
PHD2 specifically represses HIF-1α transcriptional activity (8). Furthermore, the 
tumor suppressor protein ING4 interacts with PHD2 and recruits ING4 to HIF thereby 
limiting HIF transcriptional response by recruiting transcriptional repressors in 
hypoxia (9). More interestingly, PHD2 seems to shuttle between nucleus and cytosol 
(10). However, PHD2 localization has been mainly described to be in the cytosol but 
it does not exclude the possibility that a small portion of PHD2 might be also found in 
the nucleus. FKBP38 is localized at the mitochondria and ER and therefore 
interaction with PHD2 might be a way to keep PHD2 in the cytosol (11). Of note, a 
direct involvement of the MYND-type Zn2+ finger domain of PHD2 in FKBP38 binding 
has still to be determined by site-directed mutagenesis analysis. 
FKBP38 is a member of the PPIase family. Even structurally unrelated, all members 
of this family have a common enzymatic activity that accelerates the cis to trans 
isomerization of the amino acid proline. It is thought that these enzymes play a role in 
protein folding and protein complex formation. We assumed that FKBP38 is a 
potential co-factor that plays a role in PHD2-mediated hydroxylation of HIF-α 
subunits. Though, stable RNA interference (RNAi)-mediated down-regulation of 
FKBP38 in HeLa cells increased PHD2 protein abundance and cellular hydroxylation 
activity. Genetic ablation of FKBP38 in MEFs slightly increased PHD2 protein as well. 
Conversely, elevated PHD2 protein levels delayed hypoxic HIF-1α protein 
accumulation and attenuated HIF-dependent transcriptional regulation. 
Reconstitution of FKBP38 normalized PHD2 protein levels and therefore cellular 
hydroxylation capacity and HIF-1 response. Strikingly, increased PHD2 protein 
abundance was due to prolonged PHD2 protein stability. These data suggest that 
FKBP38 determines PHD2 protein levels. 
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PHD2 transcript levels are induced in hypoxia by HIF, this induction might be 
regulated by TGFβ (12), (13). PHD2 activity is modulated by a wide range of 
components including oxygen, energy metabolism intermediates, iron and divalent 
ions, NO, ROS and antioxidants (14). However little is known about PHD2 protein 
regulation. PHD1 and PHD3 have been reported to be targeted by the E3 ubiquitin 
ligases Siah1/2 and subsequently degraded by the ubiquitin-proteasome pathway 
(15). PHD2 interacted with Siah1/2 but the functional consequence of this interaction 
remained elusive.  
Protein synthesis and protein degradation are in a dynamic equilibrium that is 
important to control protein mass in a cell. The protein degradation pathways in the 
lysosomes and proteasomes account for 80% or more of the degradation of cellular 
proteins (16).  
Figure 11. Scheme of the ubiquitin-proteasome degradation pathway (17) 
Ubiquitin is first activated by the ubiquitin-activating enzyme E1 and then transferred to a member of the ubiquitin-carrier family 
of enzymes E2 (ubiquitin-conjugating enzyme). In the final reaction ubiquitin is added to the targeted protein with the help of an 
E3 ubiquitin ligase. Additionally, further ubiquitin moieties are added to generate a poly-ubiquitin chain and subsequently, the 
targeted protein is degraded in the 26S proteasome. 
In the proteasome-ubiquitin system the protein substrate is tagged by covalent 
attachement of multiple ubiquitin molecules to generate a polyubiquitin chain (Fig. 11) 
(17). This polyubiquitin chain is the recognition marker for the degradation by the 26S 
proteasome complex and subsequently free and reusable ubiquitin and peptides are 
released from the 26S proteasome. The 26S proteasome consists of the 20S 
catalytic core protease particle and two regulatory 19S particles which cap the end of 
the 20S proteasome. Short-lived proteins such as p53, p73, ornithine decarboxylase 
that are inherently unstable are proposed to be degraded by default by the 20S 
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proteasome (18), (19). This degradation pathway does not require the ubiquitin-tag 
as recognition marker. Though these proteins can be stabilized by binding to the 
proliferating cell nuclear antigen (PCNA), antizyme or to the NAD(P)H quinone 
oxidoreductase 1 (NQO1) protein and prevent ubiquitin-independent proteasomal 
degradation (20). 
We did not find an involvement of the ubiquitin-proteasome pathway in the 
degradation of PHD2 protein. Changes of PHD2 protein levels were not observed 
when MCF-7 cells were incubated with proteasomal inhibitors like MG132 or 
lactacystin. Lactacystin has been proposed to act as a pseudosubstrate that is 
covalently linked to the hydroxyl groups on the active site threonine in the β-subunit 
of the 20S proteasome and MG132 as a peptide aldehyde is a potent transition state 
inhibitor of the chemotrypsine-like activity of the 20S proteasome (21). To completely 
exclude the possibility of ubiquitin-dependent PHD2 proteasomal degradation we 
made use of a mouse ts20 cell line that contains a temperature sensitive E1 
activating enzyme (22). Incubation of these cells under permissive (34ºC) or non-
permissive temperatures (39ºC) allowed us to monitor protein accumulation. 
Whereas the known ubiquitin-dependently degraded p53 protein strongly 
accumulated, no changes in PHD2 protein levels were observed. Simultaneous 
incubation of a mouse ts20 cell line, corrected with a non-temperature sensitive E1 
activating enzyme (H38-5), did not result either in accumulation of p53 or PHD2. 
Therefore, we have no evidence that PHD2 degradation occurs by the proteasome 
degradation pathway. Interestingly, PHD2 differs from the other PHDs by its protein 
structure with its N-terminal extension containing the MYND-type Zn2+ finger domain. 
N-terminal deletion of PHD2 rendered PHD2 susceptible to degradation by Siah1/2 
similar to the other PHDs and afterwards proteasomal degradation whereas full 
length PHD2 was not prone to proteasomal degradation (23). These data suggest 
that PHD2 N-terminal region determines PHD2 protein degradation independent of 
the 26S proteasome. 
Another well-established pathway of intracellular protein degradation involves the 
lysosomal pathway. Lysosomes contain a large variety of hydrolytic enzymes that 
degrade proteins or other substances taken into by endocytosis. Furthermore, whole 
organelles or large areas of cytoplasm can form so called autophagic vacuoles which 
fuse with lysosomes or late endosomes to degrade its content (24). Lysosomes have 
a low internal pH and proteins are degraded by the enzymatic activity of cathepsins 
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(cysteine proteases), aspartyl proteases and zinc proteases. Incubation of MCF-7 
cells with a variety of common protease inhibitors like ABSF (serine protease 
inhibitor), E64 (cysteine protease inhibitor), ALLM (calpain inhibitor) and pepstatin A 
(aspartyl protease inhibitor) did not alter PHD2 protein levels. E64 an inhibitor of the 
lysosomal pathway did not affect PHD2 protein levels excluding the lysosomes as the 
organelle for PHD2 protein degradation. To entirely eliminate the possibility of the 
involvement of autophagy of organelles like ER and mitochondria in PHD2 protein 
degradation, cells should be incubated with the well-established macroautophagic 
inhibitor 3-MA (3-methyladenine) and PHD2 levels analyzed (25). Surprisingly, 
incubation of the cells with 2 mM EDTA, but not EGTA strongly reduced PHD2 
protein levels though the physiological relevance is completely unclear (data not 
shown). These data suggest that PHD2 protein abundance is uniquely modulated. 
The FKBP38 protein structure consists of a PPIase enzymatic activity domain, three 
TPRs, a CaM binding site and a transmembrane domain. FKBP38 has been 
demonstrated to be a Ca2+-activated peptidyl prolyl cis/trans isomerase in in vitro 
protease-coupled cis/trans isomerase assays (26). Like full length FKBP38, deletion 
of the PPIase domain of FKBP38 enhanced the HIF-1α one-hybrid stability in MCF-7 
cells and reconstituted it in the FKBP38-depleted cells 2G8 and 3D6. Furthermore, 
incubation of these cells with the FKBP38 specific inhibitor GP1046 and DM-CHX did 
not impair PHD2 protein levels. Hence, we concluded that FKBP38 modulates PHD2 
protein abundance in a PPIase-independent manner. 
FKBP38 possesses a transmembrane domain that anchored FKBP38 to 
mitochondria and ER. We questioned if the transmembrane domain of FKBP38 is 
required for PHD2 protein regulation. Surprisingly, loss of FKBP38 transmembrane 
did not reconstitute HIF-1α one-hybrid stability and PHD2 protein abundance in 
FKBP38-silenced cells. Strikingly, deletion of FKBP38 transmembrane domain 
abolished the binding to PHD2 though the PHD2:FKBP38 interaction is a prerequisite 
for PHD2 protein degradation. So far, fluorescent tagged PHD2 was localized in the 
cytosol but no further sub-cellular localization was described (27). We could detect 
PHD2 together with FKBP38 in the membrane fraction containing ER and 
mitochondrial proteins. Consistent with these data, in primary rat hepatocytes PHD2 
mitochondrial staining was observed (28). Mitochondria are the cellular power plants 
because they supply the cells with ATP required for maintenance of the cellular 
metabolism. It is well established that mitochondria are also a major source for the 
CONCLUSIONS 
- 90 - 
production of ROS. Inhibition of mitochondrial activity impaired HIF-1α accumulation 
whereas the molecular mechanism is controversially discussed (29), (30). Increased 
oxidative stress impaired PHD activity, however until now PHD2 protein stability was 
not investigated so far (31). Increased oxidative stress is associated with 
accumulation of oxidized proteins and with cellular aging. Mitochondria feature a 
ubiquitous enzymatic system that can reduce oxidized proteins or target oxidized 
proteins to mitochondrial matrix proteolytic enzymes for degradation (32). The ATP-
stimulated mitochondrial matrix protease Lon degrades selectively the oxidized form 
of the mitochondrial aconitase enzyme (33). We speculate that the interface between 
FKBP38 and PHD2 at the mitochondria might make PHD2 protein susceptible to 
oxidation and degradation. Furthermore, during hydroxylation of HIF-α subunits 
PHD2 might be prone to oxidation. Though, PHD2 protein stability will be investigated 
in respiration-deficient cells (rho cells) or cellular respiration will be blocked with 
rotenone or myxothiazol or oxidative stress will be induced by hydrogen peroxide. 
Additionally, FKBP38 has been described to have chaperone function in in vitro 
refolding assays (34). However, the region containing the FKBP38 chaperone activity 
has not been described so far. Chaperone proteins have a role in the refolding of 
misfolded proteins and not successful folding led to protein degradation. It would be 
of interest to investigate a possible role of FKBP38 chaperone activity in PHD2 
protein regulation. 
In summary, we discovered that FKBP38 specifically interacts with the oxygen-
sensing prolyl-4-hydroxylase PHD2 thereby modulating the protein steady state 
levels in a PPIase-independent manner. The interaction of FKBP38:PHD2 requires 
the sub-cellular localization of FKBP38 at the ER and mitochondria and is the 
prerequisite for the regulation of the half-life of PHD2. So far, we were not able to 
identify the molecular mechanism of PHD2 protein degradation. We speculate that a 
unique protease or degradation pathway at the ER or mitochondria might be involved 
in the PHD2 breakdown. Disrupting the PHD2:FKBP38 interaction might be an 
attractive strategy to enhance PHD2 protein levels and to modulate the oxygen-
sensing pathway. 
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